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Abstract  
MicroRNAs (miRNAs) are small RNA sequences 22-25 nucleotides in length 
which play a role in post-transcriptional gene regulation by binding to target mRNA 
sequences preventing translation. Changes in miRNA expression can contribute to 
disease pathogenesis, including gliomagenesis. The release of glioblastoma specific 
exosomes containing miRNA into the circulation of patients provides a source of 
biomarkers which could be utilised in a relatively non-invasive diagnostic test.  The 
primary aim of this thesis was to identify secreted biomarkers in biofluids of 
glioblastoma patients for the diagnosis and prognosis of glioblastoma mulitforme 
(GBM). 
This is the first report of miRNA expression based on the age and sex of GBM 
patients. GBM and non-cancerous control patients were grouped into age categories 
(20-39, 40-59 and 60+ years old) and gender. Initial analysis was performed using 
miScript Brain Cancer Array (n=3 per category) and a total of 28 dysregulated miRNAs 
were identified in GBM patient serum as candidate biomarkers for further study.   
Using a new patient cohort (n=3 per category), further analysis of the 28 
miRNAs by qPCR identified five miRNAs with altered expression in GBM serum: miR-
34a-5p, miR-92a-3p, miR-20a-5p, miR-30c-5p, and miR-150-5p. Further validation 
following power analysis identified four of the five miRNA biomarkers: miR-34a-5p, 
miR-92a-3p, miR-20a-5p and miR-30c-5p to be significantly dysregulated in the serum 
of GBM patients. Grouping of patients by age and gender identified miR-34a-5p as 
significantly increased in aged 60+ patients (p < 0.05); miR-92a-3p expression was 
significantly higher in male GBM patients compared to female GBM patients (p < 0.05) 
and miR-20a-5p was significantly higher in a sub group of GBM patients (p < 0.01).  
Moreover, increased expression of miR-20a-5p in the serum of GBM patients was 
associated with a better median survival compared to those with no change in miR-
20a-5p expression.   
Investigation into the origin of the serum miRNA biomarkers using qPCR, in situ 
hybridisation and GBM tissue data from The Cancer Genome Atlas (TCGA) identified 
potential differences in origin of the four miRNA biomarkers; miR-20a-5p in the serum 
of GBM patients was likely to originate from the GBM. MiR-34a-5p showed increased 
expression in the GBM tissue analysed by TCGA. In contrast, analysis of matched 
patient serum and tissue lysate samples using qPCR demonstrated a higher expression 
of miR-34a-5p in the serum of GBM patients compared to tissue expression, possibly 
due to increased miRNA secretion by neighbouring non-cancerous cells, or from 
leukocytes as part of an immune response. Further work utilising larger patient 
samples could confirm the origin of miR-34a-5p. 
Overall four miRNAs were identified in this thesis with altered expression in 
GBM patients. Further studies could evaluate their use as diagnostic and prognostic 
serum biomarkers for glioblastoma which could provide a relatively non-invasive 
alternative to current diagnostic methods requiring surgery.  
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1.1 Glioma  
 
Gliomas are brain tumours that arise from glial cells within the brain, and account for 
81% of all malignant brain tumours (Ostrom et al., 2014). The three main types of glial 
cell are astrocytes, ependymal cells and oligodendrocytes. Tumours that arise from 
these cell types often share similar characteristics, including indistinct margins and 
increased malignancy over time (Abrey and Mason, 2009).  
 
Originally, glial cells were believed to have only a supportive function within the brain, 
but extensive research into the roles of glial cells has revealed that they also play a 
part in controlling the microenvironment, and the development of the nervous system 
(Dimou and Götz, 2014).  Radial glia are now known to have a role as neural progenitor 
cells, giving rise to both neurons and astrocytes within the gliovascular network 
(Dimou and Götz, 2014). In this network, the glia are connected by gap-junctions that 
allow communication between the cells, providing structural and functional 
organisation to the brain (Giaume et al., 2010). 
 
Glial cells are also involved in the regulation of synaptic transmission and the 
formation of new synaptic contacts (Gundersen et al., 2015). It has been proposed that 
astrocytes may contribute to neurogenesis, originally believed to involve only neuronal 
cells, by enhancing synaptic activity via the release of glial factors, including cholesterol 
(Slezak and Pfrieger, 2003) and thrombospondin (Allen and Barres, 2009). The release 
of cholesterol and thrombospondin contributes to dendrite formation and the 
promotion of synapse formation respectively, by mediation of cell-cell and cell-matrix 
interactions (Allen and Barres, 2009). 
1.1.1 WHO Classification, Grades of Glioma and Prognosis 
 
The classification of the World Health Organisation grades neoplasms from I-IV, Grade 
I being a benign tumour with low proliferative potential which, with surgical 
treatment, can have a promising prognosis and potential cure (Louis et al., 2007). 
Grade II neoplasms also display low-proliferative potential with infiltration of 
surrounding tissue, however, grade II tumours have the potential to progress to a 
higher grade and also present the risk of tumour recurrence following initial 
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treatment. Grade III tumours often have atypical nuclei and are malignant. Grade IV 
neoplasms are highly malignant and are often characterised by necrosis and infiltration 
of surrounding tissue. Even with aggressive treatment, prognosis for grade IV tumours 
is poor (Ostrom et al., 2014). According to the World Health Organisation’s 
classification of gliomas, ependymomas and oligodendrogliomas are classed as grade II 
neoplasms. Malignant oligodendrogliomas however, are classed as a grade III 
(Scheithauer, 2008). Anaplastic astrocytomas are classed as grade III (Kajiwara et al., 
2009) and glioblastoma multiforme, the most common form of glioma, is classed as 
grade IV, due to  high malignancy and poor prognosis  (Yoon et al., 2010). The grading 
and characteristics of the most common gliomas types are outlined in Table 1.1.  
Table 1.1 Outline of Common Glioma Types, Grades and Characteristics adapted from Louis, 2007 
Glioma  Classification Characteristics 
Pilocytic Astrocytoma  
Grade I Benign neoplasm with potential for 
malignant transformation can be 
removed by surgical resection. 
Ependymoma 
Grade II Slow growing, treatment with surgery 
and radiotherapy. 
Oligodendroglioma 
Grade II Slow growing, survival rate around 11-12 
years, treatment with chemotherapy or 
radiotherapy depending on specific 
mutation. 
Malignant Oligodendroglioma 
Grade III Survival rate around 3-4 years, treatment 
with chemotherapy or radiotherapy 
depending on specific mutation. 
Anaplastic Astrocytoma 
Grade III Treatment with surgery and radiotherapy 
often with chemotherapy, survival rate 
around 2-5 years. 
Glioblastoma Multiforme 
Grade IV Poor prognosis, high malignancy, 
treatment with combined radiotherapy 
and chemotherapy. 
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Patients with oligodendroglial tumours have a survival rate of between 4 and 15 years 
following diagnosis, depending on the grade of neoplasm (Abrey and Mason, 2009). 
Ependymomas are the least common form of brain tumour and complete surgical 
resection can often be curative. More malignant cases of ependymomas can be 
treated with both surgery and chemotherapy, however there is a high risk of 
recurrence and metastasis (Freyschlag et al., 2011). For low grade astrocytomas, 
treatment with surgical resection and low dose radiotherapy normally leads to a 
survival rate between 6-8 years in the majority of cases (Arko et al., 2010). 
The prognosis for higher grade gliomas is less ideal, where patients with anaplastic 
astrocytomas have a survival rate of 2-3 years following surgical and radiotherapy 
treatment, which may sometimes be combined with chemotherapy (Yoon et al., 2010). 
The most malignant grade of glioma; glioblastoma multiforme, has the least promising 
prognosis.  Aggressive treatment including maximal surgical resection and 
chemotherapy is often used in an attempt to prevent recurrence of the tumour after 
surgery, however, in the majority of cases patient survival in the UK even after 
aggressive treatment, is only 9 months (Alqallaf et al., 2014). 
1.1.2 Epidemiology  
 
In Europe, astrocytic tumours are the most common tumours of the CNS with an 
incidence rate of 4.8 per 100,000 of the population (Crocetti et al., 2012). Incidence 
and survival rates for glioma in the United Kingdom and Ireland are outlined in Table 
1.2. Between 2000 and 2002, the United Kingdom and Ireland had the highest 
incidence of astrocytic tumours in Europe with 5.1 cases per 100,000 of the population 
(Crocetti et al., 2012). The incidence of astrocytic tumours was higher in men than 
women and highest in individuals over the age of 60 years (Crocetti et al., 2012).  
Overall in Europe, five-year survival rates were slightly better for women than men; 
20.7% compared to 18.7% respectively (Crocetti et al., 2012). Again, the UK and Ireland 
had the lowest survival rates of Europe at 16.6%, however the poor incidence and 
survival rates could potentially be due to differences in diagnostic and treatment 
modalities (Crocetti et al., 2012).  
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Table 1.2: Incidence per 100,000 people and Survival of Glioma in UK and Ireland between 2000 - 2002, adapted 
from Crocetti et al., (2012). 
 
Glioma Type 
Incidence – Sex Incidence – Age Survival (%) 
Male Female 0-19 20-39 40-59 60+ 1 year 5 years 
Astrocytic 5.7 4.0 0.9 2.0 6.2 11.6 31 12 
Oligodendroglial 0.4 0.3 0.1 0.3 0.6 0.4 81 51 
Ependymal 0.2 0.2 0.2 0.2 0.2 0.2 91 78 
 
1.1.3 Symptoms and Diagnosis 
 
Symptoms of gliomas often consist of seizures caused by the compression of the cortex 
and headaches caused by intracranial pressure, which can also result in focal 
neurological deficits, including muscle weakness, numbness, or loss of coordination 
(Snyder et al., 1993). 
 
The main methods of diagnosing glioma are magnetic resonance imaging (MRI) and 
histology. MRI provides a detailed anatomical image of the neoplasm and surrounding 
structures. Histology is most often used to determine tumour grade and characteristics 
which is used to determine the most effective course of treatment to provide the best 
prognosis (Abrey and Mason, 2009).  In addition, perfusion MRI or magnetic resonance 
spectroscopy can provide information about tumour vascularity and changes in the 
normal pattern of biomolecular composition respectively (Abrey and Mason, 2009). 
For example, a computerized tomography (CT)-MRI scan can be useful when assessing 
oligodendrogliomas, which often contain deposits of calcium (calcification) and 
hyperostosis caused by invasion of glioma cells into bone in close proximity to the 
tumour (Marosi et al., 2008).  
1.1.4 Treatment of Glioma  
 
Current chemotherapeutic treatments are outlined in Table 1.3. Initial treatment for 
glioma entails resection of as much of the tumour as possible depending on the 
localisation. Functional MRI and diffusion tensor imaging sequences are used to 
visualise functional areas of the brain and intraoperative cortical and subcortical 
stimulation are used to monitor essential areas of the brain which must be avoided to 
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prevent permanent disability of the patient (Preusser et al., 2011). Resection of the 
tumour is often guided by the use of 5-aminolevulinic acid which is metabolised within 
the tumour and leads to the accumulation of fluorescent porphyrins. This allows visual 
identification of tumour margins and enables complete resection (Stummer et al., 
2006). Higher grades of glioma however are more difficult to remove surgically due to 
the infiltrative nature and cancerous cells often remain after surgical resection. 
Following resection, wafers comprising of the cytotoxic agent carmustine can be 
implanted. The use of biodegradable carmustine wafers allows localised treatment of 
the tumour for three weeks (Preusser et al., 2011). Guidelines by the National Institute 
for Health and Care excellence (NICE) recommend temozolomide (TMZ), an oral 
alkylating agent, for patients with newly diagnosed high-grade glioma, patients who 
undergo resection of 90 % of their tumour are recommended to receive carmustine 
implants.  
The main method of treatment for glioma, in particular glioblastoma, is the Stupp 
regimen which employs TMZ with concurrent radiotherapy followed by TMZ treatment 
alone (Stupp et al., 2005). TMZ is an alkylating agent which causes DNA mismatches 
and double strand breaks by alkylation of the O6-position of guanine. MGMT is capable 
of repairing the DNA damage caused by TMZ thereby reducing the chemotherapeutic 
effect of this drug. Hypermethylation of the MGMT promoter reduces its ability to 
repair DNA damage and patients with hypermethylated MGMT promoter respond 
better to treatment with alkylating agents (Von Deimling et al., 2011). MGMT status is 
determined clinically using methylation-specific PCR using primers for methylated and 
unmethylated CpG areas of the MGMT promoter region (Jansen et al., 2010).    
Patients were found to benefit from improved survival compared to those who 
received radiotherapy alone (Stupp et al., 2009) and as a result, newly diagnosed 
glioma patients are often prescribed this course of treatment. 
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Table 1.3 Current Treatments For Glioma 
Drug Mechanism of action and Limitations References 
Carmustine Alkylating agent- causes DNA methylation leading to 
disrupted mismatch repair, senescence and apoptosis. 
 
Papait et 
al., 2009 
 
Carboplatin Platinum compound – causes intrastrand and 
interstrand DNA crosslinks and DNA-protein adducts 
causing senescence and apoptosis. 
 
Samimi et 
al., 2004 
 
Cisplatin Platinum compound – forms DNA-cisplatin adducts 
leading to senescence and apoptosis. 
 
Samimi et 
al., 2004 
 
Temozolomide Alkylating agent- causes DNA methylation leading to 
disrupted mismatch repair, senescence and apoptosis. 
 
Papait et 
al., 2009 
 
Radiation Causes DNA damage, often used in combination with 
chemotherapeutics such as temozolomide to prevent 
development of secondary tumours. 
Kato, 2010 
 
 
1.1.5 Molecular Subtypes of Glioblastoma  
 
Genome-wide analysis has revealed glioblastoma to be a heterogeneous group of 
neoplasms comprising of subtypes which differ in genotypic and molecular alterations 
and subsequently clinical outcome (Dunn et al., 2012).  Analysis of sequencing data 
from The Cancer Genome Atlas (TCGA) identified four glioblastoma subtypes: classical, 
mesenchymal, proneural and neural (Verhaak et al., 2010).  The genetic aberrations 
associated with these subtypes are outlined in Table 1.4.  
The classical subtype exhibits both a gain of chromosome 7 and a loss of chromosome 
10, and for the majority of classical glioblastomas, an EGFR amplification. Although 
mutation of TP53 is prevalent in glioblastoma, it is not often observed in the classical 
subtype. The most common mutation of the mesenchymal subtype is NF1 gene 
deletion, point mutations or low levels of NF1 expression often combined with 
comutation of PTEN (Goodenberger and Jenkins, 2012). The neural subtype shares 
characteristics of the classical and proneural subtypes. Similar to classical 
glioblastomas, EGFR amplification is frequent in the neural subtype. Neural 
glioblastomas are classified by the expression of neuron marker genes not identified in 
any of the other subtypes including, NEFL, GABRA1 and SYT1.  The proneural subtype 
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exhibits point mutations in IDH1 and IDH2 as well as a high level of PDGFRA 
amplification. Proneural glioblastomas which do not display a mutation of PDGFRA 
often have P13K mutations (Goodenberger and Jenkins, 2012).   
Analysis of clinical characteristics of glioblastoma patients with differing subtypes 
showed that treatment efficacy of concurrent chemotherapy and radiotherapy was 
dependent on subtype, where patients with the classical and mesenchymal subtypes 
showed a reduction in mortality rates in comparison to patients with the proneural 
subtype in which no difference in survival was seen between treatment regimens. 
Patients with the neural subtype displayed a slight, but not significant, improvement in 
mortality (Verhaak et al., 2010).   
Table 1.4 Molecular Subtypes of Glioblastoma adapted from Verhaak et al, (2010) 
Subtype Aberrant Signalling 
Pathways 
Gene Type of Mutation 
Classical NES, Notch and Sonic 
hedgehog 
EGFR 
 
 
High level amplification/point 
mutation/ vIII EGFR mutation 
 
  CDKN2A 
 
Homozygous deletion 
  RB1 Homozygous deletion 
 
Mesenchymal AKT, NF-ĸB NF1 Hemizygous deletion 
 
Proneural  PDGFRA Focal amplification and high 
gene expression level 
  IDH1 Point mutation 
  TP53 Loss of heterozygosity 
 
Neural  EGFR Amplification 
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1.2 Biomarkers  
 
Biomarkers are defined as objectively measured characteristics within the body which 
are used to gain information about a particular disease (Pavlou et al., 2013). Due to the 
poor prognosis of glioma, early detection and effective treatment strategies for glioma 
patients are vital for improving clinical outcomes, and developing biomarkers for this 
purpose has long been an aim of research. In addition, biomarkers can provide an 
insight into the characteristics of the neoplasm. Biomarkers are either produced by the 
pathological processes of the tumour progression or by the host system in response to 
the tumour (Manne et al., 2005). As shown in Table 1.5, the information that 
biomarkers provide about cancer can be used to predict important factors such as 
prognosis (Lenos et al., 2012, Zougman et al., 2013) and response to therapy (Bauer et 
al., 2013), as well as to improve diagnosis (Qian et al., 2012) and to assist earlier 
detection (Manne et al., 2005). Biomarkers can also be used to differentiate between 
different tumour grades (Ludwig and Weinstein, 2005) and subtypes (Morrison et al., 
2012), both of which can be used to tailor treatment strategies.  
 
Current cancer biomarkers in clinical use are outlined in Table 1.5. Although these 
biomarkers are used for diagnosis and treatment, they lack sufficient sensitivity and 
specificity required for a successful biomarker (Diamandis, 2010). Current diagnostic 
biomarkers, such as prostate specific antigen (PSA), are subject to a high incidence of 
false positive diagnoses (Abu-Asab et al., 2011). Mucin-16, a serum based diagnostic 
marker of ovarian cancer, lacks sensitivity and specificity for early diagnosis because 
50% of patients in the early stages of ovarian cancer do not present with serum mucin-
16 expression (Chauhan et al., 2009). Alpha-fetoprotein and beta-human chorionic 
gonadotropin, both diagnostic markers for testicular cancer, are found to be up-
regulated in only 60% of patients therefore risking a false negative diagnosis (Favilla et 
al., 2010). The up-regulation of HER2 occurs in only 20 to 30% of breast tumours 
making it an effective biomarker for only a small population of patients (Lam et al., 
2013). There is need for biomarkers which can be identified in the majority of a patient 
population and with a greater sensitivity to reduce the risk of incorrect diagnosis.  
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Table 1.5 Current cancer biomarkers in use 
Biomarker 
Cancer Type Type of Biomarker Ref 
Prostate specific 
antigen (KLK3) 
Prostate Cancer Diagnostic (Abu-Asab et al., 
2011) 
Mucin-16 
Ovarian Cancer Diagnostic (Chauhan et al., 
2006) 
Alpha-fetoprotein 
(AFP) 
Testicular Cancer Diagnostic (Favilla et al., 
2010) 
Beta-human chorionic 
gonadotropin 
Testicular Cancer Diagnostic (Favilla et al., 
2010) 
Her-2 
Breast Cancer Prognostic and risk of 
recurrence 
(Lam et al., 2013) 
 
1.2.1 Current Biomarkers for Glioma  
 
Biomarkers currently used for glioma include O6-methylguanine-DNA-
methyltransferase (MGMT) promoter hypermethylation, combined loss of 
hetrozygosity (LOH) of chromosomes 1p and 19q, LOH of chromosome 10q, mutations 
of isocitrate dehydrogenases (IDH) and mutations of the epidermal growth factor 
receptor (EGFR). The main prognostic and predictive biomarker for glioma is MGMT, a 
DNA repair protein which catalyses the transfer of methyl groups from the O6-position 
of guanine to cysteine (Von Deimling et al., 2011). MGMT status is an important factor 
in the success of chemotherapeutic treatment with alkylating agents such as TMZ (Von 
Deimling et al., 2011).  
Mutations in the IDH genes occur mainly in low grade gliomas and secondary 
glioblastomas and are present in 50-80% of astrocytomas, oligodendrogliomas and 
oligoastrocytomas (Von Deimling et al., 2011). Mutations in IDH1 and IDH2 are rare in 
primary de novo glioblastomas and ependymal tumours and therefore provide a useful 
method of differential diagnosis (Von Deimling et al., 2011). Patients with IDH 
mutations often have a better prognosis than those without, however IDH mutations 
as prognostic biomarkers are still being defined (Foote et al., 2015). IDH1 mutations 
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can be identified using immunohistochemistry with an antibody for mutant Arg132His 
IDH1 protein (Jansen et al., 2010).  
In 60% of glioblastomas the epidermal growth factor receptor (EGFR) is overexpressed 
and in addition, is often mutated (Jansen et al., 2010). The most common EGFR 
mutation is EGFR variant III (EGFRvIII). EGFRvIII does not contain a ligand binding 
domain and as a consequence is constitutively activated causing continual activation of 
the EGFR-phospho-inositide 3-kinase pathway contributing to oncogenesis. 
Glioblastomas with the EGFRvIII mutation have been found to exhibit more aggressive 
characteristics and patients with this mutation may benefit from treatments which 
target EGFR (Jeuken et al., 2009).  EGFRvIII protein can be detected 
immunohistochemically using antibodies specific for this mutation and amplification of 
EGFR can be determined using fluorescent in situ hybridisation (FISH) (Jansen et al., 
2010). 
For patients with oligodendroglial tumours, co-deletion of the 1p and 19q 
chromosomal arms is a prognostic biomarker. Patients with this deletion have been 
found to display enhanced chemosensitivity and longer overall survival which has been 
attributed to mutations of tumour suppressor genes FUBP1 and CIC mutations in 1p 
and 19q respectively (Foote et al., 2015). Clinically, 1p/19q status can be determined 
using FISH or PCR-based LOH assays (Jansen et al., 2010).  
The difficulty in identifying a specific biomarker for glioma lies partly in the complex 
heterogeneous nature of the cancer itself. The multiple mutations a tumour cell 
undergoes during transformation and the frequency of genomic changes between 
grades, and sub-types within the grades all contribute to this heterogeneity. Using a 
group of biomarkers to detect a range of these characteristics or a set of related 
biomarkers for one specific characteristic is more beneficial than using a single 
biomarker. This has driven research to the identification of multiple biomarkers which 
could be used together in a panel (Tainsky, 2009). These panels could be detected 
using a range of readily accessible high-throughput techniques including qRT-PCR 
(Garcia-Bilbao et al., 2012, Urquidi et al., 2012) and ELISA (Barderas et al., 2012). One 
such family of molecules which promises increased sensitivity and specificity as a 
biomarker is microRNA (miRNA).  
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1.3 MicroRNAs 
1.3.1 MicroRNA Biogenesis and Function  
 
MiRNAs are small non-coding RNAs which are 22-25 nucleotides in length. MiRNAs 
regulate gene-expression at a post-transcriptional level by binding to mRNA. MiRNA 
function to regulate cell behaviour (Wang et al., 2011), and modulate gene expression 
at the post-transcriptional level, by binding to mRNA and suppressing translation 
(Baraniskin et al., 2012). 
 Since the discovery of the first miRNA in 1993 (Lee et al., 1993), the biogenesis and 
maturation of miRNA has been well researched (Graves and Zeng, 2012). To date 2,588 
human miRNA genes have been discovered, however the function of many of these 
has not yet been elucidated. Most miRNA genes are located within introns of both 
coding and non-coding transcripts, those that are located in the introns of protein-
coding genes share the promoter sequence (Ozsolak et al., 2008).  
The basic process of miRNA biogenesis involves transcription of the miRNA gene to 
produce a primary miRNA (pri-miRNA) which is processed into a stem-loop precursor 
miRNA (pre-miRNA). Cleavage of the pre-miRNA produces a miRNA duplex which is 
again cleaved into 5p and 3p mature miRNA strands, named in relation to the 
orientation of the seed sequence. The mature miRNA strand which is not subsequently 
incorporated into the RISC complex is labelled as miRNA* (Ha and Kim, 2014) (Figure 
1.1). 
MiRNAs are transcribed by RNA polymerase II producing a long hairpin primary miRNA 
(pri-miRNA) containing a stem-loop (Lee et al., 2002) (Figure 1.1).  The transcription of 
miRNAs is regulated by transcription factors and epigenetic mechanisms including DNA 
methylation (Saito et al., 2006) and histone modification (Scott et al., 2006). The stem-
loop of the pri-miRNA is cropped by a microprocessor complex, consisting of RNAse III 
Drosha and DGCR8, to create a smaller hairpin with a 3’ overhang known as a pre-
miRNA (Denli et al., 2004).  
Pre-miRNA is subsequently exported into the cytoplasm by a transport complex 
consisting of exportin 5, RAN·GTP and the pre-miRNA. Following transport GTP is 
hydrolysed, disassembling the complex and releasing the pre-miRNA into the cytosol 
(Bohnsack et al., 2004). Following translocation into the cytosol, the stem-loop of the 
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pre-miRNA is cleaved by Dicer which binds to the 3’ overhang produced by Drosha 
within the microprocessor complex, producing a small RNA duplex (Bernstein et al., 
2001).  
 
 
 
Figure 1.1 MiRNA Biogenesis Pathway. Cleavage and incorporation of miRNA and miRNA* into RISC complex. Pre-
miRNA is cleaved by DICER to produce a predominant mature strand and a complementary miRNA* strand, both of 
which can be incorporated into RISC and function as post-transcriptional regulators (Tumilson, 2015).  
 
The small RNA duplex is loaded onto an AGO protein to form the RNA-induced 
silencing complex (RISC) (Pratt and MacRae, 2009). The duplex consists of a guide 
strand and a passenger strand, following loading into RISC the duplex is unwound and 
removed leaving the guide strand (Kawamata and Tomari, 2010). The 5’ 
monophosphate of the guide strand is anchored to a 5’-phosphate-binding pocket 
within AGO and the 3’ end binds to the PAZ domain of the AGO protein (Schirle and 
MacRae, 2012).  The seed sequence of the guide strand has an A-form helix 
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conformation, a short compact helical structure with bases not perpendicular to the 
helix axis, which allows scanning of target mRNA for complementation and cleavage of 
target mRNA by the PIWI domain (Ha and Kim, 2014).  
Mature miRNAs which share 2-8 nucleotides are considered to be from the same 
family (Bartel, 2009). Some mature miRNAs are encoded by separate loci and are 
identified by numerical suffixes such as miR-92a-1 and 92a-2. MiRNA genes which 
share similar sequences are termed ‘miRNA sisters’, these miRNA may differ by only 
one or two nucleotides in their seed sequence and share common targets. Sister 
sequences are identified by lettered suffixes such as miR-181a and 181b. The small 
difference in seed sequence however, means that these miRNA may also target 
distinct mRNAs (Ha and Kim, 2014).   
1.3.2 MicroRNA Profiles in Glioma  
 
In 2005, the first miRNA profiles were obtained from a range of cancers using bead-
based flow cytometry. MiRNA expression profiles were found to differ across cancer 
types, but a general decrease in miRNA expression was observed in all samples (Lu et 
al., 2005). One explanation for this could be that exportin 5, necessary for 
translocation of pre-miRNA into the cytosol during maturation, is truncated in some 
tumours, and prevents transport of pre-miRNA from the nucleus resulting in a global 
reduction of mature miRNAs (Ha and Kim, 2014).  
Profiling was also able to discriminate between the developmental origin of samples 
(Lu et al., 2005). This could be particularly useful in metastatic cancers to determine 
the tissue of origin and location of the primary neoplasm (Rosenfeld et al., 2008). 
Different mutations within the same cancer type, demonstrated by differences in 
miRNA expression, were also observed within this study (Lu et al., 2005). These 
differences in expression have been linked to response to treatment and prognosis 
(Duffy et al., 2011), and to identify these mutations using specific miRNA profiles 
would permit better understanding of the tumour and enable improved treatment 
decisions and patient outcomes (Duffy et al., 2011).  
MiRNA signatures have been identified in both glioblastoma tissue and the circulation 
of glioblastoma patients. Recently, the employment of deep sequencing in which 
sequences are read multiple times to reduce errors in base calling, produced one of 
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the largest sets of miRNA profiles for glioblastoma and control brain tissue (Hua et al., 
2012b). This study identified 33 up-regulated miRNA in the glioblastoma tissue and 40 
down-regulated. In addition, 18 novel miRNA and 16 novel miRNA-3ps were identified 
(Table 1.6). Moreover, analysis of miRNA isoforms, termed ‘isomiRs’, identified 23 
miRNAs whose most abundant isomiRs were those with 5’ variations.   
 
Table 1.6 Novel miRNA-3p identified in glioblastoma and non-cancerous tissue, Hua et al. (2012b). 
Novel miRNA-3p Discovered 
miR-539 miR-758 
miR-382 miR-98 
miR-1307 miR-873 
miR-212 miR-135a-2 
miR-204 miR-511-1 
miR-301a miR-1271 
miR-181b-1 miR-381 
miR-3676 miR-487a 
 
Increasing the glioblastoma sample size by utilising multiple studies from public 
databases increases the statistical likelihood that the miRNA signature found will be 
clinically relevant. One such study from The Cancer Genome Atlas (TCGA) public 
repository analysed individuals with glioblastoma and identified an expression 
signature of ten miRNA which could be used to predict survival.  Three up-regulated 
miRNA - 20a, 106a and 17-5p, in the signature were associated with a better survival 
rate. The remaining seven - 31, 222, 148a, 221, 146b, 200b and 193a, were associated 
with poor survival. It was concluded that these miRNAs could also be used as 
therapeutic targets for the treatment of glioblastoma in addition to being used as 
prognostic markers (Srinivasan et al., 2011). Analysis of the TCGA data showed 19 
miRNA in glioblastoma with gender, race, therapy and recurrence dependent 
differences; including miR-222, 181, 34 and 140. These findings indicated a range of 
population variables which could affect miRNA expression and therefore biomarker 
panel selection. Taking these variables into account will increase the success of such 
panels as well as their specificity towards their intended populations (Delfino et al., 
2011).  
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As previously discussed in Section 1.1.6, glioblastoma consists of subclasses which vary 
in clinical and genetic characteristics, these subclasses can also be differentiated by 
miRNA signatures. Analysis of profiles from the TCGA identified five subclasses relating 
to neural precursor types. Identification of sample subclasses in a study could provide 
subtype specific miRNA biomarkers. Furthermore, additional information of patient 
characteristics within the subtypes such as age and response to treatment could be 
extrapolated to predict survival. MiRNA markers identified for these characteristics 
included miR-222 for gender, miR-137 as a race dependent marker and miR-140 as a 
marker for survival (Kim et al., 2011). Another study analysing the TCGA dataset has 
demonstrated this approach and identified subtype specific prognostic miRNA 
biomarkers which were subsequently validated using qRT-PCR. Each subtype displayed 
a panel of biomarkers which contained both positive and negative prognostic markers, 
some of which were shared by more than one subtype (Li et al., 2014). The classical 
subtype of GBM displayed seven prognostic miRNAs, five indicative of a poor prognosis 
– miR-26a, 767-3p, 153, 31, 222, and two indicative of a good prognosis – miR-654 and 
422b. Identification of a patient’s glioblastoma subtype will provide important 
information on response to treatment and prognosis as well as providing a diagnosis.  
The main appeal of miRNA biomarkers is the tissue and cell specificity of expression. 
For example, miR-10b is specifically expressed in glioma (Gabriely et al., 2011). MiR-
10b has been identified in both low and high grade glioma but is not present in non-
cancerous brain tissue. As well as demonstrating tissue specificity in expression 
profiles, miRNA are known to contribute to the progression of glioma. Through loss-of-
function studies, miR-10b was implicated in the regulation of glioma proliferation and 
apoptosis. In these studies, the overexpression of miR-10b caused the up-regulation of 
cell cycle regulators including cyclin B1 and D1. Up-regulation of miRNAs usually causes 
a down-regulation of direct miRNA targets rather than an up-regulation as observed in 
this study, which led to the suggestion that miR-10b promotes glioma cell growth by 
indirectly influencing cell cycle regulators (Gabriely et al., 2011) (Figure 1.2). The 
inhibition of miR-10b led to senescence, growth arrest and apoptosis, both in vitro and 
in vivo (Gabriely et al., 2011). The role of miRNA in glioma development and 
progression, and the tissue specificity, makes miRNA important candidate biomarkers 
that could provide important characteristic information of a tumour and improve 
treatment and prognosis.  
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1.3.3 Role of MicroRNAs in Glioma 
 
Research into the effect of dysregulated miRNA and the role in glioma progression has 
identified the importance of miRNA within pivotal signalling pathways. These signalling 
pathways are important when determining glioma characteristics which affect 
prognosis and treatment outcomes and provide potential targets for biomarker 
development. Understanding the role of miRNA in signalling pathways and how they 
affect progression permits the identification of miRNA biomarkers for specific 
purposes, for example diagnosis or treatment choice. This section outlines the role of 
miRNA in such pathways which affect glioma behaviour and contribute to a range of 
characteristics including migration, invasion and proliferation.  
Although miRNAs have different targets in different signalling pathways, their effects 
can all lead to one common tumour characteristic (Figure 1.2). For example, miR-23b, 
miR-130b and miR-107 regulate different signalling pathways but all contribute to 
invasion. This underlines the complexity and importance of miRNA in glioma biology 
and altered expression signatures could again provide important information 
characteristic of a particular tumour. A recent study into the role of miR-107 in glioma 
migration and invasion identified Notch2 as a key target (Chen et al., 2013). MiR-107 is 
down-regulated in glioma, and over-expression in glioma cell lines led to down-
regulation of Notch2, which controls a number of tumour characteristics including 
migration (Figure 1.2). The authors concluded that down-regulation of miR-107 in 
glioma promotes migration and invasion through Notch2 signalling pathways (Chen et 
al., 2013). A comparison of miRNA expression profiles in migratory glioblastoma cell 
lines identified miR-23b as a regulator of both migration and invasion when compared 
to migration restricted control cell lines (Loftus et al., 2012). MiR-23b down-regulation 
results in increased expression of the non-receptor tyrosine kinase Pyk2 which leads to 
cell migration and invasion (Figure 1.2). It was concluded that identifying miRNA 
important in regulating glioma invasion could provide targets for modulation to reduce 
invasion and improve treatment outcomes of glioma (Loftus et al., 2012).  MiR-23a 
shares sequence similarities to 23b and has been found to be regulated by cAMP 
response element-binding protein (CREB) and through increased expression promotes 
glioma cell growth and survival (Tan et al., 2012b) (Figure 1.2). An isoform of p63 
containing a transactivation domain known as TAp63 is known to be structurally and 
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functionally similar to the tumour suppressor protein p53. TAp63 has been identified 
as a tumour suppressor which represses metastasis. In a study involving both mouse 
and human tumour cell lines, Dicer and miR-130b were shown to be targets of TAp63. 
Binding of TAp63 to the Dicer promoter led to transcriptional activation. As well as 
regulation of Dicer, TAp63 was found to target miR-130b leading to its up-regulation 
and decrease in invasion (Figure 1.2). Inactivation of TAp63 led to increased metastasis 
and invasion (Su et al., 2010). 
Dysregulation of the transforming growth factor β (TGF-β)/smad pathway in high grade 
glioma is known to contribute to tumour progression (Song et al., 2012). MiR-182 has 
been shown as a target of TGF-β which, once activated, down-regulates the expression 
of NF-κB inhibitors (Figure 1.3). One such inhibitor is ubiquitin carboxyl-terminal 
hydrolase (CYLD) which is known to be expressed at a lower level in glioma. Although 
CYLD is down-regulated in glioma, CYLD mRNA levels do not alter, suggesting 
regulation by direct targeting by miR-182 (Song et al., 2012) (Figure 1.3).  NF-κB and 
the associated signalling pathways are constitutively activated in cancer including 
glioma, and contribute to tumorigenesis (Karin et al., 2002). The inhibition of the NF-κB 
negative feedback loop by over-expression of miR-30e-3p constitutively activates this 
signalling pathway in glioma (Jiang et al., 2012b) (Figure 1.2 and 1.3). Although further 
research is needed to elucidate the full function of miR-182 in this pathway, miR-182 
may also inhibit the negative feedback loop and either miRNA may function 
individually or together to sustain NF-κB signalling in cancer cells and tumorigenicity in 
glioma.   
To sustain hyperproliferation within a tumour, cells must adapt their metabolic 
pathways to utilise energy sources available to them both in hypoxic and normoxic 
conditions. MiR-451 has been found to regulate pathways involved in the adaptation 
of cancer cells to metabolic stress. MiR-451 is a regulator of the liver kinase B1/Amp 
activated protein kinase (LKB1/AMPK) signalling pathway. Down regulation of the 
pathway in the absence of glucose permits the activation of LKB1, allowing cancer cells 
to adapt to cellular stress by reducing proliferation and activating migratory processes 
(Godlewski et al., 2010). Furthermore down-regulation of miR-451 in glioblastoma 
patients is associated with reduced survival, providing a potential prognostic 
biomarker (Godlewski et al., 2010) (Figure 1.2).  
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1.3.4 MicroRNA Biogenesis and Glioma  
 
Research is beginning to identify new levels of complexity in miRNA regulation and 
current studies are showing that deregulation of biogenesis and maturation can also 
contribute to tumorigenesis.  The biogenesis of miRNA is known to be subject to 
regulation by RNA editing.  Pri-miRNA transcripts can undergo conversion of adenosine 
(A) to inosine (I) by adenosine deaminase acting on RNA (ADAR), known as A to I 
editing (Kawahara et al., 2008). A to I editing has been found to affect pri-miRNA 
processing and has been shown in some studies to result in a reduction in levels of 
mature miRNA (Yang et al., 2006). Alternatively, editing can also lead to the production 
of mature miRNA with altered sequences, known as ‘isomiRs’, which target different 
mRNA transcripts (Kawahara et al., 2008) and can contribute to tumour progression. 
 Evidence suggests that miRNA transcripts in glioma, particularly high-grade, undergo A 
to I editing as a result of dysfunctional ADARs (Galeano et al., 2012). Editing within the 
seed sequence can alter the target of a miRNA. This disrupts regulation of protein 
expression and contributes to progression (Galeano et al., 2012). On the other hand, 
lack of editing can also lead to altered gene and protein expression. One such study 
identified reduced editing of the miR-376 cluster in glioblastoma as a result of lower 
expression of ADAR and the isoform ADARB1. This caused accumulation of unedited 
miR-376a-3p transcripts and was shown to contribute to invasiveness and migration of 
glioma cells (Choudhury et al., 2012) (Figure 1.2). The low expression of ADAR could 
potentially affect other, currently unknown, targets which may also contribute to the 
progression of high grade glioma (Choudhury et al., 2012). Another source of 
alternative miRNA transcripts is the cleavage of miRNA duplexes during maturation. 
The duplexes are cleaved to produce a functional mature miRNA which is incorporated 
into the RISC and a miRNA* believed to be degraded following cleavage (Figure 1.1). 
One such study however, found that miRNA* transcripts are functional and capable of 
translational repression of mRNA targets, which could therefore have a notable effect 
in the pathology of disease (Yang et al., 2011). 
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Figure 1.2 Role of miRNAs in Glioma. Altered expression of miRNA affects a number of different targets which influence the same glioma characteristic (Tumilson et al., 2014). 
 
21 
 
 
Figure 1.3 Role of miR-30e* and 182 in TGF-β and NFĸB signaling contributing to glioma progression adapted from KEGG. Constitutive activation of the TGF-β/Smad pathway 
increase miR-182 expression. MiR-182 reduces inhibition of NF-κB intermediary signalling molecules by binding to CYLD mRNA causing increased activation of the pathway. MiR-30e* 
binds to IKβα mRNA preventing action of the negative feedback loop and again, increasing the activity of the NF-κB pathway, and thereby contributing to aggressiveness in glioma 
(Tumilson et al., 2014). 
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1.4 Circulating MicroRNA  
1.4.1 Exosome Packaging and Release 
 
To prevent degradation in the circulation, miRNA are released by cells in both 
exosomes and miRNA/protein complexes (Cortez et al., 2011). Exosomes are lipid 
vesicles ranging between 50-100 nm in size and contain a range of molecules including 
mRNA, miRNA, DNA and proteins (Hannafon and Ding, 2013). The detection of 
biomarkers within serum is attractive due to the relatively non-invasive process of 
collection (Yang et al., 2013a) and subsequent isolation of miRNA from the circulation 
is a convenient method for biomarker detection.  
Exosomes originate from multi-vesicular bodies (MVB) within the cell which fuse with 
the cell membrane through a secretion pathway involving Rab GTPases to release the 
exosomes into the extracellular environment (Trajkovic et al., 2008). Analysis of the 
lipid membranes of exosomes has shown them to be enriched in the sphingolipid 
ceramide suggesting it to be a pivotal component of exosome formation (Trajkovic et 
al., 2008). It has been shown that lipid-raft microdomains containing high levels of 
sphingomyelin promote the inward budding of MVBs following the production of 
ceramide from sphingomyelin, to form exosomes (Trajkovic et al., 2008). Silencing of 
two members of the Rab GTPase family, Rab27a and Rab27b, resulted in a reduction of 
MVB docking to the cell membrane in the HeLa cell line (Ostrowski et al., 2010), 
showing that Rab27a and Rab27b and the effector proteins can promote intracellular 
trafficking of MVBs and subsequent exosome secretion in certain instances. Further to 
this study, the authors investigated the function of Rab27a and Rab27b in in vivo 
murine breast carcinoma models. Although they found that Rab27a modulates 
exosome secretion as shown in the previous study, Rab27b on the other hand was not 
required for exosome secretion in the murine models. These findings suggest that MVB 
trafficking and secretion is a complex pathway which may not be identical across cell 
types and therefore must be further elucidated (Bobrie et al., 2012).   
Analyses of exosome composition have identified a number of different proteins, 
lipids, mRNAs and miRNAs which differ dependent on the cell type from which they 
are released and the physiological status of that cell (Hannafon and Ding, 2013). The 
most commonly identified proteins in exosomes, which seem to be present in most 
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exosomes regardless of the cell type of origin are membrane transport and fusion 
proteins, heat shock proteins, GTPases and MVB biogenesis proteins (Hannafon and 
Ding, 2013). Exosomes frequently contain lipids including cholesterol, sphingolipids 
and phospholipids (Hannafon and Ding, 2013). Commonly identified exosomal proteins 
and lipids are outlined in Table1.7.  
Table 1.7 Commonly found exosomal proteins and lipids 
Proteins Lipids  
Tetraspanins – CD9, CD63, CD81 Cholesterol  
Heat Shock proteins – Hspa8, Hsp90 Diglycerides 
GTPases – EEF1A1, EEF2 Sphingolipids 
MVB biogenesis protein – Alix  Phospolipids 
Cytoskeletal proteins – Actin, Syntenin, Moesin Glycerophospholipids 
Metabolic enzymes – GAPDH, LDHA, PGK1, Aldolase, PKM Polyglycerophospholipids 
Signal Transduction proteins – Annexin, 14-3-3ε  
Albumin   
 
1.4.2 Glioblastoma derived Exosomes  
 
Exosomes are known to be released by both non-cancerous and cancerous cells (Chen 
et al., 2012) as a form of cellular communication, and perform a variety of functions 
depending on the contents and cellular context. Exosomes originating from different 
cell types share a standard set of proteins including tetraspanins and heat shock 
proteins (Chen et al., 2012), as well as proteins specific to the cell of origin such as the 
tumour specific EGFRvIII (Skog et al., 2008). The abundance of circulatory exosomes 
has been shown to increase with tumour progression (Xiao et al., 2012). Although it is 
unclear how miRNA, mRNA and proteins are packaged into exosomes, research has 
shown that the packaging of exosomes is a specific and selective process (Chen et al., 
2012). Only certain miRNA are incorporated and released into the circulation due to 
the selectivity of exosome packaging. As a result, certain deregulated miRNA within 
glioma cells may not be present within isolated exosomes and therefore tissue 
biomarkers may not translate into circulatory biomarkers. This leads to the conclusion 
that miRNA signatures for tissue and circulatory biomarkers need to be investigated 
independently (Jarry et al., 2014).  
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Analysis of primary glioblastoma tissue and exosomes by qRT-PCR identified the 
presence of 11 miRNAs, including miR-21 in both sample types. These miRNAs were 
commonly up-regulated in glioma and present in the exosomes, albeit at a lower level 
than in the corresponding glioblastoma tissue, however there was a good correlation 
with the tissue profile leading to the conclusion that circulating exosomes could 
provide a ‘snapshot’ of the glioblastoma transcriptome (Skog et al., 2008). Over 28 
miRNAs, including miR-21, have been identified in exosomes from the U251 
glioblastoma cell line, and at least 22 were significantly enriched in exosomes isolated 
from culture media compared to cell line expression suggesting specific tumour 
modulatory roles (Li et al., 2013). Further to this, not only was there an enrichment of 
certain miRNAs, there was also a higher level of 9 miRNA* including miR-181a*, 93*, 
452* and 106a* compared to the mature miRNA form as well as an increase in 3p 
miRNA when the 5p form was also present. The authors concluded that this change in 
abundance of the less dominant miRNAs could result in different mRNA being targeted 
within recipient cells than those in the glioma cells. 
Compared to other biomarker types such as protein biomarkers, detection of a small 
panel of miRNA from the circulation using techniques such as qRT-PCR provides 
increased sensitivity. The starting concentration of total RNA required from biofluid 
samples for biomarker detection is relatively low, as little as 25 pg of RNA (Chen et al., 
2005). The selective packaging of miRNA into exosomes containing components 
indicating the cell of origin and the detection of tissue specific miRNAs in the 
circulation provides specificity for miRNA biomarkers. In addition the detection of 
more than one tissue specific miRNA provides the advantage of reducing overlap with 
other pathologies which may share deregulated miRNA biomarkers (Sheinerman and 
Umansky, 2013).  
Solexa sequencing of pooled sera identified a panel of seven down-regulated 
circulating miRNA which could be used as a signature for glioma (Yang et al., 2013a). 
The seven miRNAs which made up this panel included miR-15b*, miR-23a, miR-133a, 
miR-150*, miR-197, miR-497 and miR-548b-5p. In addition to this main panel, certain 
miRNA made up smaller groups which could be used to differentiate between benign 
and malignant astrocytomas, as well as other primary brain tumours (Yang et al., 
2013a). The expression of miR-15b*, miR-23a, miR-150*, miR-197, and miR-548b-5p 
25 
 
were significantly up-regulated in malignant neoplasms in comparison to benign 
samples.  
A less studied source of miRNA biomarkers is plasma, one such study showed the 
levels of certain miRNA including 21, 128 and 342-3p, were altered in the plasma of 
glioblastoma patients in comparison to non-cancerous plasma samples (Wang. et al., 
2012). This particular study used qRT-PCR to identify target miRNAs from individual 
plasma samples which could account for differences between the miRNAs identified in 
the seven miRNA panel, as well as other variables including a smaller sample size, 
different extraction and qRT-PCR reagents being used. This study not only identified 
potential miRNA biomarkers but also showed that isolation of miRNA need not be 
restricted to serum alone.  
Due to the close proximity of cerebrospinal fluid (CSF) to the brain and spinal cord, 
disorders arising in the CNS can often cause an alteration in CSF composition. The 
presence of a glioma within the CNS results in the alteration of CSF composition as a 
result of: humoral responses (Tainsky, 2009); breakdown of structures within the CSF 
such as the blood-brain barrier (BBB) (de Bont et al., 2006); or as a result of up-
regulated production and secretion by the glioma cells themselves (Niclou et al., 2010). 
Alternatively, the function of the structures related to CSF production and composition 
can become affected and subsequently contribute to pathophysiology (Tainsky, 2009). 
The role of CSF in the pathogenesis of glioma is mainly the delivery of substances that 
play a role in tumourigenesis. These substances include growth factors, hormones and 
signalling molecules, as well as many other components of CSF and are believed to 
contribute to a number of glioma characteristics such as invasion, migration and 
metastases (Tainsky, 2009). 
The presence of miRNA in the CSF of glioma patients has initiated studies into the 
potential of CSF as a source of biomarkers. Although CSF is not routinely obtained from 
patients with glioma (Baraniskin et al., 2012), the proximity of CSF to a glioma, and its 
isolation from general circulation, means it could provide a more specific and accurate 
miRNA profile in comparison to serum and plasma (Teplyuk et al., 2012). In 2012, the 
identification of miR-21 and 15b within the CSF of patients with malignant glioma was 
reported (Teplyuk et al., 2012). MiR-21 promotes migration and invasion by targeting 
MMP inhibitors RECK and TIMP3 (Gabriely et al., 2008), miR-15b is a cell cycle 
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regulator which targets CCNE1 (Xia et al., 2009) (Figure 1.2). This initial study 
highlighted CSF as a potential source for miRNA biomarkers and concluded that in the 
future, CSF miRNA could differentiate between glioma subtypes (Baraniskin et al., 
2012). Following this, a pilot study (Teplyuk et al., 2012) identified miRNA which could 
potentially be used to diagnose glioblastoma or discriminate between glioblastoma 
and metastatic cancer, once again highlighting the potential of cerebrospinal fluid as a 
source of biomarkers for glioma. Both studies highlighted miR-21 in the CSF of 
glioblastoma patients but the latter study also found miR-10b significantly up-
regulated. Furthermore, members of the miR-200 family, which share the same seed 
sequence to each other, were up-regulated in the CSF of patients with brain 
metastasis. A member of the miR-200 family, miR-200b targeted CREB1 and regulated 
glioma growth thereby acting as a tumour suppressor (Figure 1.2) (Peng et al., 2013).  
Table 1.8 outlines deregulated miRNAs in glioma, sample types they have been 
identified in and the target signalling pathways.                                                      
27 
 
Table 1.8 Deregulated microRNAs from different sample types in glioma and their corresponding signalling pathway 
MicroRNA Up/Down 
regulation 
Targets/Signalling Pathway Sample Type References 
10b Up BCL2L11/Bim, CDKN1A/p21, 
CDKN2A/p16 
Tissue, cell lines, CSF (Gabriely et al., 2011, Teplyuk et al., 
2012) 
15b* Down - Serum (Yang et al., 2013a) 
15b Up CCNE1 CSF (Baraniskin et al., 2012) 
17-5p Up Cyclin D1 Tissue (Srinivasan et al., 2011) 
20a Up E2F1, Cyclin D1 Tissue (Srinivasan et al., 2011) 
21 Up PI3k/Akt Tissue, serum, plasma, CSF (Baraniskin et al., 2012) 
23b Down Pyk2 Cell lines (Loftus et al., 2012) 
23a Down IL6R Serum (Yang et al., 2013a) 
30e-3p Up NF-κB Tissue, cell lines, primary 
culture 
(Jiang et al., 2012b) 
31 Down FIH Tissue (Srinivasan et al., 2011) 
106a Up FASTK Tissue (Srinivasan et al., 2011) 
107 Down Notch2 Tissue, cell lines (Chen et al., 2013) 
128 Down E2F3a Plasma (Wang. et al., 2012) 
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133a Down CAV1, LIM, LASP1 Serum (Yang et al., 2013a) 
146b Down MMP Tissue (Srinivasan et al., 2011) 
148a Down DNMT1 Tissue (Srinivasan et al., 2011) 
150* Down - Serum (Yang et al., 2013a) 
182 Up TGFβ/smad,  NF-κB Tissue, cell lines, primary 
culture 
(Song et al., 2012) 
193a Down Mcl-1 Tissue (Srinivasan et al., 2011) 
197 Down Fus1 Serum (Yang et al., 2013a) 
200b Down RND3 Tissue (Srinivasan et al., 2011) 
221 Down PTEN, p27 and p57 Tissue (Srinivasan et al., 2011) 
222 Down PTEN, p27 and p57 Tissue (Srinivasan et al., 2011) 
342-3p Down BMP7 Plasma (Wang. et al., 2012) 
451 Down LKB1/AMPK Cell lines (Godlewski et al., 2010) 
497 Down BCL2 Serum (Yang et al., 2013a) 
548b-5p Down PTEN, CDK6 Serum (Yang et al., 2013a) 
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1.4.3 Uptake of Exosomes by Recipient Cells 
 
 Tumour derived exosomes have the ability to transfer their contents to recipient cells 
and promote angiogenesis and metastasis. It is believed that there may be a number of 
mechanisms of exosome uptake, which could be dependent on the target cell, 
however this remains to be elucidated (Svensson et al., 2013).  Recently, uptake of 
exosomes originating from GBM cells has been shown to occur by non-clathrin 
dependent, lipid raft-mediated endocytosis and ERK1/2-HSP27 signalling (Svensson et 
al., 2013). Further to this, heparan sulfate proteoglycans (HSPGs) have been shown to 
play a role in mediating the uptake of exosomes by recipient cells. The binding of 
exosomes to HSPGs induces activation of the ERK1/2 signalling and subsequent uptake 
(Christianson et al., 2013).  Malignant tumours are often characterised by an acidic 
microenvironment and it has been suggested that the low pH of the tumour 
microenvironment may promote both the release and uptake of exosomes (Parolini et 
al., 2009). An acidic microenvironment influences membrane rigidity of exosomes and 
increases fusion capacity with recipient cells. The increased fusion capacity of 
exosomes in a low pH is believed to be a result of the increased formation of lipid rafts 
in the exosome membrane, which modulate the efficiency of membrane fusion 
(Parolini et al., 2009). The increased ability of exosomes to fuse with recipient cells in 
an acidic environment suggests that exosome trafficking occurs more frequently within 
tumours compared to non-cancerous tissues (Parolini et al., 2009).    
1.5 MicroRNAs as Biomarkers 
1.5.1 MicroRNA Biomarkers for Diagnosis and Prognosis  
 
The diagnosis of glioma is currently performed by MRI and subsequent histological 
examination of tumour sections which are obtained by surgery. Therefore the 
development of a non-invasive test for glioma diagnosis would be highly beneficial to 
patients and would potentially allow early diagnosis. Circulating miRNA could provide a 
minimally invasive diagnostic tool however the main focus of research has been on 
miRNAs for the prediction of prognosis and response to therapy. One study which 
investigated circulating miRNAs for the diagnosis of glioma was Manterola et. al. 
(2014) who identified a signature comprising of two miRNA; miR-320 and miR-574-3p, 
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and one small non-coding RNA, RNU6-1 which were significantly associated with GBM 
diagnosis. This signature was identified by the isolation of microvesicles from the 
serum of patients and subsequent profiling using qRT-PCR and the signature was 
validated using a second independent cohort of patients (Manterola et al., 2014).  MiR-
125b has also been identified as a potential diagnostic biomarker for glioma, analysis 
of serum samples obtained from patients using qRT-PCR identified down-regulation of 
miR-125b compared to control samples (Wei et al., 2014). Analysis of the diagnostic 
accuracy of miR-125b identified a sensitivity of 82 % for detection of glioma grades II-
IV (Wei et al., 2014).   
Evaluation of the miR-29 family, miR-29a, miR-29b and miR-29c, in the serum of glioma 
patients identified that this family of miRNAs had good sensitivity and specificity for 
the diagnosis of high-grade glioma (Wu et al., 2014). Serum samples from high-grade 
and low-grade glioma patients were analysed using qRT-PCR and the miR-29 family 
was found to be down-regulated in both high and low-grade glioma serum, with a 
greater down-regulation observed in high-grade samples (Wu et al., 2014). The authors 
concluded however, that the miR-29 family may not have sufficient sensitivity to 
detect early-stage glioma but could be useful in the identification of glioma 
progression (Wu et al., 2014).  
A number of studies have identified miRNAs within tumour tissue for predicting the 
prognosis of glioma patients. Some miRNAs identified as prognostic biomarkers are 
outlined in Table 1.9. One such study identified miRNA expression patterns which 
could be used to identify subgroups of glioblastoma patients with differing prognosis 
(Niyazi et al., 2011). Tissue sections obtained from glioblastoma patients were 
analysed using microarray and identified two differing expression patterns of 30 
miRNA which was used to group patients into ‘long-term’ or ‘short-term’ survivors 
(Niyazi et al., 2011). This study, however was limited by the small sample size of 
patients and was retrospectively performed.  
Analysis of serum from astrocytoma patients identified three serum miRNAs; miR-19a-
3p, miR-106a-5p and miR-181b-5p, which were significantly correlated with survival 
(Zhi et al., 2014). Patients with an up-regulation of these three miRNAs exhibited a 
poorer survival rate than those with a down-regulation (Zhi et al., 2014).  
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Table 1.9 Prognostic miRNAs and miRNA signatures identified in serum and tissue samples from glioblastoma.   
MiRNA Source Expression Prognosis Reference 
miR-124 Frozen tissue Down-regulation Poor (Chen et al., 2015) 
miR-155 Frozen tissue Up-regulation Poor (Sun et al., 2014) 
30 miRNA 
signature 
FFPE tissue 
sections 
Up and down-
regulation 
Long-term and 
short-term 
survival 
(Niyazi et al., 
2011) 
miR-335 Frozen tissue Up-regulation Poor (Jiang et al., 
2012a) 
miR-196a, 
miR-196b 
Frozen tissue Up-regulation Poor (Guan et al., 2010) 
Ten miRNA 
signature 
TCGA dataset Seven up-
regulated, three 
down-regulated 
Good and poor 
prognosis 
(Srinivasan et al., 
2011) 
Six miRNA 
signature  
FFPE tissue  Up and down-
regulation  
Good and poor 
prognosis  
(Sana et al., 2014) 
Six miRNA 
signature  
Frozen tissue  Up and down-
regulation  
Good and poor 
prognosis  
(Barbano et al., 
2014) 
miR-19a-3p, 
miR-106a-5p, 
miR-181b-5p 
Serum  Up-regulation  Poor Prognosis  (Zhi et al., 2014) 
 
1.5.3 MicroRNA biomarkers for response to therapy 
 
In the treatment of glioma, chemoresistance can be a pivotal factor in the prognosis of 
a patient. The ability to predict response to treatment could improve prognosis by 
selecting the right treatment course as soon after diagnosis as possible and permit 
rapid adaption of treatment to the acquisition of chemotherapeutic and radio-
resistance. This not only benefits the patient by improving their prognosis but also 
improves the cost-effectiveness of chemotherapeutics by using them only when they 
are expected to succeed. Furthermore, the use of predictive biomarkers in clinical 
trials could identify patients most likely to respond to new anti-cancer therapies, 
thereby accelerating the development of novel therapeutics (Carden et al., 2010). 
Currently, the gold standard for glioblastoma treatment is TMZ usually combined with 
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radiotherapy. Only a small subset of patients respond to TMZ treatment, as patients 
with the functional O6-methyl guanine methyltransferase (MGMT) DNA repair protein 
reverse the guanine methylation caused by TMZ leading to chemoresistance and 
limited success of this drug (Zhang et al., 2012). MiR-181d could be used as a 
biomarker to identify patients who would respond the best to TMZ, because MGMT is 
a candidate target of miR-181d, and a higher expression of miR-181d correlates with a 
lower expression of MGMT and subsequently improved response to TMZ (Zhang et al., 
2012).  
 
Whilst miR-181d up-regulation may correspond to a better response to TMZ, up-
regulation of miR-21 on the other hand, may predict poor response linked to the high 
rate of TMZ resistance which develops in patients. MiR-21 is one of the most 
frequently up-regulated miRNAs in glioblastoma and has been found to protect 
U87MG glioblastoma cells from TMZ-induced apoptosis (Shi et al., 2010). Inhibition of 
miR-21 in the resistant D54MG cell line enhanced chemosensitivity to TMZ (Wong et 
al., 2012). Both of these findings suggest that miR-21 could be used as a biomarker to 
predict or monitor the acquisition TMZ resistance in glioblastoma patients to enable 
quick adaptation in treatment strategy and maintain a good prognosis. Further to the 
role as a chemotherapeutic marker, miR-21 has also been shown to function in the 
acquisition of radio-resistance. Analysis of radio-resistance in a number of 
glioblastoma cell lines including U87MG and U373 showed that radio-sensitivity was 
closely related to the expression level of miR-21 (Gwak et al., 2012). The silencing of 
miR-21, using anti-miR-21 in radio-resistant malignant glioma cell lines led to the 
sensitisation of these cells to radiation (Gwak et al., 2012). Anti-miR-21 was found to 
sensitise U87MG and U373 cells through inactivation of the PI3K/Akt signalling 
pathway. Whilst these findings point towards a mechanism of acquired radio-
resistance, they also highlight miR-21 levels could be an important predictor of 
acquired radio-resistance which if monitored would permit quick adaptation of 
treatment plans and effective treatment of the glioblastoma as it progresses.  
 
As well as affecting TMZ and radio-resistance miRNA 21 along with miR-30b and 30c 
have been identified as regulators of TNF-related apoptosis-inducing ligand (TRAIL) 
induced apoptosis. These three miRNAs therefore, could affect the sensitivity of glioma 
cells to treatment with the TRAIL ligand (Quintavalle et al., 2012). A study of glioma cell 
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lines and primary cultures found that miRNA-21, 30b and 30c were significantly up-
regulated in TRAIL-resistant glioma cell lines (Quintavalle et al., 2012). Consequently 
TRAIL-sensitive cells were found to exhibit down-regulation of these three miRNA. The 
targets of these miRNA were found to include caspase-3 by the miR-30 family and 
Tap63 by miR-21. It was concluded that these miRNA regulate apoptotic programs 
within glioma cell lines. The results obtained also demonstrated a difference in miRNA 
expression between TRAIL sensitive and resistant cells (Quintavalle et al., 2012). These 
miRNA biomarkers for response to treatment and therapeutic resistance are outlined 
in Table 1.10.  
 
Table 1.10 MicroRNA Biomarkers for Response to Therapy 
 
 
 
 
 
 
 
 
 
 
 
1.6 Challenges in biomarker discovery 
 
Although miRNA appear to be extremely promising biomarkers and research into the 
identification of miRNA biomarkers for cancer remains on the increase, to date, there 
are no clinically utilised miRNA biomarkers for glioma. On-going clinical studies 
investigating miRNA profiles for a number of cancers have been outlined in a previous 
review (Nana-Sinkam and Croce, 2013). Researchers believe that the lack of clinical 
miRNA biomarkers compared to the number identified in research, is due to limitations 
in standardising of sample type collection (Git et al., 2010), determining optimal 
MiRNA Therapeutic Response 
MiR-181d 
 
Temozolomide resistance  
MiR-21 Temozolomide resistance, TRAIL resistance, Radio-
resistance 
MiR-30b 
 
TRAIL resistance 
MiR-30c  
 
TRAIL resistance  
MiR-425-5p Radiochemotherapy response  
 
MiR-93-5p Radiochemotherapy response  
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methods of extraction, and processing of both samples (McDonald et al., 2011) and 
data (Qureshi and Sacan, 2013), all of which can affect the reproducibility of individual 
findings.  
The choice of sample type, and the origin of miRNA, can be a limitation in biomarker 
discovery. An analysis of circulating miRNA isolated from plasma samples identified 
miRNA of hematopoietic cell origin. The presence of these miRNA in plasma samples is 
a pre-analytical variable which could affect the analysis of circulating miRNA 
expression. The employment of sub-fractionation to remove cellular miRNA improves 
specificity of circulating miRNA markers. The use of miRNA categories for the 
classification of circulating and cellular miRNA in plasma samples was proposed as a 
method that could improve miRNA biomarker studies (Duttagupta et al., 2011). The 
expression of specific miRNAs can differ between sample types used in studies (Wang. 
et al., 2012). Whilst miR-15b did not appear to be significantly dysregulated in a study 
using plasma samples, a significant increase in miR-15b levels in CSF samples has been 
reported (Baraniskin et al., 2012).  
Initial collection of sample biofluids must also be taken into account as there are 
variables in this process that may also affect miRNA data. Differences in collection tube 
type and phlebotomy techniques have both been suggested as factors which may 
cause variability in circulating miRNA expression. Hemolysis of the sample can increase 
the abundance of certain miRNA in biofluid samples which can subsequently affect 
biomarker selection (McDonald et al., 2011) therefore effective removal of cells is 
essential when using plasma and serum samples for biomarker detection. In addition 
to cells, other components of serum and plasma which are present in high levels, such 
as lipids and proteins, can affect the isolation of the RNA (Zampetaki and Mayr, 2012).    
Although tumour cells are known to shed exosomes, non-neoplastic cells and platelets 
also release exosomes. Serum isolated exosomes were used to identify mRNA 
expression patterns in glioblastoma patients (Noerholm et al., 2012). When compared 
with control serum samples, the expression patterns of mRNA within the exosomes 
could differentiate between those patients with glioblastoma and those without, 
however, the down-regulation of mRNA in serum exosomes could either be due to 
tumour exosomes, or from exosomes with an altered expression due to disease states 
and lifestyle from non-cancerous cells (Noerholm et al., 2012). Like mRNA expression, 
35 
 
the release of miRNAs from non-neoplastic cells must be taken into account in 
circulating miRNA expression studies for the identification of biomarkers (Pritchard et 
al., 2012b). 
The tissue and cell specificity of miRNA and individual variations due to diet, disease, 
infection or even age and gender, could potentially affect the detection of circulating 
miRNA biomarkers. One such review illustrated the influence of a number of 
environmental factors including diet, infection and stress on epigenetic mechanisms 
including microRNA expression (Mathers et al., 2010). Although the focus was the 
effect of these factors on cancer susceptibility, it also shows that inter-individual 
variations in lifestyle can affect the expression of miRNA which could subsequently 
affect the detection and use of miRNAs as biomarkers. The analysis of gene expression 
in the peripheral blood of healthy subjects also demonstrated inter-individual 
variability depending on the ratio of different blood subsets, age, gender and even the 
time of day when the blood sample was collected (Whitney et al., 2003). This has an 
important meaning for the identification of circulating biomarkers from blood samples 
as inter-variation in both cancerous and control sample sets may alter the miRNA 
levels within samples. Subsequently selection of a miRNA biomarker deregulated as a 
result of the glioblastoma and not of any other factor becomes difficult and accurate 
patient information capturing this data needs to be recorded in public miRNA 
databases.  
 
The presence of other diseases or infections, which is likely in older patients, could also 
skew data toward deregulated miRNAs as a result of an unrelated pathology leading to 
the failure of that miRNA biomarker in further studies.  MiRNA expression and levels 
are also subject to change following therapeutic treatment (Summerer et al., 2013). 
MiR-425-5p and 93-5p abundance alters in response to radiochemotherapy in head 
and neck squamous cell carcinoma patients and could be used as a biomarker to 
monitor response to treatment. At the same time this study illustrates the importance 
of knowing the origin of samples used in studies and any treatment undertaken before 
collection of the sample. Ideally, samples for use in biomarker identification studies, 
particularly for diagnostic markers, should be taken before any treatment or surgery to 
ensure any candidate miRNAs are up-regulated as a result of the glioblastoma and not 
the response of the tumour to treatment. In addition, this further highlights the need 
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to analyse data subsets where patterns of miRNA profiles can be extrapolated from 
patients grouped depending on age, gender, sampling time, treatment and other 
variables.  
The methods of isolating and measuring miRNA expression employed in a study can 
also affect the identification of miRNA biomarkers and cause variability between 
studies. A comparison of two RNA isolation methods and their effect on serum 
microarray expression analysis identified differences in miRNA expression between the 
two methods. Overall, a higher expression of miRNA was observed when using a total 
RNA isolation method (guanidine isothiocyanate) compared to a silica-gel column 
based method for isolating small RNA alone (Podolska et al., 2011). It was concluded in 
the latter that the high lipid content of serum samples affected the isolation of RNA. 
The total RNA isolation method removes lipids from the sample before isolation and 
therefore provides a better recovery of RNA (Podolska et al., 2011). Following 
isolation, miRNA expression is frequently determined using microarray and qRT-PCR 
methods. The data produced from these methods requires an endogenous candidate 
ubiquitously expressed across all samples for normalization (Peltier and Latham, 2008). 
For serum and plasma samples, there have been no significant endogenous control 
established for use in normalisation (Mitchell et al., 2008).  As a result, researchers use 
a number of different methods such as mathematical models or synthetic miRNA 
spike-ins, to normalise their data. While this permits research into circulating miRNA to 
be performed, the resulting data from different studies is often incomparable and not 
reproducible contributing to the failure of these biomarkers to reach clinical trials. 
Standardisation of methods for extraction and data analysis would therefore improve 
the reproducibility of biomarker research and speed the discovery of a clinically 
effective biomarker panel. 
There is a need for standardisation of isolation and analysis techniques to improve the 
reliability of candidate miRNA biomarker data. A large scale multi-centre study into the 
optimal techniques and protocols for miRNA biomarker discovery from a range of 
sample types including tissues and biofluids would provide data which could be used 
to reach a consensus on standard techniques to be used by all researchers. This would 
subsequently improve the success of miRNA biomarkers for all disease states including 
glioma. Conducting a study to identify miRNA biomarkers from biofluids must be 
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strictly regulated throughout the whole process from patient selection and sample 
collection through to processing and analysis. Stringent guidelines to minimise 
variability in patient cohorts, and validate the source of miRNAs, normalisation 
methods and good experimental design should be agreed upon to ensure 
reproducibility of data and the efficacy of these markers during further studies and 
clinical trials.  
1.7 Aims  
 
Glioblastoma is a highly malignant tumour with a poor prognosis despite aggressive 
treatment. Therefore the need for new, sensitive diagnostic and prognostic biomarkers 
is essential for early detection and selection of the most appropriate treatment regime 
to improve patient outlook. The global aim of this study is to identify diagnostic and 
prognostic miRNA biomarkers in the serum of glioblastoma patients. Current research 
investigating miRNA biomarkers for glioblastoma patients often does not account for 
age and gender variables in miRNA expression therefore this study aimed to identify 
miRNA biomarkers which may be gender or age specific to provide more accurate 
biomarkers.  
Following a review of the literature it was found that biofluids were the most attractive 
sample for non-invasive analysis of circulatory biomarkers for early diagnosis of GBM 
and prediction of prognosis. Gaps in current miRNA research include whether GBM 
tissue miRNA biomarkers translate into circulatory biomarkers and conversely, 
whether uptake of circulating exosomes containing miRNA can alter intracellular 
glioma and miRNA expression and subsequent extracellular release.  
 
The first aim was to identify the effect of serum on intracellular miRNA expression and 
miRNA released by glioma or glial cells. This was achieved by developing an in vitro cell 
culture model to investigate miRNA expression utilising human serum, U87MG 
(glioma) and SVGp12 (non-cancerous, glial) cell lines to 1) define miRNA expression in 
the respective cell lines and 2) to determine the influence of serum type (Foetal bovine 
serum and human serum (from glioma patients or controls)) on cell behaviour and 
intracellular glioma/glial miRNA expression and miRNA released by cells into the 
media. 
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The second aim was to identify miRNAs with altered expression in the serum of 
glioblastoma patients and investigate the use of these miRNA as biomarkers. Initial 
studies determined the miRNA expression profile of glioblastoma patients grouped by 
gender and age: 20-39, 40-59 and 60+. Dysregulated miRNAs identified from profiling 
were validated in larger patient cohorts and survival data was utilised to investigate 
identified miRNAs as prognostic biomarkers. To address some of the pre-analytical 
challenges outlined in Section 1.6 serum samples utilised in this thesis were obtained 
pre-operatively before treatment was begun and samples were initially centrifuged 
prior to homogenisation in the total RNA extraction protocol to ensure the removal of 
contaminants such as lipids and polysaccharides.  
The final aim was to identify whether dysregulated miRNAs in the serum originated 
from the glioblastoma tissue or from an alternative source such as leukocytes as part 
of an immune response. miRNA profiles of glioblastoma patient tissue and miRNA 
tissue data from TCGA were compared to serum miRNA expression data obtained in 
Chapter 4 to determine any differences in expression which might suggest an 
alternative source of the serum miRNAs than the glioblastoma. Further investigation of 
miRNA origin was performed in Chapter 5 using In situ hybridisation (ISH) with tissue 
sections selected from patients whose serum was used in Chapter 4. ISH data was 
compared with matched serum and tissue miRNA expression data to determine 
whether miRNA expression was significantly different across these three sample types.    
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
 
 
 
 
 
2. Materials and Methods 
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2.1 Patient Samples  
 
Human tissue, whole blood, serum and cerebrospinal fluid samples were obtained 
from the Brain Tumour North West tissue bank, Royal Preston Hospital. NHS ethical 
approval was obtained for the collection and storage of patient samples by Brain 
Tumour North West (REC Ref: 09/H0304/88). BTNW Tissue Bank approval and 
university ethical approval was obtained for the use of the patient samples in this 
study (Appendix 1). All patients provided written informed consent for the storage and 
use of their biological samples for research.   
2.2 Culture of Immortalised Cell Lines 
 
U87MG (human grade IV Glioblastoma) and SVGp12 (human non-cancerous foetal 
astrocytes) were obtained from the European Collection of Cell Cultures (ECACC: HPA, 
Salisbury, UK) and maintained in T75 flasks (Corning, Flintshire, UK) with 10 ml Eagle’s 
minimal essential medium (EMEM, Lonza, Slough, UK), supplemented with 2mM L-
Glutamine (Sigma-Aldrich, Dorset, UK) and 10 % foetal bovine serum (FBS) (Biosera, 
East Sussex, UK) for both cell lines. Cells were incubated at 37 ᵒC in 5 % CO2 and 
passaged at 70 % confluency.   
To passage the cells at a ratio of 1:2, medium was aspirated and cells washed with 0.1 
M phosphate buffered saline pH 7.4 (PBS, Life Technologies, Paisley, UK), the PBS was 
then aspirated and  1 X trypsin-EDTA (Sigma-Aldrich, Dorset, UK)  added and incubated 
with the cells for 5 minutes. After incubation, an equivalent volume of medium was 
added to the detached cells and transferred to new flasks containing EMEM.  
2.2.1 Cell Count and Trypan Blue Assay  
 
Trypan blue is a dye which is able to permeate necrotic and apoptotic cells while being 
excluded by live cells {Strober, 2001 #653}. This improves the accuracy of cell counting 
as it ensures only viable cells are included. Briefly, cell suspensions were diluted 1:10 
with trypan blue, and the cell suspension was then placed onto the haemocytometer 
and the count performed. Cells containing the blue dye were not counted. The cells 
within five 4x4 squares were counted excluding any cells which lay across the outer 
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lines of the 4x4 square. An average of the cell counts for each 4x4 square was 
calculated then multiplied by 10 to determine the number of cells x 104/mL.  
2.2.2 Standard Growth Curves  
 
Growth curves for each cell line used were performed in 24 well plates to ensure that 
all subsequent experiments were performed in the logarithmic phase of growth. Cells 
were seeded at a density of 2 x 103/mL per well and incubated at 37 °C in 5 % CO2. 
Cells were trypsinised and counted using the trypan blue exclusion method {Strober, 
2001 #653} in triplicate each day over a seven day period. The growth curve was 
plotted and the lag and exponential phase were determined for each cell line, to 
determine the optimal seeding density for the serum replacement cultures.  
2.2.3 Weaning of Cell Lines onto Replacement Serum 
 
Serum from patients was obtained from the Brain Tumour North West (BTNW) tissue 
bank, Royal Preston Hospital. Local (Ref STEM041) and NHS ethical approval via BTNW 
tissue bank approval (Ref 1206) and informed patient consent was obtained for the 
use of patient serum samples.  Cells were weaned gradually to allow acclimatisation to 
a new serum type and to minimise stress (van der Valk et al., 2010). Cells were 
cultured in T25 flasks initially with a concentration of 2 % human serum and 8 % FBS. 
After 48 hours of incubation the concentration of human serum was increased in 
increments of 5 %, 7 % and 10 %. At the same time the concentration of FBS was 
decreased to 5 %, 3 % and 0 %, thus the total concentration of serum in the medium 
was maintained at 10 %. For the serum free medium condition, cells were cultured in 
25 % serum free medium and 75 % standard culture medium. The concentration of 
serum free medium was increased to 50 %, 75 % and 100 % at 48 hour intervals.  
2.2.4 Serum Replacement Method I – Investigation of Morphological Changes 
 
To determine the response of cell lines to serum replacement in terms of changes in 
morpohology, cells were cultured in T25 flasks and weaned off 10 % FBS and onto one 
of three conditions; 1) 10 % human serum from a pool of glioma patients (BTNW, Royal 
Preston Hospital), 2) a pool of 10 % non-cancerous human serum (BTNW, Royal 
Preston Hospital) or 3) 100 % serum free medium, a low protein, serum and animal 
product free substitute (Sigma-Aldrich, Dorset, UK). Samples from three patients of 
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each sex were obtained and pooled (Table 2.1).  Weaning was performed in triplicate 
and three biological repeats were carried out.  
Table 2.1 Serum pools of patients used in each biological repeat 
Pool Age Sex Diagnosis 
1 60+ Male Glioblastoma 
2 60+ Female Glioblastoma 
3 60+ Male Non-Cancerous 
4 60+ Female Non-Cancerous 
 
2.2.5 Serum Replacement Method II – Investigation of Changes in Phenotype  
 
To determine phenotypic changes in the cell lines following serum replacement, 
U87MG and SVGp12 cells were seeded at a density of 1 x 103 in BD Falcon 8 well 
chamber slides (BD Biosciences, Oxford, UK). Four wells contained medium with 
human serum from glioma patients and four wells contained medium with FBS as a 
control.  For each serum weaning experiment, cells were seeded in wells in triplicate, 
initially with a concentration of 2 % human serum and 8 % FBS. After 48 hours 
incubation the concentration of human serum was increased in increments of 5 %, 7 % 
and 10 %. At the same time the concentration of FBS was decreased to 5 %, 3 % and 0 
%.   
2.2.6 Serum Replacement Method III – Investigation of MicroRNA Expression  
 
To determine the changes in miRNA expression in response to serum replacement, 
cells were seeded at 2 x 104 cells in 96 well plates. After 24 hours incubation to allow 
the cells to attach, weaning was started and the medium was replaced with a 
concentration of 2 % human serum and 8 % FBS. The cells were subsequently weaned 
following the method outlined in Section 2.1.3. A 10 % FBS control was included and a 
medium change for the FBS control performed at the same time as the glioma and 
non-cancerous serum concentration was increased to ensure all cells received fresh 
medium. Weaning was performed in triplicate and three biological repeats were 
carried out. 
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2.2.7 Serum Replacement Growth Curves  
 
To determine rate of growth during the process of serum replacement, U87MG and 
SVGp12 cell lines were seeded in 96 well plates at a density of 2 x 103 cells and 
incubated overnight. Wells were trypsinised and counted using a haemocytometer to 
determine the cell count for each day over a nine day period. At the same time, cells 
were weaned gradually onto 10 % non-cancerous human serum or 10 % serum from 
glioma patients following method III, Section 2.1.6. Cell counts were performed in 
triplicate and a trypan blue assay performed during each cell count. A 10 % FBS control 
was included and fresh medium was added at the time that the replacement serum 
concentration was increased in the other conditions.  Growth curves were performed 
in triplicate and three biological repeats were performed.   
2.3 Immunostaining  
 
After 72 hours incubation of cells in BD Falcon 8 well chamber slides (BD Falcon, 
Oxford, UK) with 10 % human serum or 10 % FBS, cells were fixed and stained for 
neuronal and mesenchymal markers (Table 2.2).  
Medium was aspirated and cells were washed three times with 0.1 M PBS. Ice cold 
methanol and ice cold acetone at a ratio of 1:1 was added to the chambers and fixed 
at -20 ˚C for 10 minutes. Following aspiration of the methanol and acetone, cells were 
left to air dry and subsequently rehydrated with 0.1 M PBS.  
The PBS was then removed and 100 µl of primary anti-mouse antibody (Table 2.2) was 
added to each chamber and incubated with the lid on the slide to prevent the cells 
from dehydrating for 30 minutes at room temperature. The antibody was then 
removed and the cells washed three times with 0.1 M PBS. 
A volume of 100 µl of biotinylated secondary antibody diluted 1:200 (Vectastain ABC 
Kit, Vector Labs, Peterborough,UK) was added to the chambers and incubated for 30 
minutes with the lid on the slide. The antibody was then removed and the cells washed 
three times with 0.1 M PBS.  
A volume of 100 µl of streptABC complex (Vectastain ABC Kit, Vector Labs, 
Peterborough, UK) was added to each chamber and incubated for 30 minutes at room 
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temperature and then removed and washed three times with 0.1 M PBS. 3,3’-
diaminobenzidine (DAB) solution (Vectastain ABC Kit, Vector Labs, Peterborough, UK)  
was then added to each chamber and incubated for five minutes, aspirated and 
washed twice with distilled water. The cells were then counterstained with a few drops 
of hematoxylin (Sigma-Aldrich, Dorset, UK) for five minutes and rinsed with warm 
running water until the water became clear.  
The cells were then dehydrated using 95 % ethanol followed by 100 % ethanol and 
finally xylene.  The chamber was removed and the cells mounted with Eukitt mounting 
medium and a coverslip then viewed using a Nikon light microscope (Nikon, Surrey, 
UK) at x 10 objective.  
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Table 2.2 Antibodies and dilutions used for immunostaining 
Marker 
Group 
Antibody Species  Ig 
Type 
Marker Type Starting 
Concentration 
Dilution 
Glial 
GFAP 
(Dako, 
Cambridgeshire, 
UK) 
Mouse IgG1 Glial Marker 0.042 g/L 1:50 
S100B 
(Leica 
Biosystems, 
Milton Keynes, 
UK) 
Mouse IgG1 Astrocyte 
Marker 
8 g/L 1:100 
 
 
 
Neuronal 
Nestin 
(Merck 
Millipore, 
Hertfordshire, 
UK) 
Mouse IgG1 Type IV 
intermediate 
filament 
protein 
1 g/L 1:100 
Neurofilament 
(Leica 
Biosystems, 
Milton Keynes, 
UK) 
Mouse IgG1 Neuron 
Specific 
Cytoplasmic 
Filament 
0.022 g/L 1:25 
Synaptophysin 
(Leica 
Biosystems, 
Milton Keynes, 
UK) 
Mouse IgG1 Presynaptic 
Vesicle 
membrane 
glycoprotein 
0.072 g/L 1:50 
NeuN 
(Merck 
Millipore, 
Hertfordshire, 
UK) 
Mouse IgG1 Neuronal 
Nuclei 
1 g/L 1:250 
 
 
 
Vimentin 
(Leica 
Biosystems, 
Mouse IgG1 Type III 
Intermediate 
filament 
0.016 g/L 1:100 
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Mesenchymal 
Milton Keynes, 
UK) 
protein 
expressed in 
mesenchymal 
cells 
Desmin 
(Leica 
Biosystems, 
Milton Keynes, 
UK) 
Mouse IgG1 Type III 
Intermediate 
filament 
protein 
expressed in 
mesenchymal 
cells 
0.027 g/L 1:25 
α-SMA 
(Leica 
Biosystems, 
Milton Keynes, 
UK) 
Mouse IgG1 Myofibroblast 
marker 
expressed in 
mesenchymal 
cells 
0.0045 g/L 1:25 
 
2.4 MicroRNA Isolation  
2.4.1 MicroRNA Isolation from Cell Lines 
 
After the cell lines were weaned onto 10 % human serum (either non-cancerous or 
from glioma patients) as per Section 2.1.6, for 72 hours, the total isolation of RNA from 
the cells was performed using the mirVana miRNA Isolation Kit (Life Technologies, 
Paisley, UK).  
To maintain an RNase free environment, RNase free consumables including pipette 
tips and eppendorfs were utilised and workspaces were wiped down with RNase Zap 
(Life Technologies, Paisley, UK).  
Medium was aspirated from the cells and the cells washed with 0.1 M PBS, trypsinised 
and counted to ensure there were 102 – 107 cells as required. The cells were 
transferred to a 1.5 mL RNase free centrifuge tube (Life Technologies, Paisley, UK) and 
centrifuged at 4500 x g for five minutes, the supernatant discarded and the cells 
washed in 0.1 M PBS. The cells were centrifuged again at 4500 x g for five minutes and 
placed on ice. The PBS was aspirated and a volume of lysis buffer was added according 
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to the number of cells counted, a larger volume of lysis buffer was added for a larger 
cell number. Cells were vortexed for 30 seconds to obtain a homogenous lysate.  
Homogenate additive was added to the lysate at one tenth of the volume and vortexed 
for 30 seconds to mix. The cells were then incubated on ice for 10 minutes. Acid-
phenol chloroform was added at a volume equal to the lysate volume before the 
homogenate additive was added and vortexed for 30 seconds to mix. The lysate was 
then centrifuged using an Eppendorf 5415D microcentrifuge (Eppendorf, Stevenage, 
UK) for five minutes at 16,100 x g to separate the phases and make the interphase 
compact. The aqueous upper phase was removed and transferred to a new centrifuge 
tube and the volume of liquid removed was recorded. 
The elution solution was preheated to 95 ˚C over two hours, using a Grant UBD heat 
block (Grant Instruments, Cambridge, UK). Ethanol was added at 1.25 times the 
volume of the aqueous phase. A maximum volume of 700 µl of aqueous phase was 
pipetted onto the filter of a centrifuge collection tube. The collection tubes were 
centrifuged for 15 seconds at 9300 x g. The flow through was discarded from the tube 
and repeated with the remaining aqueous phase. Wash solution 1 was added to the 
collection filter and centrifuged for five seconds at 9300 x g. The flow through was 
then discarded and the filter replaced. Wash solution 2/3 was added and centrifuged 
for five seconds at 9300 x g, the flow through was discarded and the wash was 
repeated with solution 2/3. The flow through was discarded and the collection tubes 
were centrifuged for one minute at 9300 x g to remove residual fluid. The filter was 
transferred to a new collection tube and 100 µl of elution was added to the filter and 
spun for 30 seconds at 16,100 x g to recover the RNA. The concentration of the RNA 
was then quantified using the RNA quantification protocol in Section 2.5.   
2.4.2 Exosome Isolation from Spent Media 
 
After 72 hours incubation in the new serum conditions outlined in Section 2.1.6, 
exosomes were isolated using Total Exosome Isolation (from cell culture media) 
Reagent (Life Technologies, Paisley, UK).  An equal volume of isolation reagent was 
added to spent medium, vortexed for 30 seconds to mix and incubated overnight at 2 
˚C. Following incubation the medium was centrifuged at 10,000 x g for one hour at 4 ˚C 
in an Eppendorf 5415R microcentrifuge (Eppendorf, Stevenage, UK). The medium was 
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then aspirated and the pellet resuspended in 0.1 M PBS. Total RNA was isolated from 
the pellet using the cell line isolation protocol (Section 2.3.1) and expression measured 
using the qRT-PCR protocol in Section 2.6 and 2.7.  
2.4.3 Total RNA Isolation from Serum and Cerebrospinal Fluid  
 
Cerebrospinal fluid samples were obtained from glioblastoma and hydrocephalus 
patients at the University of Athens, Greece. Local and NHS ethical approval and 
informed patient consent was obtained for the use of patient CSF samples. To isolate 
total RNA from serum and cerebrospinal fluid samples, three parts Trizol LS reagent 
(Life Technologies, Paisley, UK) was added to one part serum, the sample was 
homogenised by pipetting up and down several times and incubated at room 
temperature for five minutes. The samples were then centrifuged for 10 minutes at 4 
˚C at 12,000 x g, to remove extracellular matrix, polysaccharides and high molecular 
weight DNA.  
The supernatant containing RNA was transferred to a new tube and incubated at room 
temperature for five minutes. A volume of chloroform equal to one quarter of the 
supernatant volume was added to the sample and shook vigorously by hand for 15 
seconds, then incubated for 10 minutes at room temperature. The sample was then 
centrifuged at 12,000 x g at a temperature of 4 ˚C for 15 minutes to separate the 
phenol and aqueous phase.  
The aqueous phase was transferred to a fresh tube and 100 % ice cold isopropanol was 
added and incubated for 10 minutes at room temperature. The sample was then 
centrifuged at 12,000 x g at a temperature of 4 ˚C for 10 minutes.  The supernatant 
was removed and 75 % ethanol was added to the pellet and vortexed for 30 seconds to 
mix. The sample was then centrifuged at 7500 x g, 4 ˚C for five minutes. The 
supernatant was removed and air dried for two minutes and resuspended in RNase 
free water (Invitrogen, Paisley, UK).  The RNA concentration was measured using a 
nanodrop as outlined in Section 2.5. 
2.4.4 MicroRNA Isolation from Frozen Tissue  
 
Local and NHS ethical approval and informed patient consent was obtained for the use 
of patient tissue samples. To isolate total RNA from frozen tissue samples, samples 
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were thawed on ice. The tissue was transferred to a 1.5 mL RNase free eppendorf tube 
(Life Technologies, Paisley, UK) containing Trizol LS reagent (Life Technologies, Paisley, 
UK) and homogenised using an OMNI tissue homogenizer (VWR, Leighton Buzzard, UK) 
to generate a tissue lysate.  Following homogenization total RNA was extracted as 
outlined in Section 2.3.3 and the RNA concentration was measured using a nanodrop 
as outlined in Section 2.5.  
2.5 Isolation of Mononuclear Cells  
 
To determine the expression of miRNA in mononuclear cells, fresh blood samples were 
obtained from the BTNW tissue bank (Royal Preston Hospital, Preston, UK) and 
processed within two hours following collection. Local and NHS ethical approval and 
informed patient consent was obtained for the use of patient blood samples.  Blood 
samples were diluted 1:1 in 0.1 M PBS and layered on top of a volume of lymphoprep 
(Alere LtD, Stockport, UK) double that of the blood and PBS. Samples were centrifuged 
for 30 minutes, 800 x g at 21 °C in an ALC PK 120R centrifuge (DJB labcare, 
Buckinghamshire, UK). The top layer of media was aspirated and the buffy coat layer 
containing mononuclear cells was removed and retained using a glass Pasteur pipette. 
Total RNA was extracted from the buffy coat using Trizol LS (Section 2.3.3), quantified 
following Section 2.5 and miRNA expression analysis was performed as outlined in 
Section 2.6 and 2.7.   
2.6 RNA Quantification  
 
Following extraction, total RNA concentration was measured using the Nanodrop 1000 
Spectrophotometer (Thermo Scientific, Loughborough, UK) at a wavelength of 280 nm. 
Purity of the total RNA was determined using the 260/280 ratio, RNA samples with a 
260/280 ratio of ~2.0 were considered ‘pure’ and used for downstream analysis 
(Majumdar et al., 2015).  
To determine the accuracy of RNA Quantification known concentrations of a synthetic 
miRNA were quantified. The miRNA standard (Integrated DNA Technologies, Glasgow, 
UK) was diluted to produce a solution of known concentration by adding RNase free 
diethylpyrocarbonate (DEPC) treated water (Invitrogen, Paisley, UK) producing a stock 
concentration of 1 µg/µl. Subsequent serial dilutions were performed to produce a 
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range of concentrations; 100 ng/µl, 10 ng/µl, 5 ng/µl, 1 ng/µl and 0.1 ng/µl. The 
solutions were then used to determine the accuracy of the nanodrop for determining 
the concentration of miRNA within a solution.  Measurements were performed in 
triplicate and the nanodrop was blanked using RNase free DEPC water (Invitrogen, 
Paisley, UK).  Data shown in Appendix 2, total RNA concentrations above 1 ng/µl were 
found to be accurately measure by the nanodrop.  
2.7 MiScript MiRNA PCR Array  
 
Miscript miRNA PCR Array Brain Cancer panels (Qiagen, Manchester, UK), were used to 
select miRNA for a preliminary panel.  Following isolation from serum samples, total 
RNA was reverse transcribed using the miScript RT II kit (Qiagen, Manchester, UK) and 
the expression level of 84 miRNAs associated with brain cancer were determined using 
qPCR. The C.elegans miR-39 miScript Primer Assay (Qiagen, Manchester, UK) was used 
as a control to normalise qPCR data. 
Total RNA was isolated from serum and cerebrospinal fluid as outlined in Section 2.3.3 
and from tissue as outlined in Section 2.3.4. The C.elegans miR-39 miScript Primer 
Assay) was diluted to a final concentration of 1.6 x108 copies/µl (Table 2.3) and added 
to the sample following homogenisation and lysis. Total RNA was diluted to a final 
concentration of 12.5 ng/µl and then reverse transcribed. The master mix components 
excluding the reverse transcriptase mix were thawed at room temperature and the 
master mix was prepared following Table 2.4.  The reverse transcriptase was removed 
from -20 ˚C immediately before adding to the master mix and then immediately 
replaced into -20 ˚C to maintain integrity of the enzyme. The master mix was mixed by 
pipetting, centrifuged at 2000 x g for five seconds in a Technico mini centrifuge (Fisher 
Scientific, Loughborough, UK) stored on ice and then incubated at 37 ˚C for 60 minutes 
followed by 95 ˚C for five minutes.  
Table 2.3: Dilution and Final Concentration of C. elegans miR-39 miScript Primer Assay. 
 Dilution Concentration (Copies/µl) 
Initial Stock 300 µl DEPC treated H2O + 10 
pmol lyophilised sample 
2 x 1010 
Dilution 4 µl stock + 16 µl RNase-free 
water 
4 x 109 
Working Solution 2 µl of dilution + 48 µl RNase 1.6 x108 
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free water 
 
Table 2.4: Reverse Transcription Master Mix, Components and Final Working Concentrations. 
Component Volume Final Concentration 
5 X miScript HiSpec Buffer 4 µl 1 X 
10 X miScript Nucleics Mix 2 µl 1 X 
RNase-free water Variable - 
MiScript Reverse Transcriptase 
Mix 
2 µl - 
Template RNA Variable 12.5 ng/μl 
Total Volume 20 µl - 
 
Following reverse transcription cDNA was diluted 1:10 in RNase free DEPC water (Life 
Technologies, Paisley, UK) prior to qPCR. The qPCR master mix components were 
thawed at room temperature and pipetted following Table 2.5.  The brain cancer 
panels were thawed at room temperature, and 25 µl of reaction mix was added to 
each well and the plate sealed with optical adhesive film. The plate was then 
centrifuged at 1000 x g for one minute to ensure all the master mix was at the bottom 
of the well. The C.elegans, reverse transcription control and positive PCR control wells 
within the brain cancer panels were utilised in this study. 
The qPCR reaction was performed on an Applied Biosystems 7500 Real Time PCR 
System in standard mode using the parameters outlined in Table 2.6 and a dissociation 
analysis step added at the end of the run.  
Table 2.5: qPCR Master Mix and Final Working Concentration. 
Component Volume (µl) Final Concentration 
2 X QuantiTect SYBR Green 
PCR Master Mix 
1375  1 X 
10 X miScript Universal Primer 275  1 X 
RNase free water 1000  - 
Template cDNA (diluted) 100  - 
Total Volume 2750  - 
 
52 
 
Table 2.6: qPCR Parameters. 
 
The data were analysed using the miScript miRNA PCR Array Data Analysis tool 
(SABiosciences) available online at http://pcrdataanalysis.sabiosciences.com/mirna.  
Threshold cycle (Ct) values were normalised using the C.elegans miR-39 miScript 
Primer Assay (Qiagen, Manchester, UK). Normalisation was performed by subtracting 
the Ct value of the C.elegans spike in from the target miRNA Ct value. Each miRNA was 
scored either A, B or C by the miScript data analysis tool based on the average Ct to 
determine whether the calculated fold change was representative of the actual fold 
change within the sample (Table 2.7). ‘A’ being representative of the actual fold 
change and ‘B’ suggesting a variation in fold change between samples which may not 
be representative of the actual fold change. MiRNAs were scored ‘C’ if the average Ct 
of either the target sample or the control sample was beyond the defined cut off of 35 
cycles, making the calculated fold change invalid. Following analysis using the miScript 
miRNA PCR Array Data Analysis tool, data was examined and miRNAs with a fold 
change scored as a ‘C’ were omitted from the study.  
Table 2.7 Fold Change Scoring system defined by the miScript data analysis tool. 
Score Definition 
A This gene’s average threshold cycle is relatively high (> 30) in either the control or the 
test sample, and is reasonably low in the other sample (< 30).These data mean that 
the gene’s expression is relatively low in one sample and reasonably detected in the 
other sample suggesting that the actual fold-change value is at least as large as the 
calculated and reported fold-change result. 
B This gene’s average threshold cycle is relatively high (> 30), meaning that its relative 
expression level is low, in both control and test samples. 
Enzyme Activation Hold 15 minutes 95 ˚C 
PCR - 40 Cycles Denature Hold 15 seconds 94 ˚C 
Anneal Hold 30 seconds 55 ˚C 
Extend Hold 34 seconds 70 ˚C 
Melt curve 
analysis – 1 
Cycle 
Dissociation  60-95 ˚C 
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C This gene’s average threshold cycle is either not determined or greater than the 
defined cut-off (default 35), in both samples meaning that its expression was 
undetected, making this fold-change result erroneous and un-interpretable. 
 
2.8 NCode miRNA First-Strand cDNA Synthesis  
 
For subsequent analysis of miRNA expression following the use of the miScript arrays, 
total RNA was polyadenylated and reverse transcribed using the NCode miRNA First-
Strand cDNA synthesis kit (Life Technologies, Paisley, UK). Following extraction of total 
RNA as outlined in Section 2.3.3, the samples were polyadenylated and reverse 
transcribed using the NCode miRNA First-Strand cDNA Synthesis kit. RNA samples were 
diluted in RNase free DEPC water to 200 ng. Stock 10 mM dATP was diluted 2:50 with 1 
mM Tris, pH 8.0. A master mix for Polyadenylation was prepared as detailed in Table 
2.8.  
Table 2.8: Polyadenylation Reaction Master Mix 
Component Volume (µl) Final Concentration 
5 X miRNA Reaction Buffer 5 1 X 
25 mM MnCl2 2.5 2.5 mM 
Diluted ATP 1 0.8 mM 
Poly A Polymerase 0.5 - 
Diluted total RNA 16 12.5 ng/µl 
Total  25 - 
   
The samples were incubated in a Grant UBD heat block (Grant Instruments, 
Cambridge, UK), pre-heated to 37 °C, for 15 minutes. Immediately following 
incubation, the samples were reverse transcribed. A volume of 4 µl of polyadenylated 
RNA was used in the following cDNA synthesis reaction. The RNA samples were 
combined with annealing buffer and universal RT primer in the volumes outlined in 
Table 2.9.  
Table 2.9: Initial cDNA Synthesis Master Mix 
Component Volume (µl) Final Concentration 
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Polyadenylated RNA 
 
4 12.5 ng/µl 
Annealing Buffer 
 
1 - 
Universal RT Primer (25 µM) 
 
3 9.375 µM 
Total 
 
8 - 
 
The tubes were incubated for five minutes in a Veriti Thermal cycler (Life Technologies, 
Paisley, UK) pre-heated to 65 °C and then placed on ice for one minute. Further 
components were added to the tubes, shown in Table 2.10 and incubated at 50 °C for 
50 minutes followed by five minutes at 85 °C to stop the reaction. The cDNA was 
stored at -20 °C before proceeding to qPCR.  
Table 2.10: Secondary cDNA Master Mix 
Component Volume (µl) Final Concentration 
2 X First-strand reaction mix 
 
10 1 X 
SuperScript III RT enzyme mix 
 
2 - 
Total 
 
12 - 
 
2.9 GoTaq SYBR Green qPCR Reaction  
 
Following first strand cDNA synthesis as outlined in Section 2.7, cDNA samples were 
diluted 1:10 in RNase free DEPC water. The qPCR master mix was prepared as outlined 
in Table 2.11 using the universal reverse primer provided with the NCode miRNA First-
Strand cDNA synthesis kit and miRNA specific forward primers outlined in Section 2.9.1 
(Integrated DNA Technologies, Glasgow, UK).   
Table 2.11: GoTaq SYBR Green qPCR Master Mix  
Component Volume (µl) Final Concentration 
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2 X qPCR master mix 
 
12.5 1 X 
Forward primer, 10 µM 
 
0.5 200 nM 
Universal reverse primer, 10 µM 
 
0.5 200 nM 
RNase free water 
 
6.5 - 
Total 20 
 
- 
 
The cDNA was diluted 1:5 with qPCR master mix and added to each well of a 
MicroAmp Optical 96-Well Reaction Plate (Life Technologies, Paisley, UK) the plate was 
sealed with MicroAmp Optical Adhesive Film (Life Technologies, Paisley, UK) and 
centrifuged for one minute at 1000 x g.   
The qPCR reaction was performed on an Applied Biosystems 7500 Real Time PCR 
System (Life Technologies, Paisley, UK) in standard mode using the parameters 
outlined in Table 2.12 and a dissociation analysis step added at the end of the run. 
Data was analysed using the ΔCt method and normalised using the C.elegans miR-39 
miScript Primer Assay (Qiagen, Manchester, UK).  
 
Table 2.12: qPCR run parameters  
 
2.9.1 Primer Design  
 
Enzyme Activation Hold 2 minutes 95 ˚C 
PCR - 40 Cycles Denature Hold 15 seconds 95 ˚C 
Anneal/Extend Hold 60 seconds 60 ˚C 
Melt curve 
analysis – 1 
Cycle 
Dissociation  60-95 ˚C 
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Specific forward primers (Integrated DNA Technologies, Glasgow, UK), were designed 
using sequences obtained from miRBase available online www.miRBase.org (Table 
2.13).  
2.10 MiRNA Expression in TCGA Dataset 
 
To determine the tissue expression of miRNA in a larger patient cohort of 558 patients, 
microarray data was analysed from the TCGA by Josie Hayes, Leeds Institute of 
Molecular Medicine. Log fold change expression in glioblastoma patients compared to 
patients without glioblastoma was determined and a comparison of expression and 
age was determined using Pearson’s correlation. Survival analysis was performed using 
both cox regression and log-rank above and below the median.  
 
 
 
Table 2.13 Specific forward primers designed and utilised in this study. 
Primer  Sequence  
hsa-let-7-5p 5’-TGA GGT AGT AGG TTG TAT AGT T-3’ 
hsa-miR-7-5p 5’-TGG AAG ACT AGT GAT TTT GTT GT-3’ 
hsa-miR-9-3p 5’-ATA AAG CTA GAT AAC CGA AAG T-3’ 
hsa-miR-15b-5p 5’-TAG CAG CAC ATC ATG GTT TAC A-3’ 
hsa-miR-16-5p  5’-TAG CAG CAC GTA AAT ATT GGC G-3’ 
hsa-miR-17-5p 5’-CAA AGT GCT TAC AGT GCA GGT AG-3’ 
hsa-miR-18a-5p 5’-TAA GGT GCA TCT AGT GCA GAT AG-3’ 
hsa-miR-19a-3p 5’-TGT GCA AAT CTA TGC AAA ACT GA-3’ 
hsa-miR-19b-3p 5’-TGT GCA AAT CCA TGC AAA ACT GA-3’ 
hsa-miR-20a-5p 5’-TAA AGT GCT TAT AGT GCA GGT AG-3’ 
hsa-miR-21-5p 5’-TAG CTT ATC AGA CTG ATG TTG A-3’ 
hsa-miR-23a-3p 5’-ATC ACA TTG CCA GGG ATT TCC-3’ 
hsa-miR-25-3p 5’-CAT TGC ACT TGT CTC GGT CTG A-3’ 
hsa-miR-26a-5p 5’-TTC AAG TAA TCC AGG ATA GGC T-3’ 
hsa-miR-29b-3p 5’-TAG CAC CAT TTG AAA TCA GTG TT-3’ 
hsa-miR-29c-3p 5’-TAG CAC CAT TTG AAA TCG GTT A-3’ 
hsa-miR-30b-5p 5’-TGT AAA CAT CCT ACA CTC AGC T-3’ 
hsa-miR-30c-5p 5’-TGT AAA CAT CCT ACA CTC TCA GC-3’ 
hsa-miR-34a-5p 5’-TGG CAG TGT CTT AGC TGG TTG T-3’  
hsa-miR-92a-3p 5’-TAT TGC ACT TGT CCC GGC CTG T-3’ 
hsa-miR-93-5p 5’-CAA AGT GCT GTT CGT GCA GGT AG-3’ 
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hsa-miR-101-3p 5’-TAC AGT ACT GTG ATA ACT GAA-3’  
hsa-miR-148a-3p  5’-TCA GTG CAC TAC AGA ACT TTG T-3’  
hsa-miR-150-5p 5’-TCT CCC AAC CCT TGT ACC AGT G-3’ 
hsa-miR-181a-5p 5’-AAC ATT CAA CGC TGT CGG TGA GT-3’  
hsa-miR-181b-5p 5’-AAC ATT CAT TGC TGT CGG TGG GT-3’ 
hsa-miR-185-5p 5’-TGG AGA GAA AGG CAG TTC CTG A-3’  
hsa-miR-191-5p 5’-CAA CGG AAU CCC AAA AGC AGC UG-3’ 
hsa-miR-320a 5’-AAA AGC TGG GTT GAG AGG GCG A-3’ 
hsa-miR-328-3p  5’-CTG GCC CTC TCT GCC CTT CCG T-3’ 
hsa-miR-451a 5’-AAA CCG TTA CCA TTA CTG AGT T-3’ 
hsa-miR-486-5p 5’-TCC TGT ACT GAG CTG CCC CGA G-3’ 
cel-miR-39-3p 5’-TCA CCG GGT GTA AAT CAG CTT G-3’ 
 
 
 
 
2.11 In Situ Hybridisation  
2.11.1 Preparation of Buffers and Stock solutions  
 
To determine the localisation of microRNAs within tumour tissue sections, in situ 
hybridisation (ISH) was performed using the miRCURY LNA microRNA ISH Optimization 
Kit (FFPE) (Exiqon, UK) and the ISH protocol outlined by Gerard Nuovo (Nuovo, 2010).  
Prior to the ISH experiment proteinase-K (Exiqon, UK) was reconstituted in 10 mM Tris-
HCl (pH 7.5) to produce a 20 mg/mL stock which was aliquoted and stored at - 20 °C.  
Proteinase-K buffer, 0.2 X saline-sodium citrate (SSC) solution (Sigma-Aldrich, Dorset, 
UK) and 0.1 % PBS-Tween (PBS-T, pH 7.4) were also prepared prior to the ISH 
experiment as outlined in Table 2.14 and autoclaved to minimise RNase activity.  
Table 2.14: Buffers and solutions prepared prior to ISH 
Buffer Component Volume (mL) Final Concentration 
Proteinase-K Buffer RNase free water 
1 M Tris-HCl (pH 7.4) 
5 M NaCl 
500 
2.5  
0.1  
- 
 
0.2 X SSC RNase free water 
20X SSC 
495 
5  
- 
0.2 X 
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PBS-T pH 7.4 PBS 
Tween-20 
500  
0.5  
- 
0.1 % 
 
Prior to the ISH experiments stocks of the hybridisation solution containing each probe 
were prepared. To prepare the hybridisation mix, 2 X microRNA ISH buffer (miRCURY 
LNA microRNA ISH Optimization Kit) was diluted 1:1 with RNase free DEPC water to 
produce a final concentration of 1 X.  The double-DIG-labelled probes were diluted in a 
2 mL non-stick RNase free tube (Life Technologies, Paisley, UK). The probes were 
denatured at 90 °C for 4 minutes using a Grant UBD heat block (Grant Instruments, 
Cambridge, UK) and 1 X microRNA ISH buffer was added to each of the tubes to dilute 
the probes to the appropriate final concentration. The probe stocks were aliquoted 
and stored at - 20 °C. 
 
2.11.2 Optimisation of Proteinase-K Step 
 
Optimisation of the proteinase-K concentration and duration of treatment was 
performed using the LNA U6 snRNA double-digoxygenin (DIG) labelled detection probe 
(Exiqon, UK). The LNA U6 snRNA probe was diluted in microRNA ISH buffer in a 2 mL 
non-stick RNase free tube (Life Technologies, Paisley, UK) to produce a range of 
concentrations between 0.1 and 2 nM as outlined in Table 2.15.  
Table 2.15: Concentrations of LNA U6 snRNA Probe used for Proteinase-K Optimisation  
Dilution Factor Probe Volume (µl) 1 X ISH Buffer Volume 
(mL) 
Final Concentration (nM) 
1:5000 0.4 2 0.1 
1:1000 2 2 0.5 
1:500 4 2 1 
1:333 6 2 1.5 
1:250 8 2 2 
 
Immediately before proteinase-K treatment of slides, proteinase-K stock solution was 
added to the proteinase-K buffer to produce a final concentration of 15 µg/mL. Diluted 
proteinase-K was added to each slide to cover the tissue section and incubated for 10 
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minutes at 37 °C in a HYBAID Micro-4 hybridisation oven (VWR, Leighton Buzzard,UK). 
Following negative probe signal from sections incubated with 15 µg/mL proteinase-K 
for 10 minutes, a second optimisation experiment was performed with 15 µg/mL 
proteinase-K incubated at 37 °C for 20 minutes, which produced a signal using the U6 
probe.  
2.11.3 Optimisation of Hybridisation Temperature and Incubation Time 
 
Following optimisation of the proteinase-K step, optimisation of the hybridisation 
temperature for the U6 and miR-21 positive control probes was performed. The U6 
snRNA probe was diluted to a final concentration of 10 nM. The miR-21 positive 
control probe and the scrambled negative control probe were both diluted to a final 
concentration of 40 nM (Table 2.16). The hybridisation mix was added to each slide to 
cover the section, a sterile cover glass was added and sealed with fixogum and 
hybridised overnight at 37 °C or 4 °C.  
Table 2.16 Probe dilutions and final concentrations for hybridisation temperature optimisation. 
Probe Dilution Factor Probe Volume 
(µl) 
1 X ISH Buffer 
Volume (mL) 
Final 
Concentration 
(nM) 
U6 snRNA 1:250 4 1 10 
miR-21 1:625 3.2 2 40 
Scrambled 1:625 3.2 2 40 
 
Following optimisation of the hybridisation temperature, optimisation of incubation 
times for anti-DIG AP and NBT-BCIP was performed. Slides were incubated for one 
hour with anti-DIG AP and one hour with NBT-BCIP, two hours with anti-DIG AP and 
one hour with NBT-BCIP and two hours with anti-DIG AP and two hours with NBT-BCIP. 
2.11.4 Optimised In Situ Hybridisation of Target MiRNAs 
 
Prior to ISH of miRNA biomarkers optimisation of proteinase-K concentration (Section 
2.10.2), duration of proteinase-K treatment (Section 2.10.2) and optimisation of probe 
hybridisation temperature (Section 2.10.3) was carried out.    
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Local and NHS ethical approval and informed patient consent was obtained for the use 
of patient tissue section samples. Glioblastoma FFPE tissue sections (BTNW tissue 
bank, Royal Preston Hospital, UK) were deparrafinised for five minutes in histoclear 
(Fisher Scientific, Loughborough, UK) and five minutes in 100 % ethanol. Following 
deparaffinisation, slides were air dried at room temperature.  
Immediately before proteinase-K treatment of slides, proteinase-K stock solution was 
added to proteinase-K buffer to produce the final concentration of 15 µg/ml as 
optimised in Section 2.10.2. Diluted proteinase-K was added to each slide to cover the 
section and incubated for 20 minutes at 37 °C in a HYBAID Micro-4 hybridisation oven 
(VWR, Leighton Buzzard, UK). Slides were washed briefly in RNase free water followed 
by 100 % ethanol and air dried at room temperature.  
Hybridisation mix was added to each slide to cover the section and a sterile cover glass 
was applied and sealed with fixogum rubber cement (Amazon, London, UK). Slides 
were incubated at 65 °C for five minutes and subsequently incubated overnight at 37 
°C.  
Immediately prior to continuing the ISH experiment antibody blocking solution, 
antibody diluent solution and anti-DIG reagent were prepared. To prepare the 
antibody blocking solution sheep serum (Sigma Aldrich, Dorset, UK) was added to 0.1 
% PBS-T (pH 7.4) to produce a final concentration of 2 % sheep serum. 5 mL of blocking 
solution was aliquoted into a new tube for the antibody diluent solution. Stock 30 % 
BSA was added to the blocking solution to produce a final concentration of 1 %. To 
prepare the antibody diluent solution, 30 % BSA was added to 0.1 M PBS to produce a 
final concentration of 1 % BSA. Sheep-anti-DIG-AP was diluted 1:200 in antibody 
dilutant solution.   
Following overnight hybridisation, the cover glass was detached and slides were placed 
in 0.2 X SSC in a glass jar placed in a Grant JB1 water bath (Fisher Scientific, 
Loughborough, UK) set at 50 °C for 10 minutes.  
A hydrophobic barrier was made around each section and antibody blocking solution 
was added to each slide and incubated for 15 minutes at room temperature. The 
blocking solution was removed and anti-DIG-reagent was added to each slide and 
incubated for two hours at 37 °C in humidifying conditions in a HYBAID Micro-4 
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hybridisation oven (VWR, Leighton Buzzard, UK). The slides were subsequently washed 
for three minutes in PBS-T prior to application of the substrate.  
Immediately prior to use alkaline phosphatase (AP) substrate was prepared by 
dissolving one nitro-blue tetrazolium and 5-bromo-4-chloro-3’-indolyl-phosphate (NBT-
BCIP) tablet (Roche, Hertfordshire, UK) in 10 mL of double distilled water pre-heated to 
37 °C. Levamisol stock (Sigma-Aldrich, UK) was added to the NBT-BCIP to produce a 
final concentration of 0.2 mM.  The AP substrate was applied to each section and 
incubated for one hour at 37 °C in a HYBAID Micro-4 hybridisation oven (VWR, 
Leighton Buzzard, UK), the slides were protected from light. The slides were washed 
for one minute with running tap water.  
Nuclear fast red (Vector Laboratories, UK) was added to each slide to cover the section 
for one minute for nuclear counter staining. Slides were placed in a glass jar and rinsed 
with running tap water for 10 minutes, dipped in 100 % ethanol and allowed to air dry.  
Slides were dipped in histoclear and subsequently mounted with one drop of Eukitt 
quick-hardening mounting medium (Sigma-Aldrich, Dorset, UK) and a sterile glass 
cover slip. The precipitate was allowed to settle overnight and viewed with a Nikon 
Eclipse E200 Phase Contrast microscope (Nikon, Surrey, UK) on the brightfield setting 
at x10 and x100 objectives the following day.  
2.12 Power Analysis  
 
To ensure any miRNA biomarkers identified were statistically significant, power 
analysis was performed to determine the sample size required for 80 % power. Power 
analysis was performed using the GraphPad Statmate software (San Diego, USA). 
Standard deviations for each of the miRNA biomarkers were used to determine the 
sample number required to detect a difference between means of 1 Ct value.   
2.13 Data Analysis  
 
Data were analysed using GraphPad Prism 5.0 statistical software (San Diego, USA). 
Raw ΔCt values for both target and control data were used for statistical analysis. 
Following statistical analysis control ΔCt values were presented as a standard fold 
change value of one in figures with no standard deviation. Where sample numbers 
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permitted, a Kolmogorov Smirnov test was used to determine whether data were 
normally distributed. Data consisting of two groups were analysed by student’s t-test 
with Levene’s F test or the non-parametric Mann-Whitney U test. Data consisting of 
three groups were analysed by one-way ANOVA with Tukey post-hoc test or non-
parametric Kruskal-Wallis with Dunn’s post-hoc test. Data consisting of paired groups 
were analysed by two-way ANOVA with Tukey post-hoc test. Following analysis of both 
one-way and two-way ANOVA using the Tukey post-hoc test, data was tested for 
multiple variances by adjusting the p-value for the number of groups. Survival data 
were analysed using Log-rank (Mantel Cox) test to determine whether differences 
between survival curves were significantly different. The TCGA dataset was analysed 
by Josie Hayes (Leeds Institute of Molecular Medicine) using log-rank above and below 
the median. Correlations between miRNA expression and age were determined using 
Pearson’s correlation. All data except the miSCript brain cancer array data in Chapters 
3 and 5 were displayed as means of triplicate experiments + SD. A p-value of < 0.05 
was considered significant.  
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3. Effect of Serum Replacement on 
Immortalised Cell Lines  
 
 
 
 
 
 
 
 
 
 
3.1 Introduction           
 
Foetal bovine serum (FBS) is the standard serum type used to supplement basal 
medium in the culture of immortalised cell lines including U87MG and SVGp12 cells. 
FBS contains high levels of hormones, proteins and growth factors required to 
stimulate growth and proliferation of cell lines (Zheng et al., 2006). Although 
commonly used for the culture of numerous cell lines, FBS is poorly defined and the 
exact composition is unknown. The composition of FBS can vary between different 
batches and therefore can have varying effects on the growth of cell lines (Zheng et al., 
2006). Whilst not used for the maintenance of immortalised cell lines, human serum is 
one of a variety of serum types that is used for the ex vivo expansion of mesenchymal 
or human embryonic stem cells (hESC) prior to in vivo transplantation (Mannello and 
Tonti, 2007). Studies have shown that the culture of hESC with human serum 
encourages the maintenance of the hESC karyotype and pluripotency even after 
prolonged culture (Mannello and Tonti, 2007).  
64 
 
During disease, factors within human serum may change in abundance or the presence 
or absence of certain components may occur (Tirumalai et al., 2003). One such 
component is exosomes, small lipoprotein vesicles which are present in the serum of 
both healthy and diseased individuals. Exosomes are believed to be a method of 
intercellular communication (Colombo et al., 2014) and are capable of immune 
modulation (Blin and Fitzgerald, 2015) and manipulation of tumour 
microenvironments (Milane et al.). Exosomes contain mRNA, miRNA and proteins 
which can be released and taken up by neighbouring cells (Meckes et al., 2010). The 
specific contents of exosomes often reflect the cell of origin therefore those derived 
from tumour cells contain proteins and RNA with the ability to promote tumour 
characteristics in recipient cells including invasion and proliferation (Meckes et al., 
2010).   
Glioblastoma cells release exosomes containing angiogenic proteins as well as mRNA 
and miRNA which stimulate tubule formation in recipient endothelial cells (Skog et al., 
2008). The release of glioblastoma specific exosomes can therefore play an important 
role in stimulating invasion and metastasis (Katakowski et al., 2010), a vital 
characteristic which contributes to the malignancy of glioblastoma and hinders 
successful treatment (Demuth and Berens, 2004).    
 
The release and uptake of exosomes has been demonstrated in vitro in U87MG and 
U251 glioblastoma cell lines (Katakowski et al., 2010). Furthermore, studies have 
shown that recipient cells incorporate exosomal miRNA into cellular pathways 
resulting in altered protein expression (Katakowski et al., 2010). Short-term 
glioblastoma derived from primary cells are also able to influence protein expression 
of endothelial cells in culture and promote angiogenesis (Skog et al., 2008). In addition, 
isolation of exosomes from primary glioblastoma cells and incubation with U87MG 
cells caused an increase in proliferation compared to untreated U87MG cells (Skog et 
al., 2008), showing exosomes of in vivo origin can influence the behaviour of 
immortalised cell lines. The aforementioned studies investigating the function of 
circulating miRNAs in cell lines have utilised the standard FBS culture conditions, 
however as FBS is of bovine origin this may affect data collected. Cell culture using 
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human serum as a supplement may, therefore, provide a more representative model 
for miRNA function in humans and could provide more accurate data.  
The aim of the current study was to establish a human serum based cell culture model 
which could be used to investigate miRNA expression. Once established, the behaviour 
of U87MG and SVGp12 cells in culture with glioblastoma patient serum and non-
cancerous human serum was investigated. Further studies were performed to 
determine whether human serum could alter the miRNA expression of immortalised 
cell lines and whether the resulting phenotype differed between cells cultured in 
serum from cancerous and non-cancerous subjects.  It was hypothesised that the 
composition FBS, human serum from glioma patients and non-cancerous control 
patients would differ and therefore alter the growth behaviour and expression of 
selected miRNAs in the cell lines.  
 
 
 
 
 
3.2 Results  
3.2.1 Culture of U87MG and SVGp12 cells in replacement serum resulted in 
increased cell number  
 
To determine whether the weaning of cell lines off standard FBS and onto human 
serum had an effect on growth characteristics, growth curves were performed during 
the weaning phase. Cells were initially seeded with 10 % FBS and subsequently weaned 
onto increasing concentrations of human serum pooled from three glioblastoma 
patients or three control patients in increments of 2 %, 5 %, 7 % and 10 % whilst 
decreasing the FBS at increments of 8 %, 5 % , 3 % and 0 % to maintain the total serum 
concentration at 10 % (Section 2.1.7). Cells were cultured for 48 hours in each serum 
concentration to allow completion of one cell cycle of growth before increasing the 
replacement serum concentration (Section 2.1.7).  
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The growth of U87MG cells in all three serum conditions was not significantly different 
(p > 0.05) until 48 hours culture in 7 % replacement serum; after which there was a 
significant increase in cell number in both the 7 % serum from glioblastoma patients 
and 7 % serum from non-cancerous patients compared to cells cultured in 10 % FBS (p 
< 0.05) (Figure 3.1). There was also a significant increase in cell number in the glioma 
patient serum compared to the non-cancerous subjects after 48 hours incubation. 
(Figure 3.1D). Following culture in 10 % replacement serum, U87MG cells cultured in 
10 % glioma patient serum showed the greatest increase in cell number (p < 0.001) 
compared to those cultured in FBS, followed by U87MG cells cultured in 10 % non-
cancerous human serum (p < 0.01).  
A similar trend in growth was observed with the SVGp12 cell line where cell number 
was not significantly different until after 48 hours incubation with 7 % replacement 
serum (Figure 3.2). In contrast to the U87MG cell line, SVGp12 cells grown in 7 % non-
cancerous human serum and 3 % FBS showed the greatest increase in cell number 
compared to both the 7 % glioma patient serum and 10 % FBS conditions (p < 0.001) 
(Figure 3.2D). Following culture in 10 % replacement serum SVGp12 cells incubated in 
10 % glioma patient serum showed a similar cell number to those cultured in 10 % FBS 
and no significant difference in cell number was observed between the glioma patient 
serum and FBS conditions (Figure 3.2D). 
Comparison of the two cell lines cultured in the same serum condition showed that cell 
numbers for U87MG were significantly higher than SVGp12 following 48 hours 
incubation with 7 % replacement serum and in the 10 % FBS control condition. Cell 
numbers were not significantly different for both cell lines in the same condition prior 
to incubation in 7 % replacement serum.   
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Figure 3.1 Growth of U87MG cells during serum replacement. A) U87MG cells cultured in glioblastoma patient serum. B) U87MG cells cultured in non-cancerous human serum. C) U87MG cells 
cultured in FBS. D) Combined growth curves of all serum types. Cell number for U87MG cells cultured in glioblastoma patient serum was signifcantly higher compared to those cultured in non-
cancerous human serum and FBS, ***p < 0.001. U87MG cells cultured in non-cancerous human serum had significantly higher cells numbers compared to FBS, **p < 0.01. Data shown as mean of 
triplicate experiments (n=9) with SD, analysed by two way ANOVA with Tukey post-hoc test. Ratios are shown as percentage of replacement serum to percentage of FBS.  
A B C 
D 
*** 
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Figure 3.2 Growth of SVGp12 cells during serum replacement. A) SVGp12 cells cultured in glioblastoma patient serum. B) SVGp12 cells cultured in non-cancerous human serum. C) SVGp12 cells 
cultured in FBS. D) Combined growth curves of all serum types. There was no significant difference in cell number between cells cultured in glioblastoma patient serum and those cultured in FBS. 
SVGp12 cells cultured in non-cancerous human serum had a significantly higher cell number compared to those cultured in glioblastoma patient serum and FBS. Data shown as mean of triplicate 
experiments (n=9) with SD, analysed by two way ANOVA with Tukey post-hoc test ***p < 0.001. Ratios are shown as percentage of replacement serum to percentage of FBS. 
A B C 
D 
*** 
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3.2.2 The culture of U87MG and SVGp12 cells in replacement serum resulted 
in morphological changes  
 
The process of serum replacement was observed to have a morphological effect on 
U87MG cells. When cultured in the presence of either non-cancerous human or 
glioblastoma patient serum, the cells underwent changes in appearance (Figure 3.3).  
Serum-free medium was used as a control in morphology studies to determine the 
morphological response of cells to an absence of serum. 
The morphology of U87MG cells in non-cancerous human serum displayed spiky 
processes were star-like (Figure 3.3E-H). In human serum obtained from glioma 
patients, U87MG cells exhibited a more arranged morphology forming branched linear 
structures similar to an epithelial phenotype (Figure 3.3A-D). Conversely, the 
appearance of SVGp12 cells did not visibly alter when cultured in both cancerous and 
non-cancerous human serum compared to those cultured in 10 % FBS (Figure 3.4A-H).  
Changes in morphology of the U87MG cells was observed from 48 hours culture in 3 % 
replacement serum and 7 % FBS (Figure 3.3A). The linear structures of an epithelial 
phenotype were observed most frequently after 48 hours incubation with 10 % glioma 
serum alone (Figure 3.3D). In addition to the observed morphological changes, the 
culture of U87MG cells in human serum led to an increase in spheroid formations. 
These spheroids were mainly attached to the flask and those in the glioma patient 
serum were also incorporated into the linear structures which radiated from a central 
spheroid (Figure 3.3B).  The changes in morphology were most pronounced after 48 
hours culture in 10 % glioma patient serum (Figure 3.2D). 
The culture of cells in varying concentrations of serum free medium also led to a 
change in morphology. Non-viable cells for both U87MG and SVGp12 were observed as 
dark, detached, rounded cells (Figure 3.3I and 3.4I). In addition, the confluency of both 
cell lines was also greatly reduced compared to the other serum conditions. The 
culture of SVGp12 and U87MG cells in serum free medium led to the formation of both 
detached and attached spheroids (Figure 3.3 and 3.4). 
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Figure 3.3 Morphology of U87MG cells cultured in glioma patient serum and non-cancerous human serum. The culture of U87MG cells in glioblastoma patient serum was shown to cause a change 
in morphology with the formation of attached spheroids and elongated uniform arrangements of cells (A-D), seen most prominently following culture in 10 % human serum (D). U87MG cells cultured 
in non-cancerous serum exhibited a ‘star-like’ appearance similar to that of fibroblasts (E-H). Following culture in 10 % non-cancerous serum, spheroids were also observed (H). U87MG cells cultured 
in serum-free medium were observed to form detached spheroids (I). (J) U87MG cells cultured in standard 10 % FBS conditions. Images taken following 48 hrs culture in replacement serum 
concentrations at x10 magnification. 
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Figure 3.4 Morphology of SVGp12 cells cultured in 10 % glioma patient serum and 10 % non-cancerous human serum. Culture of SVGp12 in both glioma patient serum (A-D) and non-cancerous 
human serum (E-H) did not show any visible changes in morphology. SVGp12 cells cultured in serum free medium showed reduced confluency and an increase in necrotic cells (I). (J) SVGp12 cells 
cultured in standard 10 % FBS conditions. Images taken following 48 hrs culture in replacement serum concentrations at x10 magnification.  
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3.2.3 Immunostaining of U87MG and SVGp12 following serum replacement 
indicated cells had not undergone an epithelial-mesenchymal transition  
 
Changes in serum type could stimulate changes in cell phenotype due to differences in 
composition such as growth factors and miRNAs. To determine whether the 
morphological changes observed in Section 3.2.2 following serum replacement were 
associated with changes in cell phenotype, cells were immunostained for various 
markers. Neuronal and epithelial-mesenchymal transition markers were used to 
determine whether the structures seen were related to de-differentiation and re-
differentiation into an alternative cell phenotype and glial markers were also used to 
determine whether the cell lines had not changed in phenotype. SVGp12 and U87MG 
cells stained positive for glial fibrillary acidic protein (GFAP), a glial cell marker, and 
S100B, an astrocyte marker, in all serum conditions (Figure 3.5). U87MG and SVGp12 
cell lines cultured in all three serum conditions were negative for the neuronal specific 
markers (Figure 3.6 and 3.7). In the mesenchymal marker set all immunostaining of 
cells were negative except for vimentin which was positive for both 10 % glioma 
patient serum and 10 % FBS control in both SVGp12 and U87MG cultures (Figure 3.8).  
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Figure 3.5 Immunostaining of glial markers and negative control in U87MG and SVGp12 cells following serum replacement. U87MG and SVGp12 cells cultured in both glioma patient serum and FBS 
showed positive staining (indicated by brown colour) for GFAP and S100B and negative staining for the negative control containing no primary antibody. Cells were counterstained with haematoxylin. 
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Figure 3.6 Neuronal marker immunostaining of U87MG cells cultured in 10 % glioma patient serum and 10 % FBS.  
U87MG cells cultured in both glioma patient serum and FBS were negative for all neuronal markers. Positive 
controls GFAP and S100B (Figure 3.5). Cells were counterstained with haematoxylin.  
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Figure 3.7 Neuronal marker immunostaining of SVGp12 cells cultured in 10 % glioma patient serum and 10 % FBS.  
SVGp12 cells cultured in both glioma patient serum and FBS were negative for all neuronal markers. Positive 
controls GFAP and S100B (Figure 3.5).  Cells were counterstained with haematoxylin. 
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Figure 3.8 Mesenchymal marker immunostaining of U87MG and SVGp12 cells cultured in 10 % glioma patient serum and 10 % FBS.  SVGp12 and U87MG cells cultured in both glioma patient serum 
and FBS stained positive for vimentin. SVGp12 and U87MG cells cultured in both serum conditions were negative for both desmin and α-SMA. Positive controls GFAP and S100B (Figure 3.5).   
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3.2.4 MicroRNA expression of U87MG in standard culture conditions 
compared to SVGp12 
 
To elucidate the effect of serum replacement on miRNA expression of U78MG and 
SVGp12 cell lines, expression of miRNAs in cell lines cultured in standard conditions (10 
% FBS) was determined using the miScript brain cancer array panel.  MiRNA expression 
in U87MG cells was measured against SVGp12 cells as a control. MiR-29b-3p showed 
the greatest increase in fold change of 3.94 in U87MG compared to SVGp12. The 
remaining three up-regulated miRNAs, miR-9, miR-101 and miR-328, exhibited around 
a two-fold change (Figure 3.9).  Overall there was a greater number of miRNAs with a 
decrease in expression in the U87MG cell line compared to SVGp12. From the 84 
miRNAs within the panel, 28 showed a decrease in expression in the U87MG cell line 
compared to SVGp12 (Figure 3.10). Comparing the 28 miRNAs with reduced 
expression, miR-326 and miR-31-5p showed the greatest decrease in fold change of 
0.0065 and 0.0244 respectively.  
 
Figure 3.9 Intracellular expression of up-regulated miRNA in U87MG in standard culture conditions. Four miRNAs 
showed an increase in expression in U87MG cells cultured in 10 % FBS (n=1) compared to SVGp12 cells (n=1). MiR-
29b-3p showed the greatest increase in expression. MiR-101-3p, miR-328 and miR-9-5p showed a similar increase in 
expression in U87MG cells. Data shown as fold change expression compared to SVGp12 set at a standard value of 1. 
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Figure 3.10 Intracellular expression of miRNA with reduced expression in U87MG in standard culture conditions. A total of 28 miRNAs showed reduced expression in U87MG cells 
cultured in 10 % FBS (n=1) compared to SVGp12 cells (n=1). MiR-326 and miR-31-5p showed the greatest decrease in expression in U87MG cells. Data shown as fold change expression 
compared to SVGp12 set at a standard value of 1.  
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3.2.5 MicroRNA expression in U87MG and SVGp12 cells following Serum 
Replacement 
 
Following analysis of miRNA expression of U87MG and SVGp12 in standard FBS 
conditions (Section 3.2.4), the four up-regulated miRNAs (miR-101-3p, 29b-3p, 328, 9-
5p) and four miRNAs (miR-326, 31-5p, 141, 148a) with the largest magnitude of 
reduced expression were chosen to determine whether serum replacement would 
cause a change in intracellular miRNA expression in the cell lines. U87MG and SVGp12 
cells were weaned from 10 % FBS onto either 10 % serum from glioma patients or 10 % 
serum from non-cancerous patients (Section 2.1.7). Cells were cultured for 48 hours in 
10 % replacement serum to allow one full cell cycle, then total RNA was extracted and 
used to analyse miRNA expression. Further to this, extracellular miRNA expression in 
the spent media of weaned cell lines was compared to those cultured in FBS, to 
determine whether serum replacement would affect the expression of secreted 
exosomal miRNAs.  The miRNAs with reduced expression, miR-141 and 31-5p, were 
not detected in any of the serum conditions intracellularly or extracellularly for both 
U87MG and SVGp12.  
From the eight miRNAs chosen for this study, miR-148a alone was found to be 
expressed in exosomes isolated from the spent media of both SVGp12 and U87MG cell 
lines (Figure 3.11), for all three serum conditions. Changing the serum in the culture 
media from 10 % FBS to 10 % glioma patient serum or 10 % control serum did not 
significantly alter miR-148a secreted into the spent media extracellularly for either 
U87MG or SVGp12 (Figure 3.11A and B). MiR-148a detection was significantly higher (p 
< 0.001) in the medium of U87MG cells cultured in 10 % glioma serum (Figure 3.11C), 
10 % non-cancerous serum (Figure 3.11D), and 10 % FBS (p < 0.01)(Figure 3.11E) 
compared to the media of SVGp12 cells.  
80 
 
 
Figure 3.11 Extracellular expression of miR-148a in U87MG cells following serum replacement. A) Comparison of miR-148a expression in U87MG cultured in different serum conditions. No 
significant difference was observed between the three serum conditions by one-way ANOVA with Tukey post-hoc test. B) No significant difference in miR-148a expression was observed in SVGp12 
cells cultured in 10 % replacement human serum compared to 10 % FBS by one-way ANOVA with Tukey post-hoc test. C) MiR-148a expression in U87MG cells cultured in 10 % glioma patient serum 
was significantly higher compared to SVGp12 by student’s t-test. D) MiR-148a expression in U87MG cells cultured in 10 % non-cancerous human serum was higher compared to SVGp12. E) MiR-148a 
expression in U87MG cells cultured in 10 % FBS was significantly higher compared to SVGp12.Data shown as mean of triplicate experiments with SD with control SVGp12 expression set to a standard 
value of 1. Significance between groups indicated by a solid black line, p > 0.05, **p < 0.01, ***p < 0.001. 
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A comparison of intracellular U87MG cells cultured in the three different serum 
conditions showed a significantly (p < 0.01) higher level of expression of miR-148a in 
U87MG cells cultured in non-cancerous human serum and those cultured in FBS 
(Figure 3.12A). There was no significant difference in intracellular expression of miR-
148a in SVGp12 cells cultured in the three serum conditions (Figure 3.12B). 
Intracellular miR-148a expression was significantly (p < 0.01) reduced in U87MG cells 
cultured in glioma patient serum and FBS compared to SVGp12 cells cultured in the 
same conditions (Figure 3.12C and D). There was no significant difference in 
intracellular miR-148a expression between U87MG and SVGp12 cells cultured in non-
glioma patient serum (Figure 3.12D).   
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Figure 3.12 Intracellular expression of miR-148a in U87MG cells following serum replacement. A) Comparison of miR-148a expression in U87MG cells cultured in three serum conditions. MiR-148a 
was significantly higher in U87MG cells cultured in 10 % non-cancerous serum compared to 10 % FBS by one way ANOVA with Tukey post-hoc test. B) Expression of miR-148a in SVGp12 cells cultured 
in varying serum conditions was not significantly different. C) Expression of miR-148a in U87MG cells cultured in 10 % glioma patient serum was reduced compared to SVGp12, student’s t-test. D) 
Expression of miR-148a in U87MG cells cultured in 10 % non-cancerous human serum was not significantly different compared to SVGp12. E) Expression of miR-148a in U87MG cells cultured in 10 % 
FBS was down-regulated compared to SVGp12. Data shown as mean of triplicate experiments with SD with control SVGp12 values set to a standard value of 1 (A, C-E) and B) control FBS set to a 
standard value of 1. Significance between groups indicated by a solid black line, p > 0.05, **p < 0.01, ***p < 0.001. 
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MiR-101 was expressed in U87MG cells alone (Figure 3.13). Furthermore, expression of 
miR-101 was not detected in the spent media of U87MG cells cultured in all three 
serum conditions. Higher expression of miR-101 in U87MG cells compared to SVGp12 
correlated with the data shown in Figure 3.9. MiR-101 was significantly higher (p = 
0.0106) in U87MG cells cultured in 10 % glioma patient serum compared to those 
cultured in FBS. U87MG cells cultured in 10 % non-cancerous human serum also 
exhibited a significantly higher expression (p = 0.0106) of miR-101 compared to FBS. 
There was no significant difference in miR-101 expression between U87MG cells 
cultured in glioma patient serum and non-cancerous human serum.  
 
                
Figure 3.13 Intracellular expression of miR-101 in U87MG cells following serum replacement. Expression of miR-
101 in U87MG cells cultured in 10 % glioma patient serum and 10 % non-cancerous human serum was significantly 
higher compared to U87MG cells cultured in standard 10 % FBS conditions by one way ANOVA with Tukey post-hoc 
test, p<0.05. Data shown as mean of triplicate experiments with SD with 10 % FBS control value set to a standard 
value of 1. Significance between groups indicated by a solid black line, *p = 0.0106. 
 
Intracellular miR-29b was significantly higher (p < 0.01) in all three serum conditions 
for U87MG compared to SVGp12 (Figure 3.14B, C and D).  
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Figure 3.14 Intracellular expression of miR-29b in U87MG cells following serum replacement. A) Comparison of miR-29b in U87MG cells cultured in three serum conditions. There was no significant 
difference in miR-29b expression in U87MG cells cultured in 10 % human serum or 10 % FBS. B) Expression of miR-29b in U87MG cells cultured in  10 % glioma patient serum was up-regulated 
compared to SVGp12, student’s t-test, p <0.01. C) Expression of miR-29b in U87MG cells cultured in 10 % non-cancerous human serum was up-regulated compared to SVGp12, student’s t-test, p < 
0.001. D) Expression of miR-29b in U87MG cells cultured in 10 % FBS was up-regulated compared to SVGp12, student’s t-test, p < 0.001. Data shown as mean of triplicate experiments with SD with 
control SVGp12 expression set to a standard value of 1.  
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MiR-328 was not expressed in SVGp12 cells in any of the three serum conditions but 
was expressed in U87MG cells (Figure 3.15). Expression was slightly reduced in U87MG 
cells cultured in 10 % glioma serum compared to the FBS control. U87MG cells cultured 
in 10 % non-cancerous human serum expressed miR-328 at a slightly higher level than 
cells cultured in FBS. The changes observed however, were not significantly different (p 
> 0.05).   
             
Figure 3.15 Intracellular expression of miR-328 in U87MG cells following serum replacement. Expression of miR-
328 in U87MG cells cultured in 10 % glioma patient serum and 10 % non-cancerous human serum was not 
significantly different compared to U87MG cells cultured in 10 % FBS. Data shown as mean of triplicate experiments 
with SD with control FBS set to a standard value of 1.   
 
MiR-9 was also expressed in U87MG cells alone and in all three serum conditions miR-
9 was not significantly reduced (p > 0.01) in U87MG cells cultured in glioma patient 
serum compared to those cultured in FBS. No significant difference in expression (p > 
0.01) was observed between U87MG cells cultured in non-cancerous human serum 
and either FBS or glioma patient serum (Figure 3.16).  
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Figure 3.16 Intracellular expression of miR-9 in U87MG cells following serum replacement. Expression of miR-9 in 
U87MG cells cultured in both 10 % non-cancerous human serum and 10 % glioma patient serum was not 
significantly different compared to U87MG cells cultured in 10 % FBS p > 0.01. Data shown as mean of triplicate 
experiments with SD with control FBS set to a standard value of 1.  
 
Comparison of the three serum conditions showed that miR-326 was significantly 
higher (p < 0.001) in U87MG cells cultured in non-cancerous human serum compared 
to U87MG cells cultured in glioma patient serum and FBS (Figure 3.17A). In contrast, 
miR-326 was not significantly different (p > 0.01) in SVGp12 cells grown in glioma 
serum compared to cells grown in non-cancerous serum (Figure 3.17B). SVGp12 cells 
grown in either 10 % glioma serum or FBS showed no significant difference in 
intracellular miR-326 expression than U87MG cells grown in the same conditions (p > 
0.01) (Figure 3.17C and). Conversely, U87MG cells grown in 10 % control patient serum 
showed a significantly higher level of intracellular miR-326 expression than SVGp12 (p 
< 0.01).  
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Figure 3.17 Intracellular expression of miR-326 in U87MG cells following serum replacement. A) Comparison of miR-326 expression in U87MG cells cultured in different serum conditions. MiR-326 
was significantly increased in U87MG cells cultured in 10 % non-cancerous human serum compared to those cultured in 10 % FBS. U87MG cells cultured in 10 % non-cancerous human serum had a 
higher expression of miR-326 compared to those cultured in 10 % glioma patient serum. B) Expression of miR-326 in SVGp12 cells grown in varying serum conditions was not significantly different 
between SVGp12 cells cultured in 10 % glioma serum and 10 % non-cancerous serum. C) Expression of miR-326 in U78MG cells in 10 % glioma patient serum was reduced compared to SVGp12. D) 
Expression of miR-326 in U87MG cells cultured in 10 % non-cancerous human serum was higher compared to SVGp12. E) Expression of miR-326 in U87MG cultured in 10 % FBS was reduced compared 
to SVGp12. Data shown as triplicate experiments with SD with control SVGp12 set to a standard value of 1 (A, C-E) and B) control FBS set to a standard value of 1. Significance between groups 
indicated by solid black line, *p < 0.05, **p < 0.01, ***p < 0.001.  
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3.3 Discussion  
 
A human cell culture model for the investigation of miRNA expression has been 
developed using serum replacement techniques to wean cells off FBS and onto human 
serum. The differential effects of human serum from both glioma and non-cancer 
control subjects on the morphology and growth of U87MG and SVGp12 cells suggests a 
variance in sera compositions. Whilst the precise difference in serum composition is 
unknown, changes in miRNA expression as identified in previous studies could 
potentially be a contributing factor to the results observed in this study (Roth et al., 
2011, Yang et al., 2013b). Previously, analysis of tumour derived exosomes has 
identified differences in protein, mRNA and miRNA expression (Xiao et al., 2012). 
Profiling of melanoma cell line derived exosomes and non-cancerous melanocyte cell 
line exosomes showed distinct profiles of differentially expressed proteins and mRNAs 
as well as tumour-specific oncogenic miRNAs (Xiao et al., 2012). The proteins and RNA 
present within melanoma exosomes were found to play a role in cell migration, 
invasion and proliferation (Xiao et al., 2012). The cellular uptake of exosomes of 
different protein and RNA composition present in non-cancerous and cancerous serum 
could therefore result in differences in cell growth and phenotype as observed in this 
study.  
In this study, the culture of U87MG and SVGp12 cells in sera from both cancerous and 
non-cancerous subjects resulted in an increase in cell number compared to standard 
FBS. The presence of exosomes within the replacement serum could have resulted in 
the increase in cell number. The application of glioblastoma exosomes to U87MG cells 
has previously been shown to increase their proliferative potential (Skog et al., 2008). 
The application of exosomes to cell culture in increasing concentrations has also shown 
a dose-dependent increase in proliferation and glycolytic activity (Graner, 2011). In the 
current study however, cells were not cultured with human derived exosomes alone 
but with whole replacement serum containing growth factors and signalling molecules 
which could also cause an increase in cell number. To determine whether the increase 
in cell number was a result of exosomes U87MG and SVGp12 cells could be cultured 
with exosomes, enriched from cancerous and non-cancerous serum and cell numbers 
compared to U87MG and SVGp12 cells cultured in whole replacement serum and 
standard FBS.   
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The changes in morphology observed following serum replacement could have been a 
result of transdifferentiation of cells into a different phenotype. Initial investigations 
were therefore performed to determine whether the changes were due to the 
expression of neuronal markers. Immunohistochemical staining for neuronal markers 
however was negative for both U87MG and SVGp12 in all three serum conditions. This 
suggested that the acquisition of a neuronal phenotype had not occurred following 
serum replacement.  
In glioma, including glioblastoma, cells undergo an epithelial-mesenchymal transition 
(EMT) to facilitate tumour progression and metastasis. Tumour cells undergoing EMT 
undergo both molecular reprogramming and morphological changes to acquire 
invasive characteristics which allow them to alter the microenvironment, enter the 
stroma and promote metastasis (Iwatsuki et al., 2010). EMT is initially characterised by 
the loss of endothelial markers such as E-cadherin and the acquisition of mesenchymal 
markers such as vimentin, through alterations in signalling pathways which regulate 
these proteins. E-cadherin is an epithelial-specific transmembrane glycoprotein which 
forms tight junctions with neighbouring cells, reduced expression of E-cadherin causes 
the loss of cell-cell adhesion (Iwatsuki et al., 2010). Clinically, the loss of E-cadherin is 
often associated with an aggressive phenotype and poor prognosis (Gregory et al., 
2008). Following the induction of mesenchymal marker expression, cells undergo 
cytoskeletal remodelling and subsequent changes in cell-matrix adhesion through 
activation of proteolytic enzymes such as MMPs (Iwatsuki et al., 2010).  
Research has also identified a role for miRNAs in EMT miRNA microarray profiling has 
identified the miR-200 family and miR-205 as regulators of EMT. These miRNAs repress 
EMT by targeting critical signalling pathways and inhibitors of E-cadherin, ZEB1 and 
ZEB2 (Gregory et al., 2008). Down-regulation of these miRNAs in cancer promotes EMT 
and subsequent invasion (Gregory et al., 2008). Following transition to a mesenchymal 
phenotype, cells display a spindle-shaped morphology and have increased migratory 
ability (Iwatsuki et al., 2010). 
Following serum replacement and culture in 10 % glioma serum, U87MG cells were 
observed to have spindle-shape morphology consistent with that observed following 
EMT. This morphology however was also observed in U87MG cells cultured in 10 % 
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non-cancerous serum suggesting that factors within the serum which caused this 
alteration may not be glioblastoma specific and not a result of EMT.  Further to this, 
staining for EMT markers was negative except for vimentin which stained positive for 
both cell lines cultured in both glioma serum and FBS. Vimentin is an intermediate 
filament expressed in cells (Schiffer et al., 1986) that is up-regulated in EMT (Lee et al., 
2006). The strength of staining for the vimentin marker in both cell lines did not 
appear to be increased in the U87MG cells compared to those cultured in glioma 
serum compared to FBS and the SVGp12 cell line cultured in both serum conditions. 
Along with the negative staining of desmin and α-SMA EMT markers, this suggests that 
the U87MG cells cultured in glioma serum had not undergone EMT.   
Both U87MG and SVGp12 stained positive for the glial marker GFAP and the astrocyte 
marker S100B. GFAP is the main intermediate filament in astrocytes which modulates 
astrocyte motility and shape (Eng et al., 2000). S100B is a protein of the S100-
calmodulin-troponin family and is an astrocyte specific marker (Adami et al., 2001). 
Positive staining for the glial and astrocyte cell markers again supported the conclusion 
that the cells had not undergone EMT.  
Cells undergo changes in shape and therefore morphology by rearrangement of the 
cytoskeleton changes (Bissell et al., 2003), biochemical changes and changes in gene 
expression (Kenny et al., 2007). The culture of U87MG cells in both cancerous and non-
cancerous human serum caused changes in morphology, culture of SVGp12 cells in the 
same conditions however, did not result in any clear changes in morphology and in 
addition, immunostaining confirmed retention of a glial phenotype. This suggests a cell 
type specific response to changes in serum conditions which may be a result of 
differences in gene and protein expression between the two cell lines and not 
transdifferentiation into a new cell phenotype.  
In comparison to replacement of serum type, the effect of serum-free conditions on 
cell line morphology U87MG and SVGp12 cells was also determined. Cells were 
cultured in decreasing concentrations of FBS and increasing concentrations of serum 
free medium. The culture of both cell lines in serum-free medium resulted in the 
formation of spheroids, a visual reduction in cell number and an increase in necrotic 
cells. There were no apparent similarities in morphology between U87MG and SVGp12 
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cells cultured in serum-free medium compared to those cultured in both cancerous 
and non-cancerous human serum. When cultured in serum free medium both cell lines 
showed an increase in necrotic cells and a reduction in cell number, this suggested that 
the cell may have been weaned too quickly to adjust to the stress of the new serum 
condition rather than an effect of the serum free medium.    
To determine whether the culture of U87MG and SVGp12 in human serum caused a 
change in miRNA expression, miRNA profiles of U87MG cells compared to SVGp12 cells 
both grown in standard 10 % FBS serum conditions were determined. U87MG cells in 
standard culture conditions showed reduced expression of 28 miRNAs and increased 
expression of four miRNAs compared to non-cancerous SVGp12 cells. The general 
decrease in miRNA expression is similar to the global decrease in miRNA expression 
observed in tumour tissues (Calin and Croce, 2006). MiR-326 and 31-5p showed the 
greatest decrease in expression in U87MG cell lines compared to SVGp12. Out of the 
28 miRNAs reduced in U87MG cells cultured in 10 % FBS, 16 are expressed at a lower 
level in glioblastoma tissue (Table 3.1) and 12 are increased (Table 3.2). MiR-190a 
expression, targets and role in glioma has not previously been studied. MiR-187 
altered expression has been identified, however, targets and function in glioma has 
not yet been elucidated. MiR-130b has been identified to have a role in the regulation 
of metastasis, however the targets of miR-130b have not yet been validated.  
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Table 3.1 Expression of miRNA down-regulated in both U87MG cells and glioblastoma tissue 
 
 
 
 
 
Table 3.2 Expression of miRNA down-regulated in U87MG cells and up-regulated in glioblastoma tissue 
MicroRNA Expression in GBM Targets Role Reference 
miR-107 Down VEGF,  
Notch 2 
Migration, Invasion  (Singh et al., 2012, 
Chen et al., 2013) 
miR-125a Down ERBB2, PDPN Invasion  (Henriksen et al., 
2014a, Cortez et 
al., 2010) 
miR-128 Down E2F3a Proliferation  (Zhang et al., 2009) 
miR-132 Down CDKN1A Gliomagenesis (Singh et al., 2012) 
miR-138 Down IGF1R, 
ROCK2 
Proliferation, 
apoptosis 
(Wang et al., 2012, 
Singh et al., 2012) 
miR-146a Down EGFR, 
 Notch 1 
Glioma growth and 
migration 
(Mei et al., 2011) 
miR-16 Down BCL2 Glioma growth and 
invasion 
(Yang et al., 2014) 
miR-18a Down Smad3 Migration, radiation 
resistance 
(Fox et al., 2013) 
miR-200a Down Β-catenin Cell growth and 
survival 
(Su et al., 2012) 
miR-203a Down Robo1 Migration (Dontula et al., 
2013) 
miR-31 Down Radixin Invasion and 
migration 
(Hua et al., 2012a) 
miR-326 Down PKM2,  
Notch 1/2 
Metabolism, 
proliferation  
(Singh et al., 2012) 
miR-7 Down EGFR Invasion (Kefas et al., 2008) 
miR-187 Down  - - (Wang et al., 2012) 
miR-425 Down  Notch1/2 Proliferation, 
radioresistance, 
‘stemness’ 
(Singh et al., 2012) 
MicroRNA Expression in GBM Targets Role Reference 
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Three of the four miRNAs with increased expression in U87MG cells cultured in 
standard FBS conditions have been found to show reduced expression in glioblastoma 
tissue. The four miRNAs with increased expression in U87MG cells were miR-101-3p, 
29b-3p, miR-328 and miR-9-5p. MiR-101 expression is reduced in glioblastoma tissue 
which subsequently promotes proliferation, migration and angiogenesis due to the 
overexpression of the miR-101 target EZH2 (Smits et al., 2010). MiR-29b is also down-
regulated in glioblastoma tissue and plays a role in suppressing invasion by targeting 
podoplanin membrane sialo-glycoprotein (PDPN) (Cortez et al., 2010). MiR-29b also 
targets Cdc42 a GTPase which regulates cell morphology and migration signalling 
miR-183 Up EGR1 Migration  (Sarver et al., 
2010) 
miR-106b Up RBL2 Proliferation (Zhang et al., 2013) 
miR-130b Up - Metastasis (Su et al., 2010) 
miR-141 Up PTEN, TGFB2 Glioma growth, 
invasion  
(Singh et al., 2012, 
Koul, 2008) 
miR-148a Up MIG6, BIM Apoptosis  (Kim et al., 2014) 
miR-17-5p Up PTEN Invasion, migration (Li and Yang, 2013) 
miR-17-3p Up MDM2 Proliferation and 
drug resistance 
(Li and Yang, 2013) 
miR-182 Up CYLD, TNIP1, 
OPTN, USP15 
Invasion, 
angiogenesis 
(Song et al., 2012) 
miR-19b Up PTEN Gliomagenesis (Jia et al., 2013) 
miR-20a Up E2F1/2/3, 
PTEN, NRAS 
Apoptosis, 
proliferation  
(Sylvestre et al., 
2007, Singh et al., 
2012) 
miR-93 Up Integrin-β8 Glioma growth, 
angiogenesis 
(Fang et al., 2011) 
miR-96 Up HBP1 Proliferation  (Yan et al., 2014) 
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pathways (Cortez et al., 2010) and can induce apoptosis by up-regulating p53 (Park et 
al., 2009). MiR-328 expression is also reduced in glioblastoma tissue and plays a role in 
cell cycle progression, high expression of miR-328 in U87MG cells has been shown to 
suppress proliferation (Wu et al., 2012). MiR-9 has been found to be highly expressed 
in glioblastoma tissue and suppresses the mesenchymal differentiation of GBM cells as 
well as promoting chemoresistance to TMZ by inducing the expression of the drug 
efflux transporter, p-glycoprotein (Munoz et al., 2013).   
Differences in expression between the U87MG cell line and glioblastoma may be a 
result of culture artefacts, such as mutations which occur as a result of establishment 
and long term culture of cells, therefore acquired mutations may cause an alteration in 
miRNA expression not representative of glioblastoma. Genomic analysis of established 
glioma cell lines including U87MG identified recurrent aberrations and global gene 
expression clusters not represented in primary gliomas, suggesting that established 
glioma cell lines, including U87MG, are poorly representative of primary gliomas (Li et 
al., 2008). Although miRNA expression was not determined by Li et al., changes in gene 
expression will most likely affect miRNA expression and therefore the data observed in 
this study. Conversely, the use of one U87MG and SVGp12 sample may have affected 
the data observed as the changes in miRNA expression observed in this study may be 
specific to these samples.   
Following identification of miRNAs with altered expression in U87MG cells cultured in 
FBS, the effect of serum replacement on the expression of selected miRNAs identified 
was investigated. MiR-148a alone was detected extracellularly in exosomes isolated 
from the spent media. The presence of this single miRNA out of the 8 chosen may be 
due to the selective packaging of exosomes (Chen et al., 2012). MiR-148a plays a role 
in a number of glioblastoma functions including cell growth, survival, migration and 
invasion (Kim et al., 2014). MiR-148 targets include MIG6 which regulates EGFR, and 
BIM which regulates apoptosis (Kim et al., 2014). The extracellular presence of miR-
148a may be due to its migratory and invasive promoting properties, as uptake of 
exosomal miR-148a by recipient cells may result in recruitment of neighbouring cells in 
the tumour microenvironment to promote invasion (Skog et al., 2008). Comparison of 
intracellular and extracellular miR-148a expression showed that expression of this 
miRNA was higher in the medium than in the cell. Again, this may be due to selective 
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exosomal packaging of miRNAs. Expression of miR-148a was higher in U87MG cells 
cultured in non-cancerous human serum compared to glioma serum. 
MiR-148a exhibited a higher intracellular expression in U87MG cells cultured in glioma 
serum and non-cancerous serum. This suggests that the culture of U87MG cells in 
human serum caused an increase in expression of this miRNA. Intracellular expression 
of miR-148a was higher in U87MG cells cultured in non-cancerous human serum 
compared to those cultured in glioma serum and this trend was also observed in the 
extracellular expression of miR-148a. The high expression of miR-148a in U87MG cells 
cultured in both cancerous and non-cancerous serum suggests factors in human serum 
which promote the up-regulation of this miRNA. The higher expression of miR-148a in 
U87MG cells cultured in non-cancerous serum suggests that the components which 
cause this up-regulation are present at a higher level in non-cancerous serum 
compared to glioma serum.  
Although miR-148a is a tumour promoting miRNA up-regulated in glioblastoma tissue, 
U87MG cells cultured in FBS showed a reduced expression of miR-148 compared to 
SVGp12 determined by both the miScript analysis and the subsequent serum weaning 
study.  This again highlights the difference in gene and protein expression observed 
between the U87MG cell line and glioblastoma tissue (Li et al., 2008).  
Out of the eight miRNAs, three were not detected in the SVGp12 cells in any of the 
culture conditions and miR-141 and 31-5p were not detected in any of the serum 
conditions for both cell lines. This may be due to the expression of these miRNAs being 
below the limit of detection. The detection of these miRNAs in U87MG cells suggests 
that these miRNAs may be expressed at a higher level than in SVGp12 cells.  
Expression of miR-101 was not significantly different in U87MG cells cultured in both 
glioma patient serum and non-cancerous human serum compared to those cultured in 
FBS. This suggests that factors present in both cancerous and non-cancerous human 
serum do not affect the expression of miR-101.  
The intracellular expression of miR-29b and 328 was not significantly different 
between the three culture conditions suggesting that factors within the glioma and 
non-cancerous serum do not affect the expression of these miRNAs or the 
transcription factors which may target them and regulators of their expression. 
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Furthermore miR-328 was not detected in SVGp12 cells and expression of miR-29b was 
up-regulated in all three serum conditions in U87MG compared to SVGp12, suggesting 
that both the miRNAs are up-regulated in U87MG cells however this up-regulation is 
not dependent on serum type.  
Intracellular expression of miR-9 was highest in U87MG cells cultured in 10 % FBS and 
was not significantly different in U87MG cells cultured in glioma patient serum 
compared to FBS. MiR-9 however, has been previously found to be highly expressed in 
glioblastoma (Malzkorn et al., 2010). MiR-9 inhibits proliferation of glioma cells by 
targeting CREB and promotes migration by targeting NF1 (Tan et al., 2012a). 
Expression of intracellular miR-326 was not significantly different in U87MG cells 
cultured in 10 % glioma serum and FBS compared to SVGp12. MiR-326 is a tumour 
suppressor, the down-regulation of which contributes to tumourigenesis and invasion 
in glioma (Wang et al., 2013). The culture of U87MG cells in non-cancerous human 
serum had no significant effect on the expression of miR-326. Down-regulation of miR-
326 is believed to be as a result of decreased expression of its host gene, Arrestin β1 
(Jiang et al., 2014). MiRNA expression can be down-regulated by transcriptional 
repression by various transcription factors, therefore the up-regulation of transcription 
factors in glioma serum compared to non-cancerous human serum may have resulted 
in the down-regulation observed in U87MG cells cultured in glioma serum and the up-
regulation observed in those cultured in non-cancerous serum. Conversely, the 
presence of proteins in the non-cancerous human serum which may inhibit a miR-326 
repressor may have also resulted in the observed up-regulation in U87MG cells 
cultured in this serum type. MiR-326 has been found to be up-regulated following the 
knockdown of Notch-1 (Kefas et al., 2009). Furthermore, miR-326 is part of a 
regulatory feedback loop, in which miR-326 inhibits the Notch pathway and in turn is 
inhibited itself by Notch (Kefas et al., 2009).  Comparison of U87MG miR-326 
expression in the three serum conditions showed a significant up-regulation in non-
cancerous human serum compared to both glioma patient serum and FBS. MiR-326 
was also significantly higher in U87MG cells cultured in glioma patient serum 
compared to those cultured in FBS. 
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Analysis of the effects of serum replacement on U87MG and SVGp12 cell lines showed 
that the culture of these cell lines in both cancerous and non-cancerous human serum 
had cell growth and morphological effects. Initial studies identifying miRNA expression 
of cell lines in standard culture conditions showed differences in miRNA expression 
between U87MG and SVGp12. Cell culture in human serum caused changes in miRNA 
expression suggesting differences in composition between human and bovine serum. 
Furthermore changes in miRNA expression were observed in cells cultured in non-
cancerous and cancerous serum. The intracellular miRNA expression of cell lines 
observed in this study was different to that of glioblastoma serum therefore caution 
should be exercised when extrapolating miRNA data from in vitro cell culture, and all 
components should ideally be defined to accurately determine the source of variation.   
Overall, the data collected within this study suggests that the composition of serum is 
different between patients with and without glioblastoma and that serum can alter 
miRNA expression of cells in culture. The identification of differences in miRNA could 
be used for biomarkers for diagnosis of glioblastoma. Further studies were performed 
to determine whether serum miRNA expression differed between glioblastoma 
patients and control patients and whether these differences could be used as 
biomarkers.   
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4. Identification of Serum MiRNA 
Biomarkers
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4.1 Introduction  
 
MiRNAs are present in the serum of both healthy and diseased individuals. The expression 
levels of these miRNAs can alter during disease, therefore the identification of miRNA 
which alter in a disease specific manner could be utilised as biomarkers (Chen et al., 
2008). Serum miRNA biomarkers would be particularly useful for diagnosis, prognosis and 
predicting response to treatment for glioma as they provide a relatively non-invasive test 
and would require only a blood sample in comparison to the current diagnostic method of 
surgical brain biopsy. The detection of miRNA in serum samples can be performed by 
techniques such as SOLEXA sequencing (Ji et al., 2014), qRT-PCR (Kroh et al., 2010) and 
microarray (Lodes et al., 2009). These techniques are sensitive and can detect low copy 
numbers of miRNA (Chen et al., 2005).   
Data from Chapter 3 (Section 3.2.5) showed that immortalised cell lines U87MG and 
SVGp12 cultured in either human serum from glioblastoma patients or individuals without 
glioblastoma differed in the morphology, growth and expression of miRNA. One of the 
factors which differ between cancerous and non-cancerous serum is the miRNA profile 
(Chen et al., 2008). Changes in miRNA expression in the serum of glioblastoma patients 
have already been identified and therefore have the potential to be used as biomarkers 
for this disease (Yang et al., 2013b). The aim of this chapter was to identify miRNA with 
altered expression in the serum of glioblastoma patients and investigate the use of 
miRNAs as diagnostic and prognostic biomarkers. The potential of altered miRNA 
expression in glioblastoma patient serum for prognostic information was determined 
utilising survival data of the patients used in this study.  
The attractiveness of miRNAs as circulatory biomarkers has led a number of studies to 
identify serum miRNA signatures which could be used for glioblastoma detection 
(Baraniskin et al., 2012, Chen et al., 2008, Noerholm et al., 2012), however, few of these 
studies have investigated the effects of variables such as age and gender on the 
expression profile of glioblastoma patients. Recently variables such as age and gender 
were shown to affect serum expression of some miRNAs in non-cancerous individuals 
(Sawada et al., 2014). As shown in Section 1.1.2, epidemiological data indicate that the 
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incidence of glioblastoma differs depending on the gender and age of a patient. The 
incidence of glioma is higher in males compared to females and increases with age 
(Crocetti et al., 2012) suggesting differences in the molecular characteristics of 
glioblastomas between individuals which could include miRNA expression. This study 
therefore aimed to not only identify a serum miRNA profile for glioblastoma patients but 
to also investigate the effect of age and gender on miRNA expression to provide a more 
accurate biomarker panel for glioblastoma.  
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4.2 Results 
4.2.1 MiScript MicroRNA Expression in Serum Obtained from Glioblastoma 
Patients Aged between 20 and 39 Years. 
 
In order to select miRNA biomarkers for glioblastoma, initial studies were performed to 
determine the miRNA profile of serum from glioblastoma patients analysed in gender and 
age groups selected based on those used by Crocetti et al., (2012). Serum expression 
profiles were elucidated using the miScript brain cancer array and analysed using the 
online PCR array tool. MiRNAs were scored either A, B or C by the online tool from the 
average Ct value, where C was a miRNA whose calculated fold change may not be 
representative of the actual fold change. These data were used to identify dysregulated 
miRNAs which could be further studied for use as biomarkers. Serum samples from 18 
glioblastoma patients and 18 control patients, three male and three female samples for all 
three age groups, were individually analysed in matched groups in order to identify age 
and gender specific miRNA expression.  
In the 20-39 glioblastoma age group, eight miRNAs exhibited altered expression in all 
three serum samples for both males and females compared to age matched controls 
(Table 4.1). Comparison of the eight miRNAs identified five miRNAs with a similar fold 
change in expression for both genders with the exception of miR-16-5p, 15b-5p and 451a. 
MiR-16-5p had a 3.5 fold increase in expression in male samples compared to a 15.3 fold 
up-regulation in female samples. MiR-15b-5p showed a 2.76 fold increase in expression in 
female patient serum and a 4.17 fold increase in male patient serum. MiR-486-5p showed 
a 5.1 fold increase in expression in the male samples however a reduction in expression 
was observed in the female samples. MiR-451a showed a 4.5 fold increase in expression in 
male samples whereas female samples showed a 39.7 fold increase.  
Analysis of serum samples obtained from glioblastoma patients aged between 20 and 39 
years identified 13 miRNAs with an increase in expression in all three samples tested in 
the female group (Figure 4.1A). MiR-451a exhibited the highest fold change increase in 
expression of 39.7 fold. Analysis of miRNA expression in the serum of male glioblastoma 
patients aged between 20 and 39 years identified 17 miRNAs with an increase in 
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expression, but no miRNAs were observed to be reduced. Let-7b-5p exhibited the greatest 
increase in expression in the male 20-39 age group compared to matched controls (Figure 
4.1B).   
Three miRNAs showed an increase in expression in the sera of female patients only, miR-
29c-3p, 27a-3p and 24-3p (Figure 4.2A). The expression of six miRNAs were increased in 
the sera of male 20-39 patients alone; let-7-5p, miR-25-3p, 26a-5p, 92a-3p, 144-3p and 
320a (Figure 4.2B).   
Table 4.1 MiRNAs dysregulated in the serum of both male and female glioblastoma patients aged between 20 and 39 
years compared to age and sex matched controls. 
 Female  Male  
MiRNA Average Fold Change  SD Average Fold Change  SD 
miR-15b-5p 2.76 1.09 4.17 0.42 
miR-16-5p 15.30 6.08 3.50 0.95 
miR-17-5p 2.47 2.47 2.46 0.58 
miR-19a-3p 4.38 0.86 4.71 0.72 
miR-23a-3p 3.43 0.32 2.50 0.29 
miR-148a-3p 3.68 1.23 2.25 0.25 
miR-191-5p 4.26 0.89 5.07 0.37 
miR-451a 39.70 19.73 4.50 0.82 
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Figure 4.1 Expression of miRNAs in the serum of glioblastoma patients aged between 20 and 39 years. A) Average miRNA fold change in female glioblastoma patients aged between 20 
and 39 years showed a number of miRNAs undetected in the sample set. The majority of the miRNAs dysregulated in this cohort were increased (red). B) Average fold change of miRNA 
in male glioblastoma patients aged between 20 and 39 years. The majority of miRNAs in this cohort were increased compared to gender and age matched controls. Heat map is 
representative of all three patient samples analysed showing all miRNAs scored A, B and C using online data analysis tool, line H of 96 well plate containing controls is not included in the 
heat maps. Ce: C. elegans primer assay, SN1-6: snoRNA/snRNA PCR controls, miRTC: Reverse transcription control, PPC: Positive PCR control. 
A B 
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Figure 4.2 Expression of dysregulated miRNAs in the serum of glioblastoma patients aged between 20 and 39 years 
compared to age and sex matched controls. A) 13 miRNAs were increased in the serum of female glioblastoma patients 
between 20 and 39 years, with miR-451a showing the greatest increase in expression. B) 17 miRNAs were increased in 
the serum of male glioblastoma patients aged between 20 and 39 years with let-7b-5p showing the greatest increase in 
expression. No miRNAs were observed to be reduced in the male cohort. Data shown as mean of triplicate samples plus 
SD, representative of 3 samples per group, normalised to the cel-miR-39 spike in, with an average Ct scored either A or B 
using the online array tool. Significance between glioblastoma serum expression and control patient serum indicated by 
letters. ap < 0.001, bp < 0.01, cp < 0.05.  
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a b 
c c c c c c c c c c 
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4.2.2 MiScript MicroRNA Expression in Serum Obtained from Glioblastoma 
Patients Aged between 40 and 59 Years. 
 
Analysis of serum samples obtained from three female and three male glioblastoma 
patients aged between 40 and 59 years identified eight miRNAs expressed in all three 
samples from both the male and female 40-59 age groups (Table 4.2). Four of the eight 
miRNAs, let-7b-5p, 150-5p, 181b-5p and 92a-3p, displayed an increased up-regulation in 
male 40-59 serum samples compared to age matched female samples. The remaining 
four, 21-5p, 23a-3p, 25-3p and 191-5p, were expressed at higher levels in female samples 
compared to male age matched samples.  
Most miRNAs with altered expression in all three female samples tested were up-
regulated (Figure 4.3A). The majority of miRNAs analysed were undetected in the three 
samples tested from the female 40-59 group. A greater number of miRNAs were detected 
in the male 40-59 age group compared to the female group with four of the 84 miRNAs 
being undetected in all three samples (Figure 4.3B).  
Serum obtained from female glioblastoma patients aged between 40 and 59 years showed 
an increase in expression of 20 miRNAs in all three samples compared to age and sex-
matched control samples (Figure 4.4A). MiR-21-5p was the highest expressed miRNA in 
female 40-59 patients with a fold change of 8.59, was the second highest expressed 
miRNA was let-7b-5p with a fold change of 7.97. Three of the miRNAs showed a five-fold 
increase in expression, miR-451a, miR-23a-3p and miR-25-3p with a further two exhibiting 
a four-fold increase, miR-486-5p and 191-5p.   
Out of the 84 miRNAs analysed, 18 were highly expressed in the three serum samples of 
male glioblastoma patients aged between 40 and 59 years (Figure 4.4B). Let-7b-5p had the 
highest expression with a fold change of 17.32 and miR-203a-3p being the second highest 
expressed miRNA with a fold change of 9.62. Mir-21-5p exhibited a 5.00 fold increase in 
expression with miR-222-5p and 150-5p showing a 4.00 fold increase in expression.  
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Table 4.2 MiRNAs dysregulated in the serum of both male and female glioblastoma patients aged between 40 and 59 
years.
 
 
 
 
 Female  Male  
MiRNA Average Fold Change  SD Average Fold Change SD 
Let-7b-5p 7.97 2.43 17.32 6.21 
MiR-150-5p 3.35 1.02 4.25 2.12 
MiR-181b-5p 2.59 0.87 3.42 2.14 
MiR-92a-3p 2.09 0.54 3.92 1.17 
MiR-21-5p 8.59 0.72 5.11 1.60 
MiR-23a-3p 5.44 1.42 2.38 1.02 
MiR-25-3p 5.27 0.84 2.52 1.36 
MiR-191-5p 4.27 0.26 2.20 1.81 
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Figure 4.3 Expression of miRNAs in serum samples from glioblastoma patients aged between 40 and 59 years. A) Average miRNA fold change in the serum of female patients. The 
majority of dysregulated miRNAs were found to be up-regulated (red) in this patient cohort however most miRNAs within the array were not detected in this sample set. B) Average 
miRNA fold change in the serum of male patients. Four miRNAs were not detected in this patient cohort, many of the miRNAs that were detected in this cohort showed a similar 
expression to matched controls. Heat map is representative of all three patient samples analysed showing all miRNAs scored A, B and C using online data analysis tool, line H of 96 well 
plate containing controls is not included in the heat maps. Ce: C. elegans primer assay, SN1-6: snoRNA/snRNA PCR controls, miRTC: Reverse transcription control, PPC: Positive PCR 
control.
B A 
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Figure 4.4 Expression of dysregulated miRNAs in glioblastoma patients aged between 40 and 59 years. A) 20 miRNAs 
were up-regulated in the serum of female glioblastoma patients in the 40-59 age group with miR-21-5p exhibiting the 
highest fold change. B) 16 miRNAs were up-regulated in the serum of male glioblastoma patients between the ages of 40 
and 59 years. Let-7b-5p exhibited the highest up-regulation with a fold change of 17.32. Data shown as mean of 
triplicate samples plus SD, representative of 3 samples per group, of miRNAs scored either A or B using the online array 
tool, normalised to the cel-miR-39 spike in. Significance between glioblastoma serum expression and control patient 
serum indicated by letters. ap < 0.001, bp < 0.01, cp < 0.05. 
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4.2.3 MiScript MicroRNA Expression in Serum Obtained from Glioblastoma 
Patients Aged Over 60 Years.  
 
Analysis of serum obtained from glioblastoma patients aged over 60 years identified a 
total of seven miRNAs dysregulated in the six serum samples of both male and female 
glioblastoma patients over the age of 60 years (Table 4.3). Comparison of the seven 
miRNAs identified five miRNAs which exhibited a higher expression in the male 60+ 
glioblastoma group compared to age matched females except miR-9-3p and miR-29c-3p 
which were expressed at a higher level in the female group.  
An overall trend of reduced expression in miRNAs compared to age and sex-matched 
controls was observed in all three samples obtained from female glioblastoma patients 
when all miRNAs were investigated regardless of Ct score (Figure 4.5A). Analysis of the 
dysregulated miRNAs scored A or B only showed 10 miRNAs with an increase in expression 
and no miRNAs with a lower expression compared to age and sex-matched controls 
(Figure 4.6).  Upon analysis of serum miRNA expression in male glioblastoma patients aged 
over 60 years increased expression of 42 miRNAs in all three serum samples compared to 
age and sex-matched controls was observed (Figure 4.5B). Overall the male group 
displayed a general trend of increased miRNA expression compared to age and sex-
matched controls. 
In the female group, miR-19a-3p and miR-29b-3p showed the greatest increase in 
expression compared to matched controls with a fold change of 4.99 and 4.45 respectively 
(Figure 4.6). Four miRNAs showed a 3.00 fold increase in the female group, miR-9-3p, miR-
17-5p, miR-29c-3p and miR-128-3p.  
Analysis of the male group identified miR-328-3p and 181a-5p as having the greatest 
increase in expression in comparison to matched controls with a fold change of 6.22 and 
5.9, respectively (Figure 4.7). Two miRNAs exhibited a five-fold increase, miR-181a-5p and 
miR-15a-5p and five miRNAs showed a four-fold increase, miR-29b-3p, 15b-5p, 34a-5p, 
miR-92a-3p and miR-9-5p. Nine miRNAs showed approximately a three fold increase in 
expression and 25 miRNAs showed at least a two fold increase in expression.  
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Table 4.3 MiRNAs dysregulated in the serum of both male and female glioblastoma patients aged over 60 years 
compared to age and sex matched controls. 
 Female  Male  
MiRNA Average Fold Change SD Average Fold Change SD 
miR-9-3p 3.98 0.51 3.33 0.49 
miR-15b-5p 2.38 0.65 4.91 0.27 
miR-29b-3p 4.45 0.87 4.99 0.58 
miR-29c-3p 3.22 0.74 2.48 0.27 
miR-34a-5p 2.72 0.81 4.70 0.43 
miR-181a-5p 2.28 1.30 5.90 0.68 
miR-181b-5p 2.78 0.73 3.72 0.35 
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Figure 4.5 Expression of miRNA in serum obtained from glioblastoma patients over the age of 60 years. A) Average miRNA expression in the serum of female patients showed both a 
down-regulation (green) and up-regulation (red) of miRNAs compared to gender and age-matched controls. 17 miRNAs were not detected in this patient cohort. B) Average miRNA fold 
change in the serum of male patients. The majority of dysregulated miRNAs were found to be up-regulated in this patient cohort and 20 miRNAs were not detected in this sample set. 
Heat map is representative of all three patient samples analysed showing all miRNAs scored A, B and C using online data analysis tool, line H of 96 well plate containing controls is not 
included in the figure.  
A B 
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Figure 4.6 Dysregulated miRNAs in the serum of female glioblastoma patients aged over 60 years. 10 miRNAs were increased in the serum of female 60+ glioblastoma patients with 
miR-19a-3p exhibiting the highest fold-change. Data shown as mean of triplicate samples plus SD, representative of 3 samples per group of miRNAs scored either A or B using the online 
array tool, normalised to the cel-miR-39 spike in. Significance between glioblastoma serum expression and control patient serum indicated by letters. ap < 0.001, bp < 0.01. 
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Figure 4.7 Dysregulated miRNAs in the serum of male glioblastoma patients aged over 60 years. 42 miRNAs were increased in the serum of male glioblastoma patients aged over 60 
years, with miR-328-3p showing the greatest increase in expression. Data shown as mean of triplicate samples plus SD, representative of 3 samples per group, of miRNAs scored either A 
or B using the online array tool, normalised to the cel-miR-39 spike in. Significance between glioblastoma serum expression and control patient serum indicated by letters. ap < 0.001. 
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4.2.4 Selection of Serum MicroRNA Biomarkers  
 
Following identification of miRNAs with altered expression in the sera of glioblastoma 
patients grouped by age and gender, a panel was selected for further analysis in a new 
patient cohort of 18 GBM patients and 18 control patients. Due to the small sample size 
used in the initial study, miRNAs with altered expression in more than three patient 
groups or both gender cohorts of the same age group were selected for this study. 
Following these criteria, 32 miRNAs were selected for analysis in a new patient cohort 
(Table 4.4).  
Analysis of the 32 miRNAs selected in the new patient cohort using student’s t-test with 
Levene’s F test identified 18 miRNAs that were undetected in any of the patient serum 
samples grouped by age and gender (Table 4.5).  Analysis of the 32 miRNAs identified nine 
miRNAs with no significant change (p > 0.05) in expression in glioblastoma patient serum 
compared to age and sex matched controls. Comparison of the non-significant miRNAs in 
glioblastoma patient serum compared to control patient serum is shown in Figure 4.8. 
Data were further analysed by gender and age groups which also showed no significant 
difference (p > 0.05) in expression (Appendix 3). Five miRNAs were identified to have a 
significant change in expression in the serum of glioblastoma patients, miR-20a-5p, miR-
30c-5p, miR-34a-5p, miR-92a-3p and miR-150-5p. MiR-34a expression was not 
significantly different (p > 0.05) in the serum of glioblastoma patients compared to control 
patients (Figure 4.9A). Analysis of patients grouped by gender showed no significant 
difference (p > 0.05) in miR-34a expression in both male and female glioblastoma patient 
cohorts (Figure 4.9 B and C). When grouped by age miR-34a was not detected in the 
serum of glioblastoma patients or control patients aged between 20 and 39 years. MiR-
34a expression was not significantly different (p > 0.05) between glioblastoma patients 
aged between 40 and 59 years compared to age matched controls (Figure 4.9D). 
Expression of miR-34a in the serum of glioblastoma patients aged over 60 years was found 
to be significantly up-regulated (p < 0.05) compared to age matched controls (Figure 4.9E).  
Comparison of miR-92a expression in glioblastoma patient serum compared to control 
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patient serum showed no significant difference (p > 0.05) between the two cohorts (Figure 
4.10A).  
Table 4.4 MiRNAs selected for analysis as biomarkers and average fold change of all patient groups. Red – Increased 
expression, Green – Decreased expression, Black – No change in expression compared to control samples.  
MiRNA Female 
60+ 
Male 
60+ 
Female 
40-59 
Male 
40-59 
Female 
20-39 
Male 
20-39 
let-7-5p 1.35 1.52 7.97 17.32 0.54 11.76 
7-5p 0.31 3.36 2.18 0.68 - 0.92 
9-3p 3.98 3.33 - 0.84 - - 
15b-5p 2.38 4.91 3.94 3.02 2.76 4.17 
16-5p 2.48 1.63 2.43 1.53 15.37 3.53 
17-5p 3.24 1.21 - 2.17 2.47 2.46 
18a-5p 0.49 2.61 - 0.48 - 1.59 
19a-3p 4.99 1.71 - 2.25 4.38 4.71 
19b-3p 1.50 1.81 - 2.21 3.48 2.18 
20a-5p 1.67 1.24 2.25 1.05 3.12 2.05 
21-5p 1.57 1.06 8.59 4.25 1.17 1.76 
23a-3p 0.68 2.70 5.44 2.38 3.43 2.50 
25-3p 0.33 2.32 5.27 2.52 0.80 4.75 
26a-5p 0.58 2.88 2.56 0.62 1.93 4.07 
29b-3p 4.45 4.99 - 1.38 - 1.21 
29c-3p 3.22 2.48 - 1.15 2.61 1.68 
30b-5p 0.45 2.60 - 1.01 1.71 0.93 
30c-5p 0.48 2.79 - 0.74 1.81 1.25 
34a-5p 2.72 4.70 2.44 0.75 - - 
92a-3p 0.88 4.24 2.09 3.92 0.50 2.3 
93-5p 1.85 2.32 - 2.43 2.00 2.52 
101-3p 1.14 2.33 - 0.70 2.01 3.00 
148a-3p 1.81 1.99 - 1.44 3.68 2.25 
150-5p 1.50 1.06 3.35 4.25 1.12 1.74 
181a-5p 2.28 5.90 - 1.09 - 0.69 
181b-5p 2.78 3.72 2.59 3.42 1.15 0.79 
185-5p 0.59 2.55 - 2.37 1.36 2.11 
191-5p 2.12 3.28 4.27 2.20 4.26 5.07 
320a 0.62 2.82 3.24 1.26 1.96 4.40 
328-3p 0.22 6.22 0.47 0.92 1.71 1.11 
451a 1.51 1.29 5.46 0.51 39.76 4.51 
486-5p 0.88 3.25 4.78 1.66 0.07 5.13 
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Table 4.5 MiRNAs undetected in glioblastoma patient serum samples in new patient cohort analysed using miScript 
brain cancer panel. 
Undetected miRNAs 
miR-7-5p miR-26a-5p 
let-7b-5p miR-29b-3p 
miR-9-3p miR-29c-3p 
miR-15b-5p miR-30b-5p 
miR-16-5p miR-93-5p 
miR-18a-5p miR-148a-3p 
miR-19a-3p miR-181a-5p 
miR-19b-3p miR-185-5p 
miR-21-5p miR-191-5p 
 
Analysis of miR-92a by gender showed that miR-92a was significantly up-regulated in the 
sera of male glioblastoma patients (p < 0.05) but not in female glioblastoma patients (p > 
0.05, Figures 4.10B and C). Analysis of miR-92a by age groups showed no significant 
difference in expression (p > 0.05) compared to age matched controls for all three patient 
cohorts (Figure 4.10D-F).  
Analysis of miR-20a expression displayed a significant up-regulation (p < 0.05) in the 
serum of glioblastoma patients compared to control patients (Figure 4.11A).  When 
grouped by gender miR-20a was significantly increased in the serum of both male (p < 
0.05) and female (p < 0.05) glioblastoma patients compared to sex matched controls 
(Figure 4.11 B and C).  Analysis of miR-20a by age showed a significant increase of miR-20a 
in the 20-39 (p < 0.001) and 40-59 (p < 0.05) age groups (Figure 4.11 D and E). Expression 
of miR-20a in the serum of glioblastoma patients over the age of 60 years was not 
significantly different (p > 0.05) to age matched controls (Figure 4.11F). Further analysis of 
miR-20a expression in glioblastoma patient serum identified a subgroup of nine patients 
who did not exhibit an increase in miR-20a and nine patients who exhibited an up-
regulation of miR-20a (p > 0.05, Figure 4.12A). Expression of miR-20a was significantly 
increased in glioblastoma patients between the ages of 20 and 39 years compared to 
those aged between 40 and 59 years (p < 0.01) and those aged over 60 years (p < 0.001, 
Figure 4.12B). No significant difference (p > 0.05) in expression of miR-20a was observed 
between the 40-59 age group and the 60+ age group. 
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Figure 4.8 Selected serum miRNAs with no significant change in expression.  Nine miRNAs exhibited no significant change in expression in GBM patient serum compared to matched 
controls.  Data shown as mean of triplicate samples plus SD analysed by unpaired student’s t-test, miR-486-5p analysed by Mann Whitney U test, p > 0.05.  
miR-486-5p  
miR-17-5p  miR-23a-3p  miR-101-5p  
miR-181b-5p  miR-328-5p  miR-451-5p  miR-320-5p  
miR-25-5p  
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Figure 4.9 Expression of miR-34a in glioblastoma patients aged over 60 years. Expression of miR-34a was not 
significantly different between GBM and control patients (A) or when grouped by gender (B and C).Expression of miR-
34a was not significantly different between GBM patients aged between 40 and 59 years and age matched controls (D). 
MiR-34a was significantly up-regulated in the serum of glioblastoma patients aged over 60 years compared to age 
matched controls (E). Data shown as mean plus SD of replicate samples (A - n = 18, B and C - n = 9, D and E - n = 6 per 
group), data analysed by Mann Whitney U test. Significance indicated between groups by solid black lines, * p < 0.05.  
 
A 
B C 
D E 
* 
119 
 
                        
Figure 4.10 Expression of miR-92a in serum. Expression of miR-92a was not significantly altered in the serum of GBM patients compared to controls (A) or female GBM patients (B). MiR-
92a was significantly increased in the serum of male GBM patients compared to sex matched controls (C). Expression of miR-92a was not significantly different when patients were 
grouped by age (D-F). Data shown as mean of replicates (A - n = 18, B and C - n = 9, D-F - n = 6 per group) plus SD, analysed by unpaired student’s t-test. Significance indicated between 
groups by solid black lines, * p < 0.05.  
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Figure 4.11 Expression of miR-20a in serum. MiR-20a was significantly increased in glioblastoma patient serum compared to controls (A). MiR-20a was significantly up-regulated in both 
male and female patients (B and C). When grouped by age miR-20a was significantly increased in GBM patients in the 20-39 (D) and 40-59 (E) age groups but not the 60+ age group (F). 
Data shown as mean of replicates (A - n = 18, B and C - n = 9, D-F - n = 6 per group) plus SD, A - analysed by unpaired student’s t-test B-F analysed by Mann Whitney U test. Significance 
indicated between groups by solid black lines, * p < 0.05, *** p < 0.001.  
A 
B C 
D E F 
* * 
*** * 
* 
121 
 
 
         
      
Figure 4.12 Expression of miR-20a in the serum of glioblastoma patient subgroups. A) Two groups of GBM patients 
were observed with differing miR-20a expression, those with an increase in expression (> 2 fold change, n = 9) and those 
with no change (< 2 fold change, n = 9). B) Expression of miR-20a was inversely correlated with age with GBM patients 
aged between 20 and 39 years exhibiting the highest expression. Data shown as mean of replicate samples (A- n = 18 
GBM, 18 control, B - n=6 per age group) plus SD, analysed by one-way ANOVA with Tukey post-hoc test. Significance 
between groups indicated by a solid black line, **p < 0.01, ***p < 0.001. 
 
*** 
** 
** 
*** 
A 
B 
122 
 
The subgroup of glioblastoma patients with an increase of miR-20a comprised all six 
patients aged between 20 and 39 years, one patient aged between 40 and 59 years and 
two patients aged over 60 years. The subgroup of glioblastoma patients with no change in 
miR-20a expression comprised of five patients aged between 40 and 59 years and four 
patients aged over 60 years.  
Analysis of miR-30c exhibited a significant down-regulation (p < 0.01) in the serum of both 
male and female glioblastoma patients aged between 20 and 39 years. MiR-30c was not 
detected in either the 40-59 or 60+ age groups (Figure 4.13). MiR-150 was observed to be 
significantly down-regulated (p < 0.05) in the serum of both male and female glioblastoma 
patients aged between 20 and 39 years. MiR-30c was not detected in the 40-59 or 60+ 
glioblastoma patient age groups (Figure 4.14).  
 
                     
Figure 4.13 Expression of miR-30c in the serum of glioblastoma patients aged between 20 and 39 years. MiR-30c was 
down-regulated in the serum of GBM patients aged between 20 and 39 years. Data shown as mean of replicates (n=6 
per group) plus SD, analysed unpaired student’s t-test. Significance between groups indicated by a solid black line, **p < 
0.01.  
** 
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Figure 4.14 Expression of miR-150 in the serum of glioblastoma patients aged between 20 and 39 years. Expression of 
miR-150 was significantly down-regulated in the serum of GBM patients aged between 20 and 39 years compared to 
matched controls. Data shown as mean of replicate samples (n=6 per group) plus SD, analysed by unpaired student’s t- 
test. Significance between groups indicated by a solid black line, *p < 0.05.  
 
4.2.5 Validation of MicroRNA Biomarkers by Power Analysis  
 
Following the identification of a panel of potential miRNA biomarkers, the five miRNAs 
were validated in a further study using power analysis to determine the appropriate 
sample size to ensure confidence in any significant changes observed in expression. Power 
analysis was performed using GraphPad prism Statmate and standard deviation of ΔCt 
values for each miRNA were used to determine sample size for at least 80 % power to 
detect a difference between means of 1 Ct value (Table 4.6). 
Table 4.6 Sample number required in each experimental group required for a minimum of 80 % power. 
MiRNA Standard Deviation Sample Size Required   Statistical Power  
miR-34a-5p 0.65 8 90 % 
miR-92a-3p 1.4 35 80 % 
miR-20a-5p 0.85 14 90 %  
miR-30c-5p 0.21 3 80 % 
miR-150-5p 0.68 9 80 %  
 
* 
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The power analysis determined that eight samples were required in each group for miR-
34a, 14 for miR-20a-5p, 35 for miR-92a-3p, three for miR-30c-5p and nine for miR-150-5p.  
Data from the validation study showed that miR-34a was increased in the serum of 
glioblastoma patients aged over 60 years compared to age matched controls (p < 0.001, 
Figure 4.15). MiR-34a was undetected in the 20-39 patient group, and expression was not 
significantly altered in the 40-59 age group (p > 0.05), compared to age matched controls.  
MiR-92a was significantly increased (p < 0.001) in the validation cohort of male 
glioblastoma patient serum (Figure 4.16).  
MiR-30c was found to be significantly reduced (p < 0.01) in the serum of glioblastoma 
patients aged between 20 and 39 years (Figure 4.17). Analysis of miR-20a expression 
showed an up-regulation (p < 0.01) in a subset of ten patients (Figure 4.18A) and no up-
regulation in five patients however this was not significantly different compared to 
control.  
Expression was highest in glioblastoma patients aged between 20 and 39 years, and 
lowest in patients aged over 60 years (Figure 4.18B). The patient subgroup with an 
increase of miR-20a comprised of all five glioblastoma patients aged between 20 and 39 
years, three patients aged between 40 and 59 years and two patients aged over 60 years. 
MiR-150 expression was not found to be significantly different (p > 0.01) in the serum of 
glioblastoma patients aged between 20 and 39 years in the validation cohort (Figure 4.19).  
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Figure 4.15 Expression of miR-34a in validation cohort. MiR-34a was significantly higher in a validation cohort of serum 
from GBM patients over the age of 60 years compared to age matched controls. Data shown as mean of replicate 
samples (n = 8 per group) plus SD, analysed by unpaired student’s t-test. Significance between groups indicated by a 
solid black line, ***p < 0.001.   
                             
Figure 4.16 Expression of miR-92a in validation cohort. MiR-92a was shown to be significantly higher in a validation 
cohort of serum samples from male GBM patients compared to matched controls. Data shown as mean of replicate 
samples (n=35 per group) plus SD, analysed by unpaired student’s t-test. Significance between groups indicated by a 
solid black line ***p < 0.001. 
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Figure 4.17 Validation of miR-30c expression in the serum of glioblastoma patients aged between 20 and 39 years. 
Expression of miR-30c in the validation cohort exhibited a significant reduction. Data shown as mean of replicate 
samples (n = 3 per group) plus SD, analysed by unpaired student’s t-test. Significance between groups indicated by a 
solid black line, ***p < 0.001.  
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Figure 4.18 Expression of miR-20a in validation cohort. A) Serum miR-20a was observed to be significantly increased in 
a subset of ten GBM patients in the validation cohort however this was not significantly different to control patients. 
Five patients exhibited a less than 2-fold change in expression B) Expression of miR-20a in the validation cohort was 
found to be inversely correlated with age. Data shown as mean of replicate samples (A - n= 15 gbm and 15 control, B - 
n= 5 per age group) plus SD, analysed by Shapiro-Wilk normality test and one way ANOVA with Tukey post-hoc test. 
Significance indicated by a solid black line, **p < 0.01.  
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Figure 4.19 Validation of miR-150 expression in the serum of glioblastoma patients aged between 20 and 39 years. 
Expression of miR-150 in the validation cohort showed no significant difference between 20-39 GBM patient serum and 
matched controls. Data shown as mean of replicated (n= 9 per group) plus SD, analysed by unpaired student’s t-test, p > 
0.05.  
4.2.6 Reanalysis of Unselected MiRNAs  
 
Analysis and validation of the 32 miRNAs identified in Section 4.2.4 identified four miRNAs 
with a significant change in expression in glioblastoma patient serum. The 27 remaining 
miRNAs which were not significantly different in Section 4.2.4 were used to select a small 
panel for reanalysis in a new patient cohort in order to identify additional biomarkers 
which may have been discounted due to false negative data.  
Five miRNAs from the original 32 panel were selected for reanalysis in a new patient 
cohort comprising of 18 GBM patient samples and 18 control patient samples. MiR-19a, 
miR-19b and miR-17-5p were selected for reanalysis as they are part of the miR-17~92 
cluster of miRNAs which also comprises of miR-20a and miR-92a.  MiR-29c was selected 
for reanalysis as it has not been identified in the serum of glioblastoma patients 
previously. Power analysis was performed for miR-17-5p and miR-101 using the standard 
deviations determined in Section 4.2.4 (Table 4.7) to determine the sample size required 
for at least 80 % power. MiR-19a and miR-19b were not detected in the identification 
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cohort in Section 4.2.4, consequently power analysis could not be performed therefore a 
patient cohort consisting of 18 GBM samples and 18 control samples was utilised to 
perform the reanalysis. MiR-19a was not detected in the serum of glioblastoma patients 
following reanalysis. Expression of the remaining four reanalysed miRNAs was not 
significantly different (p > 0.05) between glioblastoma patients and matched controls 
(Figure 4.20 further analysed in Appendix 4). 
Table 4.7 Power analysis for miR-17-5p and miR-101 reanalysis 
MiRNA SD  Sample Size Required for 80 % 
Power  
Power of Reanalysis cohort of 18 
patient samples 
miR-17-5p 0.37 4 99 % 
miR-101  0.55 6 99 % 
  
     
Figure 4.20 Expression of four re-analysed miRNAs in glioblastoma patient serum. Four of the five re-analysed miRNAs 
showed no significant difference in expression in GBM patient serum compared to matched controls. MiR-19a was 
undetected. Data shown as mean of replicates (n = 18 per group) plus SD, MiR-29c and 101 analysed by unpaired 
student’s t-test, miR-17-5p and 19b analysed by Mann Whitney U test, p > 0.05.      
miR-17-5p miR-19b 
miR-101 miR-29c 
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   4.2.7 Prognostic Potential of Serum MiRNA Biomarkers  
 
Following the identification of four significantly dysregulated miRNAs, survival of the 
patients utilised in both the identification and validation panel study were analysed. 
Patient survival data for the samples used in this study were obtained from the BTNW 
tissue bank. Initially, overall survival was plotted for all glioblastoma patients used 
regardless of age or gender, 78 glioblastoma patients and 73 control patients were used in 
this study. Patients were then grouped by age and gender to determine any differences in 
overall survival between these cohorts. Following analysis of patient variable such as age 
and gender, patients were subsequently grouped by expression of the miRNA biomarkers 
validated in Sections 4.2.5. Analysis of miR-20a in the serum of glioblastoma patients 
identified two groups of glioblastoma patients; those with at least a two fold increase in 
miR-20a and those without. Survival data for these patients was obtained and grouped by 
miR-20a expression to determine whether miR-20a was a prognostic indicator for 
glioblastoma patients.   
Overall survival of glioblastoma patients compared to non-cancerous control patients was 
lower with the median overall survival for glioblastoma patients used in this study being 
6.62 months (Figure 4.21). All individuals within the control group were alive during this 
study. When grouped by age, median survival for patients aged between 20 and 39 years 
was 8.88 months. For patients aged between 40 and 59 years, median survival was 6.53 
months and for patients aged over 60 years median survival was 3.36 months (Figure 
4.22). No significant difference in survival was observed between the 20-39 and 40-59 age 
groups (p > 0.05). Survival for the 40-59 age group was significantly different (p < 0.05) 
when compared to the 60+ age group and for the 20-39 age group when compared to the 
60+ group (p < 0.001). When grouped by gender no significant difference in survival was 
observed (p > 0.05). Male patients had a median survival of 5.88 months whereas female 
patients had a median survival of 7.98 months (Figure 4.23).   
Analysis of survival for glioblastoma patients over the age of 60 years from the biomarker 
identification cohort grouped by miR-34a expression showed that patients with a low 
expression of miR-34a had a median survival of 10.6 months and patients with a high 
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expression of miR-34a had a median survival of 8.78 months (Figure 4.24). Of the six 
patients analysed in the identification cohort, four exhibited a greater than two fold 
change of miR-34a, with one patient still living and two patients exhibited a less than two 
fold change, with one patient still living. Median survival between patients with and 
without a two fold change in miR-34a expression in the identification cohort was not 
significantly different (p > 0.05). 
 
Figure 4.21 Kaplan-Meier survival curve of glioblastoma (GBM) patients compared to patients without glioblastoma 
(Control). Median survival of 78 GBM patients used in this study was 6.62 months. Steps down indicate the death of a 
patient, dashes indicate patients alive at the time of this study. Survival was significantly different between the groups 
determined by Mantel-Cox test, ****p < 0.0001.   
 
 
 
**** 
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Figure 4.22 Kaplan-Meier survival curve of glioblastoma (GBM) patients grouped by age. Median survival of GBM 
patients grouped by age was 8.88 months for patients aged between 20 and 39 years, 6.53 months for patients aged 
between 40 and 59 years and 3.36 months for patients aged over 60 years. Steps down indicate the death of a patient, 
dashes indicate patients alive at the time of this study. Survival was significantly different between the 20-39 and 60+ 
age groups (p < 0.001) and the 40-59 and 60+ age groups (p < 0.05) but not the 20-39 and 40-59 age groups (p > 0.05) 
determined by Mantel-Cox test.  
 
 
Figure 4.23 Kaplan-Meier survival curve of glioblastoma (GBM) patients grouped by gender. Median survival for male 
GBM patients (n = 54) was 5.8 months compared to 7.98 months for female GBM patients (n = 24). Steps down indicate 
the death of a patient, dashes indicate patients alive at the time of this study. Survival was not significantly different 
determined by Mantel-Cox test, p > 0.05.  
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In the validation cohort, five patients exhibited a greater than two fold increase of miR-
34a expression and exhibited a median survival of 4.85 months (Figure 4.25). Three 
patients exhibited a less than two fold change in miR-34a expression in the validation 
cohort and had a median survival of 7.32 months (Figure 4.25). Median survival was not 
significantly different (p > 0.05) between patients with and without a two fold change in 
miR-34a expression.  
Combined analysis of 60+ glioblastoma patients in both the identification and validation 
cohorts showed that the nine patients with a greater than two fold increase in miR-34a 
expression exhibited a median survival of 9.49 months, the five patients with a less than 
two fold change in miR-34a expression showed a median survival of 8.05 months (Figure 
4.26). Survival was not significantly different (p > 0.05) between patients with and without 
a twofold change in expression.  
Analysis of patient survival by miR-92a expression showed no significant difference (p > 
0.05) in expression between patients with a greater than two fold change in expression 
and those without.  
 
Figure 4.24 Kaplan-Meier survival curve of glioblastoma patients over the age of 60 years grouped by miR-34a 
expression. Median survival for patients with a high expression of miR-34a was 10.6 months (n = 4). Median survival for 
patients with a low expression of miR-34a was 8.78 months (n = 2). Survival was not significantly different between 
groups determined by Mantel-Cox test, p > 0.05 
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Figure 4.25 Kapan-Meier survival curve of 60+ glioblastoma patients in the validation cohort grouped by miR-34a 
expression. Median survival for patients in the validation cohort with a greater than two fold change of miR-34a was 
4.85 months (n = 5). Median survival for patients with a less than two fold change in miR-34a expression was 7.32 
months (n= 3). Survival was not significantly different between groups determined by Mantel-Cox test, p > 0.05 
 
 
 
Figure 4.26 Kaplan-Meier survival curve of combined identification and validation patient cohorts over the age of 60 
years grouped by miR-34a expression. Median survival for patients with a two fold change in miR-34a expression was 
9.49 months (n = 9). Median survival for patients with a less than two fold change in miR-34a expression was 8.05 
months (n = 5). Survival was not significantly different between groups determined by Mantel-Cox test, p > 0.05 
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Male glioblastoma patients with an increase in expression of miR-92a had a median 
survival of 9.55 months and those with no change in miR-92a expression had a median 
survival of 6.30 months (Figure 4.27). From the nine male patients whose samples were 
used in the identification cohort, six exhibited a greater than two fold increase and three 
exhibited a less than two fold change in expression. Analysis of male glioblastoma patients 
in the validation cohort showed 28 patients with a greater than two fold increase of miR-
92a with a median survival of 5.67 months (Figure 4.28).  Eight patients exhibited a less 
than two fold change in expression and had a median survival of 5.85 months, therefore 
survival was not significantly different (p > 0.05) between patients with and without a two 
fold change in miR-92a expression (Figure 4.28). Combined analysis of both the 
identification and validation cohorts for miR-92a expression showed no significant 
difference (p > 0.05) in expression between those with a two fold increase of miR-92a and 
those without (Figure 4.29).  
 
 
Figure 4.27 Kaplan-Meier survival curve of male glioblastoma patients grouped by miR-92a expression. Median 
survival for male glioblastoma patients with a high expression of miR-92a was 9.55 months (n = 6). Median survival for 
patients with a low expression of miR-92a was 6.30 months (n = 3). Survival was not significantly different determined by 
Mantel-Cox test, p > 0.05. 
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Figure 4.28 Kaplan-Meier survival curve of male glioblastoma patients in the validation cohort grouped by miR-92a 
expression. Median survival for male glioblastoma patients with a greater than two fold change in miR-92a was 5.67 
months (n = 28). Median survival for male glioblastoma patients with a less than two fold change in miR-92a was 5.85 
months (n = 8). Survival was not significantly different determined by Mantel-Cox test, p > 0.05. 
 
 
Figure 4.29 Kaplan-Meier survival curve of male patients from both the identification and validation cohorts grouped 
by miR-92a expression. Median survival of male glioblastoma patients with a greater than two fold change in miR-92a 
expression had a median survival of 6.68 months (n = 34). Median survival of male glioblastoma patients with a less than 
two fold change in miR-92a expression had a median survival of 5.75 months (n = 11).  Survival was not significantly 
different determined by Mantel-Cox test, p > 0.05. 
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The patient cohorts used in the initial biomarker identification study and validation study 
both exhibited a reduced expression of miR-30c. The reduction in expression however, 
was greater in the validation study cohort than in the identification study cohort, 
therefore the median survival for the two cohorts was compared (Figure 4.30). Median 
survival for patients in the two cohorts was not significantly different (p > 0.05) with 
patients in the identification cohort having a median survival of 30.89 months and 
patients in the validation cohort having a median survival of 20 months (Figure 4.30). 
Patients used in the initial biomarker identification study with an increase in miR-20a had 
a median survival of 21.39 months compared to 4.45 months for patients with no change 
in miR-20a expression p < 0.001 (Figure 4.31). Patients in the validation cohort with an up-
regulation of miR-20a had a median survival of 9.49 months compared to 1.65 months for 
patients with no change in miR-20a expression p < 0.001 (Figure 4.32A). Combined 
survival analysis of patients from the initial biomarker identification phase and patients 
from the validation cohort showed that patients with an increase of miR-20a had a 
median survival of 10.12 months compared to a median survival of 3.04 months p < 0.001 
for those with no change in miR-20a expression (Figure 4.32B).  
 
 
 
 
138 
 
 
Figure 4.30 Kaplan-Meier Survival Curve of glioblastoma patients aged between 20-39 years grouped by 30c 
expression. Mean fold change of miR-30c in the serum of glioblastoma patients aged between 20-39 years was 0.17 and 
these patients exhibited a median survival of 30.89 months (n = 9). Mean fold change for patients in the validation 
cohort was -1.36 and these patients exhibited a median survival of 20 months (n = 3). Steps down indicate the death of a 
patient, dashes indicate patients alive at the time of this study. Median survival between the two cohorts was not 
significant, determined by Mantel-Cox test, p > 0.05. 
 
Figure 4.31 Kaplan-Meier survival curve of glioblastoma patients grouped by miR-20a expression. Median survival for 
GBM patients with a 2-fold or greater increase of miR-20a expression was 21.39 months (n = 9). Median survival for 
patients with less than a 2-fold change in miR-20a expression was 4.45 months (n = 9). Steps down indicate the death of 
a patient, dashes indicate patients alive at the time of this study. Survival was significantly different between groups 
determined by Mantel-Cox test, ***p < 0.001.  
*** 
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Figure 4.32 Kaplan-Meier survival curve of glioblastoma patients grouped by miR-20a expression. A) Median survival 
of GBM patients in the validation set with a greater than two fold increase of miR-20a expression was 9.49 months 
compared to 1.65 months for patients with no change in miR-20a expression. B) Combined survival data for patients 
from both initial biomarker identification and validation cohorts displayed a median survival of 10.12 months for 
patients with a greater than two fold increase of miR-20a expression and 3.04 for patients with no change in miR-20a 
expression. Steps down indicate the death of a patient, dashes indicate patients alive at the time of this study. Survival 
was significantly different between groups determined by Mantel-Cox test, ***p < 0.001. 
 
*** 
*** 
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4.2.8 Correlation between MiR-34a and Patient Age 
 
MiR-34a expression has previously been shown to have a correlation with the age of 
individuals (Li et al., 2011b, Sawada et al., 2014). The correlation between miR-34a and 
age was analysed in the serum samples used in this study to elucidate whether a similar 
trend in expression and age was observed. In order to determine the expression of miR-
34a in the control samples as well as the glioblastoma samples, delta Ct values were used 
for the analysis of miR-34a expression and age. 
Analysis of miR-34a expression in control serum showed no significant difference in miR-
34a expression in patients over the age of 60 years compared to those aged between 40 
and 59 years (Figure 4.33). MiR-34a was not detected in non-cancerous serum from 
individuals aged between 20 and 39 years. MiR-34a was increased in the sera of 
glioblastoma patients aged over 60 years compared to patients aged between 40 and 59 
years (Figure 4.33). MiR-34a was not detected in the serum of glioblastoma patients aged 
between 20 and 39 years. Expression of miR-34a was higher in glioblastoma patients over 
the age of 60 years compared to age-matched control patients. Expression of miR-34a in 
glioblastoma patients aged between 40 and 59 years was not significantly different (p > 
0.05) when compared to age-matched controls (Figure 4.33).  
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Figure 4.33 Expression of miR-34a by age in glioblastoma and control patient serum. MiR-34a was significantly higher 
in glioblastoma patients over the age of 60 years compared to the 40 and 59 group. MiR-34a was significantly higher in 
glioblastoma patients over the age of 60 years compared to age matched controls. Data analysed by one way ANOVA 
with Tukey post-hoc test. Significance between groups indicated by a solid black line,  ***p < 0.001.   
 
4.2.9 Relationship between MiR-92a and MiR-20a Expression  
 
MiR-92a and 20a are part of the 17~92 cluster of miRNAs which are located in the same 
region of the genome and transcribed together (Mendell, 2008), therefore the expression 
of these two miRNAs was analysed together in the serum of each glioblastoma and control 
patient to determine whether there was a correlation between the expression levels. 
Analysis of miR-92a and 20a in serum from control patients (Figure 4.34A) and patients 
with glioblastoma (Figure 4.34B) showed no correlation in expression. 
*** *** 
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Figure 4.34 Relationship between miR-20a and miR-92a expression. A) Analysis of serum miR-20a and miR-92a 
expression in individuals without glioblastoma showed no correlation. B) Analysis of serum miR-20a and miR-92a 
expression in glioblastoma patients showed no correlation. Data analysed by Pearson correlation, A) p > 0.05 (r = 0.19), 
B) p > 0.05 (r = 0.06).  
 
A 
B 
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4.3 Discussion  
 
The miRNA expression profiles obtained in this chapter exhibited differences in miRNA 
expression between genders and age groups of glioblastoma patients, highlighting the 
importance of considering these variables when investigating miRNA biomarkers for 
disease, including glioblastoma. Analysis of miRNA expression using the miScript brain 
cancer array identified miR-191-5p alone to be up-regulated in both male and female 
glioblastoma patients in all three age groups. MiR-191-5p has previously been 
identified to be up-regulated in glioblastoma cell lines (Ciafrè et al., 2005) however, 
there is no current research investigating the role of miR-191-5p in glioblastoma.  MiR-
191-5p is part of the miR-191/425 cluster which is expressed in an intron of the 
DALRD3 gene with which it is co-expressed (Kulshreshtha and Nagpal, 2014). Altered 
expression of miR-191 has been observed in a number of cancer types including lung, 
liver, prostate and breast cancer, however whether expression is up or down-regulated 
depends on the cancer type (Kulshreshtha and Nagpal, 2014).   
Five miRNAs were identified which displayed significantly altered expression in the 
sera of glioblastoma patients: miR-20a, miR-30c, miR-34a, miR-92a and miR-150. MiR-
34a expression was up-regulated in the serum of glioblastoma patients over the age of 
60 years. MiR-34a has been found to be down-regulated in glioblastoma tissue and is a 
target of p53, a known tumour suppressor (Okada et al., 2014). MiR-34a targets c-Met, 
Notch-1 and Notch-2 in glioblastoma tissue to inhibit proliferation and invasion (Li et 
al., 2009).  MiR-34a expression in the brain has previously been found to increase with 
age (Li et al., 2011b) which corroborated the data observed in this chapter. Analysis of 
ΔCt values of both control and glioblastoma patient serum showed an increase in 
expression of miR-34a with age. Further to the correlation between miR-34a 
expression and age, the expression of miR-34a was observed to be higher in 
glioblastoma patients compared to age matched control patients in which patients 
over the age of 60 years with glioblastoma exhibited a higher expression of miR-34a 
compared to age-matched controls. Glioblastoma patients aged between 40 and 59 
years displayed a similar expression of miR-34a compared to age-matched controls 
suggesting the presence of the glioblastoma further promoted the expression of miR-
34a in the serum of patients over the age of 60 years. 
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MiR-34a has not previously been identified in the serum of glioblastoma patients or 
any other disease, therefore the up-regulation of miR-34a in this study cannot be 
compared to other studies. A similar difference in miRNA expression between tissue 
and biofluid samples was demonstrated in a previous study investigating miR-128 
expression which was found to be up-regulated in the blood of glioblastoma patients 
but was down-regulated in glioblastoma tissue (Roth et al., 2011). Analysis of miRNA 
expression in the blood of other diseases such as multiple sclerosis and melanoma 
have also identified an inverse correlation between circulating expression and tissue 
expression (Roth et al., 2011). The difference in expression between the serum up-
regulation observed in this thesis and the tissue down-regulation of miR-34a observed 
in previous studies could be due to a number of factors such as selective exosomal 
packaging (Chen et al., 2012), or competitive interactions between glioblastoma cells 
and neighboring non-cancerous cells in the tumour microenvironment (Kosaka et al., 
2012).  
Non-cancerous epithelial cells can prevent or reduce the growth of transformed 
neighbouring cells by the release of autocrine and paracrine factors as a means of cell 
growth homeostasis in a process known as cell competition (Kosaka et al., 2012). 
Disruption of this homeostatic cell competition process has been proposed as a factor 
which can contribute to tumour initiation. Kosaka et al. (2012) demonstrated that non-
cancerous epithelial prostate cells secreted tumour suppressor miRNAs as anti-
proliferative signals which were able to attenuate proliferation of prostate cancer cells.  
Although non-cancerous cells have been shown to attenuate proliferation of 
transformed cells by the secretion of anti-proliferative miRNAs, cancerous cells can 
combat these signals by impairing the process of exosome uptake to prevent the 
incorporation of tumour suppressive miRNAs (Kosaka et al., 2012). MiR-34a exerts 
anti-proliferative effects by targeting cell cycle regulators such as Notch-1 (Li et al., 
2011a), and could potentially be released by neighbouring epithelial cells in the brain 
in response to the presence of glial tumours. Impaired uptake of exosomes containing 
miR-34a by glioblastoma cells could lead to an enrichment of these exosomes 
containing miR-34a and subsequently the increase in expression of this miRNA in 
glioblastoma patient serum samples.  
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MiR-92a expression was high in the serum of male glioblastoma patients whilst female 
glioblastoma patients exhibited no change in expression. The difference in expression 
between genders may be due to the location of multiple miR-92a sequences in the 
genome. MiR-92a-1 is found within the 17~92 cluster of miRNAs on chromosome 13 
and miR-92a-2 is found within the paralogous cluster 106~363 on the X chromosome, 
both miR-92a-1 and 92a-2 share the same miR-92a-3p sequence. Females have two X 
chromosomes and males have one, to maintain equilibrium of gene expression 
between male and females, the mechanism of X-chromosome inactivation (XCI) occurs 
during embryonic development in which one X chromosome is inactivated at random 
(Pinheiro et al., 2011). XCI can be ‘skewed’ where the X-chromosome containing a 
detrimental mutation can be preferentially silenced, this has been observed for 
recessive X-linked immune disorders, where females are carriers for the disorder and 
do not exhibit symptoms (Pinheiro et al., 2011). This mechanism can also affect 
miRNAs found on the X chromosome which are also susceptible to skewing and 
therefore could account for differences in miRNA expression between genders. 
Mutations in one X-chromosome, therefore, could cause the up-regulation of miR-92a-
2 to be silenced by XCI in females, whereas males are hemizygous, thus the same 
mutation cannot be silenced leading to an up-regulation of miR-92a-3p. Furthermore, 
as males are hemizygous for X-linked mutations in both protein encoding genes and 
miRNA, this may partially explain the difference in gender susceptibility to cancer 
(Pinheiro et al., 2011), including glioblastoma, and differences in survival as observed 
in this study.   
MiR-20a showed differential expression between glioblastoma patients in the initial 
identification cohort. One subset exhibited a more than two fold increase in expression 
compared to controls however the other subset of patients exhibited no change in 
expression. The difference in expression between the two groups of glioblastoma 
patients could indicate a difference in glioblastoma subtype. Glioblastoma subtypes 
differ in the profile of mutations present as well as miRNA expression, which could 
subsequently affect miRNA expression as observed in this study. Analysis and grouping 
of glioblastoma data in The Cancer Genome Atlas (TCGA) based on neural 
differentiation for identifying glioblastoma subtypes led to identification of miR-20a 
expression in the oligoneural precursor expression profile (Kim et al., 2011). Patients 
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used in this current study with an up-regulation of miR-20a could be of the oligoneural 
precursor subtype and those without an up-regulation could be of a different 
glioblastoma subtype. The use of miRNA biomarkers during diagnosis to identify 
glioblastoma subtypes could improve treatment decisions based on the response of a 
particular glioblastoma subtype due to the specific molecular profile.   
MiR-30c was observed to have a significantly lower expression in the serum of 
glioblastoma patients between the ages of 20 and 39 years compared to matched 
control patients. A decrease in miR-30c expression in the serum of glioblastoma 
patients has not previously been reported however, an increase in miR-30c expression 
has been reported in TRAIL-resistant glioblastomas (Quintavalle et al., 2012).  
Validation of the five miRNA biomarkers identified in Section 4.2.4 using sample 
numbers determined by power analysis confirmed that four of the five miRNAs 
showed a similar trend in the second cohort in Section 4.2.5. MiR-92a was shown to 
have a high expression in male glioblastoma patient serum by a similar fold change in 
the validation cohort compared to the initial study. MiR-34a and miR-20a were 
increased in the validation cohort as observed in the initial study, however both 
miRNAs showed a smaller increase in the validation study compared to the initial 
study. The mean expression of miR-34a in the initial study was approximately a three-
fold increase, in the validation study the mean expression of miR-34a was 
approximately a two fold increase however, the standard deviation of miR-34a 
expression in the validation study shows that there were certain samples within the 
cohort which showed a similar expression to samples within the initial study. MiR-20a 
showed the greatest variation in expression between the initial and validation groups. 
This could be due to the variation in expression of different proteins which may target 
miR-20a between different subtypes of glioblastoma. Patients with decreased 
expression in miR-30c in the identification cohort exhibited a median decrease of 0.5 
fold however patients in the validation cohort exhibited a median decrease of -1.05 
fold. The variation in median fold decrease of miR-30c expression could be due to 
variables other than glioblastoma such as drug treatments or the presence of other 
diseases which may affect miRNA expression in either the glioblastoma patient cohort 
or the control patient cohort. 
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Out of the four validated miRNAs, miR-20a showed a significant difference in median 
survival times between patients with an increase in expression of miR-20a, compared 
to those without. Patients used in the initial biomarker identification cohort with an 
increase of miR-20a had a median survival time of 21.39 months compared to a 
median survival time of 4.45 months for patients without an increase in miR-20a. 
Patients in the validation cohort with an increase of miR-20a also exhibited a better 
prognosis, 9.49 months median survival, compared to those with no change in 
expression, 1.65 months median survival. MiR-20a has the potential, therefore, to be a 
prognostic miRNA biomarker for glioblastoma patients, which could be utilised for 
improved treatment strategies. 
 Analysis of survival data for the patients used in this study identified that age and 
gender both had an effect on the median patient survival time. Overall, the median 
survival time for glioblastoma patients used in this study was 6.62 months, this is lower 
than the median survival time of 9 months generally observed for glioblastoma 
patients (Alqallaf et al., 2014). When grouped by age, glioblastoma patients aged 
between 20 and 39 years had the best median survival time of 8.88 months. Patients 
aged between 40 and 59 years had a median survival time of 6.53 months and patients 
over the age of 60 years had the worst median survival time of 3.36 months. 
Glioblastoma patients over the age of 60 years are often difficult to treat due to their 
reduced ability to cope with aggressive therapies (Arvold and Reardon, 2014). Median 
survival times for male and female glioblastoma patients were 5.88 and 7.98 months, 
respectively, but this difference was not statistically significant.  
MiR-20a and 92a-3p are expressed within the miR-17~92 cluster which comprises of a 
group of six miRNAs; miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, miR-92a-1, which 
are located on chromosome 13 and are transcribed together (Olive et al., 2010). In 
glioblastoma the 17~92 cluster is up-regulated and plays a role in apoptosis and 
proliferation. In this study, only two of the six miRNAs transcribed in this cluster were 
found to have altered expression, this suggests that the miRNAs within this cluster may 
be subject to, currently unknown, specific post-transcriptional regulation resulting in 
the varied expression profiles (Mendell, 2008). Five of the six miRNAs which make up 
this cluster were identified in the 32 miRNA panel in Section 4.2.4 however validation 
of the 32 miRNA indicated that the expression of miR-17, miR-19a and miR-19b was 
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not significantly different in the serum of glioblastoma patients. Furthermore, 
additional analysis of these miRNAs to determine false negatives again showed no 
significant difference in expression between glioblastoma patient serum and matched 
controls. MiRNAs can be subject to post-transcriptional regulation by selective 
processing to produce mature miRNAs, in this manner miRNA genes may be 
transcribed and partially processed to produce the pre-miRNA form but further 
cleavage and processing does not occur to produce the active mature miRNA which 
can go on to target mRNA (Obernosterer et al., 2006). It has been shown that for some 
miRNAs high levels of pre-miRNA can be detected in cells but little or no expression of 
the mature form is seen. These pre-miRNA appear to be localised in the nucleus 
suggesting that these miRNA genes are transcribed, processed into pre-miRNA but are 
not subsequently exported to the cytoplasm for further processing (Lee et al., 2008).  
Due to the location of miR-92a and miR-20a in the 17~92 cluster, expression of these 
two miRNAs in each individual patient sample was analysed to determine whether 
they were correlated. Expression of miR-92a and miR-20a was observed to have no 
correlation in both glioblastoma patient samples and non-cancerous control samples. 
This again suggests that although these miRNAs are transcribed together from the 
cluster, differential post-transcriptional regulation affects the expression of the mature 
miRNA forms. Conversely, miR-20a and 92a-3p may have correlated expression within 
the tissue of glioblastoma but this correlation may not extend to serum secretion, this 
could again be a result of selective exosomal packaging (Chen et al., 2012) which could 
result in differences in expression within the serum of these two miRNAs.  
In summary, data from this chapter have identified that miRNA expression is 
dysregulated in the serum of glioblastoma patients with age and gender differences in 
expression. Four miRNAs, miR-20a, miR-30c, miR-34a and miR-92a were identified and 
found to be significantly increased in the serum of glioblastoma patients which were 
validated in a larger patient cohort. In addition to being dysregulated in the serum of 
glioblastoma patients, miR-20a was also found to have prognostic potential, where a 
subset of patients exhibiting a greater than two fold increase in expression showed 
better survival than those with no change, which could be linked to an oligoneural 
precursor subtype of glioblastoma. Expression of miR-20a was found to be inversely 
correlated with age, with younger glioblastoma patients exhibiting the highest 
149 
 
expression and older patients aged over 60 years exhibiting the lowest. Further 
investigation of miR-92a, found to be expressed at a higher level in male glioblastoma 
serum sample, could provide information on possible gender susceptibility to 
glioblastoma. MiR-34a expression was increased in the serum of glioblastoma patients 
aged over 60 years. Further analysis showed that miR-34a expression was correlated 
with age in both control and glioblastoma patient serum, suggesting that a 
combination of age and the presence of the tumour led to the up-regulation of this 
miRNA in the serum of older glioblastoma patients. As miR-34a has previously been 
identified as a tumour suppressor down-regulated in glioblastoma tissue, the finding 
that it is up-regulated in the serum of glioblastoma patients may suggest an alternative 
source of miRNA biomarkers in the circulation, other than the tumour itself. This led to 
the next aim of this thesis to elucidate the origin of miRNA dysregulation in the serum 
of glioblastoma patients.  
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5. Origin of MiRNA  
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5.2 Results  
5.2.1 Identification of MicroRNA Biomarkers in Cell Lines Cultured in 10 % 
FBS 
 
Following identification of four potential miRNA biomarkers, miR-20a, miR-30c, miR-
34a and miR-92a in the serum of glioblastoma patients, U87MG and SVGp12 cells were 
cultured using the human serum cell culture model established in Chapter 3. The 
serum weaning study in Section 3.2.5 did not investigate the miRNA biomarkers 
validated in Section 4.2.5, therefore the serum weaning study was repeated to 
determine whether the serum biomarkers were expressed in the cell lines under 
standard culture conditions and to investigate the effects of serum weaning on 
expression. The investigation of serum miRNA biomarkers in immortalised cell lines 
provides a simplified model to help determine the origin of the miRNA biomarkers 
compared to in vivo systems in which there are alternative sources of miRNAs such as 
immune cells and cells from other tissues. As miRNAs are frequently part of positive 
feedback loops which promote further expression, the application of patient serum 
types in which each biomarker was up-regulated may affect the expression of the 
biomarker in recipient cells. Three of the four validated biomarkers identified in 
Section 4.2.5, miR-92a, miR-20a and miR-30c, have been found, in previous studies to 
be oncogenic (Mogilyansky and Rigoutsos, 2013, Quintavalle et al., 2012), therefore 
the release of these miRNAs in glioblastoma exosomes may also have a self-promoting 
function. To determine whether exosomes within the serum of glioblastoma patients 
could alter miRNA biomarker expression in recipient U87MG and SVGp12 cells, cells 
were weaned onto 10 % glioblastoma patient serum or 10 % control patient serum 
using new patient serum samples. Total RNA was extracted from within the cells 
following serum replacement to determine intracellular biomarker expression, and 
additionally exosomes were isolated from the spent media to determine extracellular 
biomarker expression. This would, in part, elucidate the effect of glioblastoma and 
control serum on recipient cell miRNA expression as well as changes in miRNA 
expression in secreted exosomes from the recipient cells themselves following culture 
in human serum.   
Initial analysis was performed to determine the expression of the biomarkers in pooled 
triplicate patient serum samples alone compared to U87MG and SVGp12 cells cultured 
152 
 
in FBS before serum weaning. Cells were then cultured in glioblastoma and control 
patient serum corresponding to the age and gender category in which they were found 
to be dysregulated (Sections 4.2.4 and 4.2.5) to determine whether the dysregulation 
of these miRNAs in serum could have an effect on intracellular miRNA expression in 
recipient cells. Cells were cultured in serum from patients aged over 60 years to 
determine the effect on expression of miR-34a, male patient serum for miR-92a, 
glioblastoma patient serum for miR-20a and 20-39 years glioblastoma patient serum 
for miR-30c.  
5.2.1.1 Expression of MiR-34a in 60+ Patient Serum Pools compared to 
U87MG and SVGp12 Cells Cultured in 10 % FBS  
 
Prior to serum replacement, miR-34a expression in a 60+ age glioblastoma patient 
serum pool and a 60+ age control patient serum pool to be used for weaning was 
compared to the intracellular expression of miR-34a in U87MG and SVGp12 cells and 
spent media containing 10 % FBS. Comparison of miR-34a expression in the two serum 
pools showed that miR-34a expression was not significantly different (p > 0.001) in the 
60+ age GBM patient serum pool compared to the 60+ age control patient serum pool 
(Figure 5.1). MiR-34a expression in both the 60+ age glioblastoma patient serum pool 
and the 60+ age control patient serum pool was not significantly different (p > 0.001) 
than intracellular miR-34a expression in U87MG and SVGp12 cells and spent media 
containing 10 % FBS (Figure 5.1). MiR-34a expression in U87MG cells cultured in 10 % 
FBS was not significantly different (p > 0.001) extracellularly in the spent media 
compared to intracellular expression (Figure 5.1).  Similarly, intracellular miR-34a 
expression in SVGp12 cells cultured in 10 % FBS was not significantly different (p > 
0.001) compared to extracellular expression in the spent media (Figure 5.1). 
Intracellular miR-34a expression in U87MG cells was not significantly different (p > 
0.001) to intracellular miR-34a expression in SVGp12 cells, both cultured in 10 % FBS 
(Figure 5.1). Extracellular miR-34a expression in U87MG cells cultured in 10 % FBS was 
also not significantly different to extracellular miR-34a expression in SVGp12 cells 
cultured in 10 % FBS (Figure 5.1).  
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Figure 5.1 Comparison of miR-34a expression in 60+ GBM patient serum pool and 60+ control patient serum pool. 
MiR-34a expression in cell lines cultured in 10 % FBS was significantly higher than expression in the 60+ patient 
serum pools. Data shown as mean of replicates (n = 3 per group) plus SD, analysed by one-way ANOVA with Tukey 
post-hoc test. Significance indicated between groups by a solid black line, ***p < 0.001. 
5.2.1.2 Expression of MiR-34a in U87MG and SVGp12 cells following Serum 
Replacement with 60+ Patient Serum Pools 
 
After establishing miR-34a expression in the 60+ age glioblastoma patient serum pool 
and 60+ control patient pool compared to U87MG and SVGp12 miR-34a expression 
when cultured in FBS, cells were weaned onto the 60+ age patient pools. The change in 
miR-34a expression following serum replacement was determined compared to cells 
cultured in FBS, all data were normalised using the cel-miR-39 spike in and then 
subsequently normalised to miR-34a expression in the corresponding serum pool. The 
normalisation of cell line expression to the corresponding serum pools ensured that 
expression of miR-34a produced by the cell themselves was determined. The culture of 
U87MG cells in both the 60+ age glioblastoma and 60+ age control patient serum pool 
led to a significant increase (p < 0.001) in intracellular miR-34a expression compared to 
those cultured in FBS (Figure 5.2). The increase in expression observed intracellularly in 
U87MG cells was not significantly different (p > 0.001) between those cultured in the 
*** 
*** 
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60+ glioblastoma patient serum and 60+ control patient serum (Figure 5.3). No 
significant change (p > 0.001) in miR-34a expression was observed extracellularly for 
U87MG cells cultured in either serum pool (Figure 5.2). The culture of SVGp12 cells in 
60+ patient serum did not significantly alter miR-34a expression either intracellularly 
or extracellularly compared to those cultured in FBS (Figure 5.2).  
 
 
Figure 5.2 Comparison of miR-34a expression in U87MG and SVGp12 cell lines following serum replacement with 
60+ patient serum pools. MiR-34a expression in U87MG cells cultured in 10 % 60+ GBM patient serum was 
significantly higher intracellularly compared to extracellular expression. Intracellular U87MG expression in 60+ GBM 
serum was significantly higher compared to intracellular SVGp12 or U87MG cells cultured in 10 % FBS. The same 
trend was observed in cells cultured in 10 % 60+ control patient serum. Data shown as mean of replicates (n = 3 per 
group) plus SD, analysed by two-way ANOVA with Tukey post-hoc test. Yellow bar represents miR-34a expression in 
U87MG and SVGp12 cells cultured in 10 % FBS set to a standard value of 1 from which the fold change of all other 
bars were calculated, all serum weaning data were normalised to miR-34a expression in the corresponding serum 
pool. Significance indicated between groups by a solid black line, ***p < 0.001. 
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Figure 5.3 Comparison of miR-34a expression of cells cultured in 10 % 60+ GBM patient and 10 % 60+ control 
patient serum pools. Intracellular miR-34a expression in U87MG cells was significantly higher when cultured in 
both 60+ patient pools compared to those cultured in 10 % FBS. No significant difference in intracellular U87MG 
miR-34a expression was observed between cells cultured in 10 % GBM patient serum and those cultured in 10 % 
control patient serum. No significant difference in expression was observed both intracellularly and extracellularly 
between the three serum conditions for SVGp12 cells. Data shown as mean of replicates (n = 3 per group), plus SD, 
analysed by two-way ANOVA with Tukey post-hoc test, all serum weaning data were normalised to miR-34a 
expression in the corresponding serum pool. Significance between groups indicated by a solid black line, ***p < 
0.001.  
5.2.1.3 Expression of MiR-92a in Male Patient Serum Pools compared to 
U87MG and SVGp12 Cells Cultured in 10 % FBS 
 
Prior to serum replacement, the expression of miR-92a in the male patient serum 
pools to be used for weaning was compared to the expression of U87MG and SVGp12 
cells cultured in 10 % FBS. Initial comparison of miR-92a expression in the two serum 
pools showed no significant difference in expression (p < 0.001) of miR-92a in the male 
glioblastoma serum pool compared to the male control serum pool (Figure 5.4). MiR-
92a expression was significantly lower (p < 0.001) in both male serum pools compared 
to intracellular miR-92a expression in U87MG and SVGp12 cells, and spent media 
containing 10 % FBS (Figure 5.4). Extracellular miR-92a expression in the spent media 
of U87MG cells cultured in 10 % FBS was significantly higher (p < 0.001) compared to 
intracellular U87MG miR-92a expression (Figure 5.4). Extracellular miR-92a expression 
in the spent media of U87MG cells cultured in 10 % FBS was not significantly different 
(p > 0.001) when compared to extracellular miR-92a expression of SVGp12 cells 
cultured in 10 % FBS (Figure 5.4).   
*** 
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Figure 5.4 Comparison of miR-92a expression in male glioblastoma serum pool and male control patient serum 
pool. MiR-92a expression in both male patient serum pools was significantly lower compared to U87MG and 
SVGp12 miR-92a expression when cultured in 10 % FBS. Extracellular U87MG miR-92a expression was significantly 
higher compared to intracellular U87MG expression and extracellular SVGp12 expression. Data shown as mean of 
replicates (n = 3 per group) plus SD, analysed by one-way ANOVA with Tukey post-hoc test. Significance indicated 
between groups by a solid black line, ***p < 0.001. 
5.2.1.4 Expression of MiR-92a in U87MG and SVGp12 cells following Serum 
Replacement with Male Patient Serum Pools  
 
After establishing miR-92a expression in the male glioblastoma patient serum pool and 
male control patient pool compared to intracellular expression in U87MG and SVGp12 
cells and spent media containing 10 % FBS, cells were weaned onto the male patient 
pools and the change in miR-92a expression was determined compared to cells 
cultured in FBS. The culture of U87MG cells in both male glioblastoma serum and male 
control serum pools resulted in no significant change (p > 0.001) in miR-92a expression 
either intracellularly or extracellularly (Figure 5.5). 
The culture of SVGp12 cells in the male glioblastoma serum pool resulted in a 
significant increase (p < 0.001) in intracellular miR-92a expression compared to 
extracellular miR-92a expression and SVGp12 cells cultured in FBS (Figure 5.5). The 
culture of SVGp12 cells in male control patient serum resulted no significant difference 
*** 
*** 
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of miR-92a intracellular expression (p < 0.001) compared to extracellular expression 
(Figure 5.5). When compared to SVGp12 cells cultured in FBS, intracellular and 
extracellular miR-92a expression of SVGp12 cells cultured in male control patient 
serum was not significantly different (p > 0.001, Figure 5.6).  
Comparison of the effect of the two patient serum pools on U87MG and SVGp12 miR-
92a expression showed no significant difference (p > 0.001) in miR-92a expression 
between U87MG cells cultured in male glioblastoma serum and those cultured male 
control serum (Figure 5.6). Intracellular miR-92a expression of SVGp12 cells was 
significantly higher (p < 0.001) in cells cultured in 10 % male glioblastoma patient 
serum compared to those cultured in 10 % control patient serum and 10 % FBS.  
Extracellular miR-92a expression in SVGp12 cells showed no significant difference (p > 
0.001) in expression between the three serum conditions (Figure 5.6).  
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Figure 5.5 Comparison of miR-92a expression in U87MG and SVGp12 cells following culture in 10 % male patient 
serum pools. MiR-92a expression was significantly higher intracellularly in SVGp12 cells cultured in 10 % male GBM 
serum compared to extracellular SVGp12 and intracellular U87MG miR-92a expression. Yellow bar represents miR-
92a expression in U87MG and SVGp12 cells cultured in 10 % FBS set to a standard value of 1 from which the fold 
change of all other bars were calculated, all serum weaning data were normalised to miR-92a expression in the 
corresponding serum pool. Significance indicated between groups by a solid black line, ***p < 0.001. 
 
Figure 5.6 Expression of miR-92a in cell lines following serum replacement. U87MG miR-92a expression was not 
significantly different between the three serum conditions. Intracellular miR-92a expression in SVGp12 cells 
cultured in 10 % male GBM serum was significantly higher compared to cells cultured in 10 % male control serum 
and 10 % FBS. No significant difference was observed in intracellular miR-92a expression in SVGp12 cells cultured in 
10 % male control patient serum and those cultured in 10 % FBS. Extracellular miR-92a expression in SVGp12 cells 
was not signficantly different between the three serum conditions. Data shown as mean of replicates (n = 3 per 
group), plus SD, analysed by two-way ANOVA with Bonferroni post-hoc test, all serum weaning data were 
normalised to miR-92a expression in the corresponding serum pool. Significance between groups indicated by a 
solid black line, ***p < 0.001. 
*** 
*** *** 
159 
 
5.2.1.5 Expression of MiR-20a in Glioblastoma Patient Serum compared to 
U87MG and SVGp12 Cells Cultured in 10 % FBS and following Serum 
Replacement 
 
Prior to serum replacement, miR-20a expression in the glioblastoma patient serum 
pool and the control patient serum pool to be used for weaning was compared to miR-
20a expression in U87MG and SVGp12 cells. MiR-20a expression was detected 
intracellularly in U87MG cells cultured in 10 % FBS only. MiR-20a expression was not 
significantly different (p > 0.001) in the control patient serum pool compared to 
intracellular U87MG miR-20a expression (Figure 5.7). MiR-20a expression in the 
glioblastoma patient serum pool exhibited no significant difference (p > 0.001) 
compared to miR-20a expression in U87MG cells cultured in 10 % FBS (Figure 5.7).  
The culture of U87MG cells in both glioblastoma patient serum and control patient 
serum showed no significant difference (p > 0.001) in intracellular miR-20a expression 
compared to U87MG cells cultured in FBS (Figure 5.8).   
 
Figure 5.7 MiR-20a expression in glioblastoma patient pooled serum and control patient pooled serum compared 
to intracellular U87MG miR-20a expression.  MiR-20a expression was not significantly different in the control 
patient serum pool compared to intracellular U87MG expression. MiR-20a expression in the glioblastoma patient 
serum pool exhibited no significant difference in expression compared to U87MG cells or control patient serum 
pool. Data shown as mean of replicates (n = 3 per group) plus SD analysed by Kruskal-Wallis one way ANOVA with 
Dunn’s post-hoc test. Significance indicated between groups by a solid black line, p > 0.05.    
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Figure 5.8 Intracellular miR-20a expression in U87MG cells following culture in 10 % GBM patient and control 
patient serum pools. Intracellular miR-20a expression was not significantly different between U87MG cells cultured 
in glioblastoma patient serum or control patient serum or compared to those cultured in FBS. Data shown as mean 
of replicates (n = 3 per group) plus SD, all serum weaning data were normalised to miR-20a expression in the 
corresponding serum pool. Data were analysed by Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc test, p > 
0.05. 
5.2.1.7 Expression of MiR-30c in 20-39 Glioblastoma Patient Serum 
compared to U87MG and SVGp12 Cells Cultured in 10 % FBS and following 
Serum Replacement  
 
Prior to serum replacement, miR-30c expression in the 20-39 glioblastoma patient 
serum pool and the 20-39 control patient serum pool to be used for weaning was 
compared to miR-30c expression in U87MG and SVGp12 cells. MiR-30c expression was 
detected intracellularly in U87MG cells cultured in 10 % FBS only. MiR-30c expression 
was not significantly different (p > 0.001) in the 20-39 glioblastoma patient serum pool 
compared to U87MG expression (Figure 5.9). Expression of miR-30c in the 20-39 
control patient serum pool was not significantly different (p > 0.001) to miR-30c 
expression in U87MG cells (Figure 5.9). Intracellular expression of U87MG cells 
cultured in 20-39 glioblastoma patient serum exhibited a higher expression of miR-30c 
expression compared to those cultured in FBS (Figure 5.10). U87MG cells cultured in 
20-39 control patient serum exhibited no significant change (p > 0.01) in expression 
compared to those cultured in FBS (Figure 5.10).  
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Figure 5.9 MiR-30c expression in 20-39 glioblastoma patient pooled serum and 20-39 control patient pooled 
serum compared to intracellular U87MG miR-30c expression. MiR-30c expression was not significantly different in 
the 20-39 glioblastoma patient serum pool compared to 20-39 control pool expression and intracellular U87MG 
cultured in 10 % FBS. MiR-30c expression in the 20-39 control patient serum pool exhibited no significant difference 
in expression compared to U87MG cells cultured in 10 % FBS. Data shown as mean of replicates (n = 3 per group) 
plus SD analysed by Kruskal-Wallis one way ANOVA with Dunn’s post-hoc test, p > 0.001.    
 
Figure 5.10 Intracellular miR-30c expression in U87MG cells following culture in 10 % 20-39 patient serum pools. 
Intracellular miR-30c expression was not significantly different in U87MG cells cultured in 20-39 glioblastoma 
patient serum compared to those cultured in 10 % 20-39 control patient serum and 10 % FBS. MiR-30c expression 
was not significantly different in U87MG cells cultured in 20-39 control patient serum compared to those cultured in 
10 % FBS. Data shown as mean of replicates (n = 3 per group) plus SD, analysed by Kruskal-Wallis one-way ANOVA 
with Dunns post-hoc test, all serum weaning data were normalised to miR-30c expression in the corresponding 
serum pool, p > 0.01.  
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5.2.2 MicroRNA Expression in Glioblastoma Tissue  
 
Data from Section 5.2.1 demonstrated that some of the miRNAs within the biomarker 
panel may originate from the tissue itself due to the high intracellular expression of 
these miRNAs in vitro. To further determine whether miRNAs present within the 
circulation originate from the glioblastoma itself, the expression of miRNAs was 
measured in tumour tissue samples. As the incidence of glioblastoma is most prevalent 
in individuals over the age of 60 years and three of the four biomarkers validated in 
Section 4.2.5 are all present in the serum of glioblastoma patients over the age of 60 
years, tissue samples were obtained from patients of this age group. Age-matched 
tissue samples from one male and one female patient were obtained and analysed 
separately to determine whether there were any gender differences in tissue miRNA 
expression as observed in serum.  
Analysis of the 84 miRNAs in the brain cancer panel identified 28 miRNAs that were 
highly expressed in the male tissue (Figure 5.11A). MiR-124a showed the highest level 
of expression in male tissue with a 6.04 fold increase, and 17-5p, 181b-5p, 182-5p, 
183-5p and 184 exhibited more than a five-fold change in expression. MiR-146b-5p 
and 9-5p had a greater than four-fold change in expression and miR-19b-3p, 203a, 
30b-5p, 30c-5p and 7-5p had a greater than three-fold change in expression. The 
remaining miRNAs exhibited at least a two-fold increase in expression in the male 
tissue. Ten miRNAs showed reduced expression in male glioblastoma tissue (Figure 
5.11B), miR-23a-3p showed the greatest decrease in expression of 0.06 fold, the next 
two miRNAs with the greatest decrease in expression were miR-15b-5p and miR-21-5p 
with a 0.17 and 0.18 fold decrease, respectively. Three of the five miRNAs identified in 
Section 4.2.4 were expressed in male tissue, miR-30c, miR-92a and miR-150. 
Expression of miR-92a showed a 2.12 fold increase in expression in the tissue of the 
male glioblastoma patient compared to age matched control tissue and miR-30c and 
miR-150 showed a 3.14 fold and 2.00 fold increase in expression, respectively (Figure 
5.13A).  
Five miRNAs showed a high level of expression in the female glioblastoma tissue 
(Figure 5.12A), all five miRNAs exhibited a greater than two-fold increase in expression 
with miR-184 having the greatest increase in expression. 25 miRNAs showed reduced 
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expression in female glioblastoma tissue with miR-130a-3p having the greatest 
decrease in expression of 0.06 fold (Figure 5.12B). Two of the four validated serum 
biomarkers, miR-92a and miR-30c, were detected in the female tissue. MiR-92a and 
miR-30c were both observed to have reduced expression in the female tissue by a fold 
change of 0.10 and 0.14 respectively (Figure 5.12B). MiRNAs 185-5p and 184 were up-
regulated in both male and female samples, both male and female showed a similar 
fold increase of 2.39 and 2.36 fold for miR-185-5p, however miR-184 had a greater 
increase in expression of 5.76 fold in the male sample compared to 2.50 in the female 
sample. MiR-130a-3p, 21-5p and 23a-3p were all down-regulated in both male and 
female samples. MiR-130a-3p had a greater decrease in fold change in the female 
sample of 0.06 fold compared to 0.26 fold whereas 21-5p and 23a-3p had a greater 
decrease in expression in the male sample of 0.18 and 0.06 compared to the female 
sample expression of 0.40 and 0.28 fold.     
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Figure 5.11 Fold Change of miRNAs in 60+ male glioblastoma patient tissue. A) 28 miRNAs exhibited an increase in 
expression in glioblastoma tissue obtained from a patient aged over 60 years (n=1), miR-124-3p showed the highest 
expression compared to matched control tissue. B) 10 miRNAs exhibited reduced expression in glioblastoma tissue 
obtained from a male patient aged over 60 years (n=1), miR-23a-3p showed the greatest decrease in expression 
compared to matched control tissue.   
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Figure 5.12 Fold Change of miRNAs in 60+ female glioblastoma patient tissue. A) Four miRNAs showed an 
increased expression in the tissue of a female glioblastoma patient aged over 60 years (n=1), miR-184 showed the 
greatest increase in expression compared to matched control tissue. B) 25 miRNAs exhibited reduced expression in 
the tissue of a female glioblastoma patient aged over 60 years (n=1). MiR-130a-3p showed the greatest decrease in 
expression compared to matched control tissue.  
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5.2.3 MicroRNA Expression in TCGA  
 
Following identification of four miRNAs with significant altered expression in the sera 
of glioblastoma patients, microarray data obtained from the TCGA was analysed by 
Josie Hayes from the Leeds Institute of Molecular Medicine to identify whether the 
expression of the miRNA panel correlated with miRNA expression in tissue in a larger 
cohort of 558 patients which could be grouped by age and gender. The microarray 
data was analysed to determine the expression of the miRNAs in tissue, age and 
gender differences, and prognostic potential. As it has not been previously shown to 
have a role in glioblastoma, tissue expression of miR-150 was also investigated to 
determine whether this miRNA is dysregulated in glioblastoma.  
MiR-34a expression was significantly higher (p < 0.0001) in the tissue of glioblastoma 
patients (Table 5.1) and expression was correlated with age (r = 0.23, p < 0.0001), with 
older patients exhibiting higher expression (Figure 5.15A). Higher expression of miR-
34a was associated with a poorer prognosis (p < 0.05) compared to individuals with a 
low expression (Figure 5.15B). Patients with a higher expression of miR-34a had a 
median survival time of 13.3 months and patients with a low expression having a 
median survival time of 13.9 months. Analysis of miR-34a expression based on gender 
showed no significant difference (p >0.05) in miR-34a expression between male and 
female groups (Figure 5.15C).  
MiR-92a was significantly up-regulated (p < 0.0001) in the tissue of glioblastoma 
patients compared to non-cancerous patients (Table 5.1). Expression was not 
correlated with age (r = -0.15, p < 0.0001), (Figure 5.16A). Patients with a higher 
expression of tissue miR-92a did not exhibit a significant difference (p > 0.05) in 
median survival time compared to those without (Figure 5.16B). Patients with high 
expression of miR-92a had a median survival time of 14.4 months and patients with 
low expression of miR-92a had a median survival of 12.9 months. Analysis of miR-92a 
based on gender exhibited no significant difference (p > 0.05) in expression of miR-92a 
in tissue between male and female patients (Figure 5.16C).  
MiR-20a was significantly up-regulated (p < 0.0001) in the tissue of glioblastoma 
patients (Table 5.1), furthermore, expression was inversely correlated with age (r = -
0.15, p < 0.0001) with older patients exhibiting a lower expression of miR-20a (Figure 
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5.17A). Higher expression of miR-20a in the tissue of glioblastoma patients was 
associated with a better prognosis (Figure 5.17B). Patients with a higher expression of 
miR-20a had a median survival of 15.3 months and patients with a low expression of 
miR-20a had a median survival of 12.6 months. Analysis of miR-20a expression 
grouped by gender showed no significant difference (p > 0.05) in expression between 
male and female groups (Figure 5.17C).  
MiR-20a and 92a are located within the genome in a cluster of miRNAs which are 
transcribed together therefore expression of these two miRNAs in each individual 
patient was analysed to determine whether expression was correlated. Analysis of 
patient miR-92a and miR-20a expression showed a high correlation (r = 0.46, p < 
0.0001) in expression for these two miRNAs (Figure 5.17D). 
Analysis of miR-30c and miR-150 in patient tissue found no significant difference (p > 
0.05) in expression between glioblastoma and control patients (Table 5.1). 
Furthermore, no difference in expression was observed between age groups for miR-
30c and miR-150 (r = -0.02 and -0.03 respectively, p > 0.05) or genders (Figures 5.18A 
and B and 5.19A and B). Survival analysis of miR-30c and miR-150 also showed no 
association with prognosis (p > 0.05).  
Table 5.1 Log fold change expression of serum miRNA biomarkers in glioblastoma tissue obtained from TCGA 
analysed by Josie Hayes.  
MiRNA Log fold Change  p value 
miR-34a-5p 1.30 Increased 5.3 x10-4 
miR-92a-3p 1.21 Increased 5.6 x10-9 
miR-20a-5p 1.37 Increased 6.3 x10-7 
miR-30c-5p 0.301 No change 0.24 
miR-150-5p 0.031 No change 0.87 
 
 
 
 
 
168 
 
                        
Figure 5.13 Analysis of miR-34a expression in glioblastoma tissue using the TCGA dataset.  A) Expression of miR-
34a in glioblastoma tissue was correlated with age determined by Pearson’s correlation r = 0.23 ****p < 0.0001. B) 
Patients with a low expression of miR-34a exhibited a better prognosis than those with an up-regulation 
determined by log-rank above and below the median *p < 0.05. C) No gender difference in tissue miR-34a 
expression was observed, p > 0.05. High and low miRNA expression was determined as above and below the 
median. Analysis and figures produced by Josie Hayes (Leeds Institute of Molecular Medicine). 
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Figure 5.14 Analysis of miR-92a expression in glioblastoma patient tissue using the TCGA dataset. A) Expression of 
tissue miR-92a was not correlated with age determined by Pearson’s correlation. r = -0.15, p < 0.0001. B) Patients 
with a higher expression of miR-92a did not exhibit a significantly better prognosis than those with a low expression 
by log-rank above and below the median, p > 0.05. C) No gender difference in tissue miR-92a expression was 
observed, p > 0.05. High and low miRNA expression was determined as above and below the median. Analysis and 
figures produced by Josie Hayes (Leeds Institute of Molecular Medicine).        
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Figure 5.15 Analysis of tissue miR-20a expression using the TCGA dataset. A) Expression of tissue miR-20a was not correlated with age determined by Pearson’s correlation. r = -0.15, ****p < 0.0001 
B) No significant difference in tissue miR-20a expression was observed between genders p > 0.05. C) Patients with a higher expression of miR-20a exhibited a better prognosis compared to those with 
a low expression determined by log-rank above and below the median, ****p < 0.0001 D) Expression of miR-92a and miR-20a was correlated in tissue determined by Pearson’s correlation. r = 0.46, 
****p < 0.0001. High and low miRNA expression was determined as above and below the median. Analysis and figures produced by Josie Hayes (Leeds Institute of Molecular Medicine). 
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Figure 5.16  Analysis miR-150 expression in glioblastoma patient tissue using the TCGA dataset. A) Expression of 
tissue miR-150 was not correlated with age of glioblastoma patients determined by Pearson’s correlation. r = -0.03, 
p > 0.05. B) No significant difference in miR-150 was observed between genders, p > 0.05. Analysis and figures 
produced by Josie Hayes (Leeds Institute of Molecular Medicine). 
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Figure 5.17 Analysis of miR-30c expression in glioblastoma patient tissue using the TCGA dataset. A) MiR-30c 
expression was not significantly correlated with age determined by Pearson’s correlation. r = -0.02, p > 0.05. B) 
Expression of miR-30c was not significantly different between genders, p > 0.05. Analysis and figures produced by 
Josie Hayes (Leeds Institute of Molecular Medicine). 
 
 
 
 
 
A 
B 
173 
 
5.2.4 Expression of Serum Biomarkers in Matched Tissue  
 
Following miScript analysis of miRNA expression in tissue and analysis of the four 
miRNA biomarkers tissue expression in the TCGA dataset, further studies were 
performed to determine the expression of the five biomarkers in patient tissue 
compared to matched serum samples. Matched tissue samples were not available for 
the 20-39 patient group therefore correlation between serum and tissue expression of 
miR-30c was not performed.   
MiR-34a was found to be up-regulated in the serum of glioblastoma patients over the 
age of 60 years in Sections 4.2.4 and 4.2.5. MiR-34a is a known tumour suppressor and 
is down-regulated in glioblastoma tissue (Okada et al., 2014). The expression of miR-
34a was determined in matched tissue and serum samples obtained from four 
patients, to determine the difference in expression between the sample types in order 
to elucidate whether patients used in this study also demonstrated reduced expression 
of miR-34a in the tissue as reported in previous studies and an up-regulation of miR-
34a in the serum as observed in Sections 4.2.4 and 4.2.5, or alternatively whether miR-
34a is similarly expressed in the tissue as observed in the TCGA data in Section 5.2.3. 
MiR-34a expression was higher in the serum of four glioblastoma patients over the age 
of 60 years compared to expression within the tissue obtained from the same patient 
(Figure 5.18).   
In Sections 4.2.4 and 4.2.5 miR-92a expression was higher in the serum of male 
glioblastoma patients. Analysis of miR-92a expression in three matched serum and 
tissue samples showed a significantly lower expression of miR-92a in the serum of 
male glioblastoma patients compared to the expression of miR-92a in matched tissue 
samples (Figure 5.19).  
MiR-20a expression was higher in the serum of a sub-group of glioblastoma patients in 
Sections 4.2.4 and 4.2.5. Comparison of miR-20a expression in matched serum and 
tissue samples showed no significant difference in expression between the two sample 
types (Figure 5.20).  
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Figure 5.18 Expression of miR-34a in matched serum and tissue samples. Expression of miR-34a was higher in the 
serum of glioblastoma patients over the age of 60 years compared to matched tissue samples obtained from the 
same patient. Data shown as mean of four samples with SD, with the 60+ control tissue set at a standard value of 1,  
data analysed by Mann-Whitney U test, p = < 0.05.  
 
 
Figure 5.19 Expression of miR-92a in matched male glioblastoma patient serum and tissue samples.  Expression of 
miR-92a was significantly lower in the serum of male glioblastoma patients compared to expression in matched 
tissue samples. Data shown as mean of triplicate samples plus SD, analysed by Mann-Whitney U test, p < 0.05.  
* 
* 
175 
 
 
Figure 5.20 Comparison of miR-20a expression in matched serum and tissue samples from glioblastoma patients. 
Analysis of miR-20a expression in matched samples showed no significant difference in expression between serum 
and tissue samples. Data shown as mean of 5 samples plus SD, analysed by Mann-Whitney U test, p > 0.05.  
5.2.5 In Situ Hybridisation of miRNA Biomarker Probes  
 
Glioblastoma is composed of a group of heterogenous cells, differing in miRNA 
expression (Singh et al., 2012). To determine the localisation and population of cells 
within glioblastoma which may express the miRNA biomarkers identified within the 
serum and to determine any correlation in tissue expression between the TCGA and 
qPCR analysis in previous sections, in situ hybridization (ISH) of tissue sections was 
performed. Furthermore, the invasive nature of glioblastoma and indistinct tumour 
margins allows for the identification of miRNA expression in neighbouring non-
cancerous cells that may be present on the sections. Identification of the localisation of 
miR-34a expression in particular could help to determine whether the relative high 
expression of this miRNA in the serum is due to secretion by neighbouring non-
cancerous cells as an anti-proliferative signal.   Due to the sensitive nature of the ISH 
protocol and optimisation required, three miRNA biomarkers were selected from the 
panel for investigation, miR-20a, miR-34a and miR-92a. MiR-30c was not included 
based on the non-significant tissue expression in the TCGA data in Section 5.2.2.   
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Tissue sections were selected from patients whose serum samples were used in 
Section 4.2.4 and miRNA expression of matched tissue samples was determined using 
qRT-PCR and fold change compared to serum biomarker expression for comparison 
with data obtained from ISH. Tissue sections were obtained from 12 patients, two 
male and female patients for each age group and tissue lysates were obtained for five 
of the patients for qPCR analysis. Optimisation of the ISH protocol was performed 
using the U6 small nucleolar RNA (snRNA), an endogenously expressed RNA, and miR-
21, a miRNA with high expression in glioblastoma (Figure 5.21).  U6 snRNA and miR-21 
probes were incubated overnight at both 4 °C and 37 °C, to determine the optimum 
temperature for probe incubation. Positive results were observed for both positive 
control probes at 4 ° C and 37 °C. Following these results a final temperature of 37 °C 
was selected for ISH analysis of target miRNA.  A scrambled miRNA probe was also 
used during optimisation studies which showed negative results at both temperatures.  
Following optimisation of probe temperature, incubation times for the anti-DIG AP 
antibody and NBT-BCIP substrate were optimised. Sections were incubated for one 
hour each with anti-DIG AP and NBT-BCIP, two hours anti-DIG AP and one hour NBT-
BCIP and two hours each with anti-DIG AP and NBT-BCIP. Incubation of sections for 
one hour with anti-DIG AP and one with NBT-BCIP showed positive staining for the U6 
positive control probe and negative staining for the scrambled probe however, the 
miR-34a, miR-92a and miR-20a probes produced weak signal (Figure 5.22). Incubation 
for two hours with anti-DIG AP and one hour NBT-BCIP produced signal with the U6 
positive control probes and the target miRNA probes and was negative for the 
scrambled probe (Figure 5.23). Incubation for two hours with both anti-DIG AP and 
NBT-BCIP was performed to determine whether the signal strength of the miRNA 
targets could be improved however non-specific probe binding was observed (Figure 
5.24).    
Following optimisation of the ISH protocol, analysis of tissue sections selected from 
patients used in the serum studies in Chapter 4 were performed. All tissue sections 
showed positive signal for the U6 snRNA positive control (Figures 5.22 and 5.23) and 
negative signal with the scrambled probe (Figures 5.24 and 5.25). BTNW 1336, 
obtained from a female 60+ glioblastoma patient showed extensive necrosis in the 
tissue section characterised by the lack of nuclear fast red counter staining due to a 
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reduced number of nuclei and non-specific probe signal. Patient tissue sections probed 
with the scrambled negative control all showed no signal (Figures 5.24 and 5.25). 
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Figure 5.21 Optimisation of probe hybridisation temperature.  Positive signals were obtained for both the miR-21 and U6 snRNA positive control probes and negative signals for the scrambled probe 
at both 4 ° C and 37 ° C.  Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
MiR-21 Positive Control  U6 snRNA Positive Control  Scrambled Negative Control  
4 °C 
37 °C 
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Figure 5.22 Optimisation of ISH Protocol - One hour antibody and NBT-BCIP incubation. Incubation of tissue sections with antibody for one hour at 37 ºC  followed by incubation with NBT-BCIP for 
one hour at 37 ºC  exhibited positive U6 signal and negative scrambled probe control and weak signal for the target miRNA probes. Main images x 10 magnification, inset x 100 magnification. Scale 
bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
MiR-20a  
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Figure 5.23 Optimisation of ISH protocol using one hour antibody incubation and two hours NBT-BCIP incubation.One hour incubation with antibody at 37 ºC and two hours incubation with NBT-
BCIP at 37 ºC resulted in positive U6 signal and negative scrambled probe signal and positive target miRNA staining. Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm, 
inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.24 Optimisation of ISH protocol with two hours antibody and NBT-BCIP incubation.  Incubation of tissue sections for two hours each at 37 ºC with antibody and NBT-BCIP substrate resulted 
in extensive non-specific staining for all probes. Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red 
counterstain. 
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ISH of miR-20a on female glioblastoma patients showed positive signal for three of the 
five viable tissue sections (Figure 5.29A). One section from each of the three female 
glioblastoma age groups exhibited a positive signal, BTNW 429, BTNW 871 and BTNW 
1186. Expression of miR-20a in female glioblastoma patient tissue from the 20-39 and 
40-59 age groups appeared to be uniform across the majority of the section, with 
staining mainly localised to the cytoplasm of cells (Figure 5.29A). Expression of miR-20a 
in the female 60+ patient tissue section also displayed signal in the cytoplasm of cells 
but also relatively strong signal in the nucleus also. Expression of miR-20a determined 
by qPCR for BTNW 429 and BTNW 1186 showed that miR-20a expression in the tissue 
lysate of these two patients was not significantly different (p > 0.05) to that of the 
matched serum samples and positive ISH signals were obtained for BTNW 429 and 
BTNW 1186 (Figure 5.29B). As matched tissue lysate was not available for any of the 
female tissue sections which displayed a negative ISH signal, miR-20a expression was 
not able to be determined using qPCR.  
Four of the six tissue sections obtained from male glioblastoma patients showed 
positive signal for the miR-20a probe, BTNW 850, BTNW 816, BTNW 758 and BTNW 
1078 (Figure 5.30A). One section from both the 20-39, BTNW 850, and 60+ age groups, 
BTNW 1078, showed positive signal and both sections from the 40-59 age group 
displayed positive signal. Three of the four positive tissue sections, BTNW 850, BTNW 
758 and BTNW 1078, exhibited both nuclear and cytoplasmic signal, however BTNW 
816, a male glioblastoma patient aged between 40 and 59 years, displayed cytoplasmic 
signal with no nuclear staining (Figure 5.30A). Expression of miR-20a determined by 
qPCR of tissue lysates showed a significantly higher (p < 0.01) expression of miR-20a in 
the tissue of BTNW 816 compared to serum expression and no significant difference (p 
> 0.05) in expression of miR-20a in matched tissue lysate and serum samples from 
BTNW 1078 and 1019 (Figure 5.30B). BTNW 816 displayed localised ISH signal rather 
than uniform expression across the tissue section whereas BTNW 1019 and 1078 both 
displayed uniform cytoplasmic and nuclear staining across the tissue section (Figure 
5.30B).  
ISH of the miR-34a probe in female glioblastoma patients displayed negative signal for 
the 20-39 age group (Figure 5.31A). The female 40-59 tissue sections displayed positive 
signal for both tissue sections and the viable female 60+ patient tissue section, BTNW 
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1186, displayed positive signal also which appeared to be stronger than that of the 40-
59 age group sections (Figure 5.31A). Positive staining for miR-34a was uniform across 
the section with both cytoplasmic and nuclear signal of a similar strength (Figure 
5.31A). Expression analysis of miR-34a by qPCR for BTNW 429 showed an absence of 
miR-34a expression in the tissue lysate and ISH for the BTNW 429 was also negative 
(Figure 5.31B). Expression of miR-34a determined by qPCR for BTNW 1186 showed a 
significantly lower expression (p < 0.001) of miR-34a in the tissue sample compared to 
the serum and miR-34a ISH for BTNW 1186 displayed a weak positive signal (Figure 
5.31B).   
Mir-34a ISH for male glioblastoma patient tissue sections showed positive signal for 
four of the six sections (Figure 5.32A). BTNW 850, a male glioblastoma patient aged 
between 20 and 39 years, displayed positive signal. Both male glioblastoma patients in 
the 40-59 age group and one male 60+ glioblastoma patient, BTNW 1019, exhibited 
positive signal with the miR-34a probe (Figure 5.32A). Two of the four positive 
sections, BTNW 850 and BTNW 785, showed strong nuclear signal for miR-34a 
compared to the cytoplasmic staining. BTNW 816 showed positive cytoplasmic staining 
around blood vessels with no nuclear signal. MiR-34a ISH for BTNW 816, BTNW 1078 
and BTNW 1019 all displayed a weak positive signal.   (Figure 5.32A). Expression of 
miR-34a for matched male tissue lysate samples determined by qPCR showed 
significantly lower (p < 0.01 and < 0.05) expression of miR-34a compared to serum 
miR-34a expression for all three patients (Figure 5.32B).  
ISH of miR-92a for female glioblastoma patients showed negative signal for all but two 
of the tissue sections, BTNW 1186 and BTNW 743 (Figure 5.33A). BTNW 1186 
displayed a positive miR-92a ISH signal however tissue lysate miR-92a expression 
determined by qPCR exhibited a significantly lower expression of miR-92a compared to 
serum expression (Figure 5.33B). MiR-92a ISH for BTNW 429 showed a negative signal 
for this miRNA and tissue lysate expression of miR-92a determined by qPCR exhibited a 
significantly lower expression of miR-92a compared to serum expression (Figure 5.33A 
and B).  
ISH of miR-92a for male glioblastoma patients exhibited positive staining for four 
patients BTNW 448, BTNW 850, BTNW 758 and BTNW 1078 (Figure 5.34A). BTNW 758 
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displayed positive cytoplasmic miR-92a signal, BTNW 850 and BTNW 1078 displayed 
both positive cytoplasmic and nuclear staining (Figure 5.34A). Expression analysis of 
miR-92a by qPCR showed significant down-regulation of miR-92a in tissue lysate 
samples compared to serum samples for BTNW 816, BTNW 1078 and BTNW 1019 
(Figure 5.34B).  
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Figure 5.25 ISH of U6 snRNA positive control in female glioblastoma patient tissue sections. All six female patient tissue sections displayed positive signal for the U6 snRNA positive control probe. 
BTNW 1336 showed extensive necrosis within the tissue section resulting in poor signal. Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA 
target, red signal – nuclear fast red counterstain. 
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Figure 5.26 ISH of U6 snRNA positive control in male glioblastoma patient tissue sections. All six male patient tissue sections displayed positive signal for the U6 snRNA positive control probe. Main 
images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm, inset 1µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.27 ISH of scrambled negative control probe on female glioblastoma patients. All female glioblastoma patient tissue sections showed no probe signal for the negative control scrambled 
probe. BTNW 1336 showed extensive necrosis within the tissue section resulting in poor signal.  Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm. Blue signal – miRNA 
target, red signal – nuclear fast red counterstain. 
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Figure 5.28 ISH of scrambled negative control probe on male glioblastoma patients. All male glioblastoma patient tissue sections showed no probe signal for the negative control scrambled probe. 
Main images x 10 magnification, inset x 100 magnification. Scale bars – 10 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.29 MiR-20a ISH of female glioblastoma patient tissue sections and qPCR of matched frozen tissue samples. A) Positive signal for miR-20a was obtained for three of the five viable female 
tissue sections in each of the three age groups. MiR-20a signal was observed to be distributed both in the nucleus and cytoplasm of cells within the sections. B) Comparison of tissue and serum miR-
20a expression  determined by qPCR demonstrated no signficant difference in miR-20a expression between matched tissue lysate and serum samples for BTNW 429 and 1186 who also demonstrated 
positive miR-20a ISH signals. Data shown as mean of replicates (n = 3) plus SD, analysed by Mann-Whitney U test, p > 0.05. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – 
nuclear fast red counterstain. 
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Figure 5.30 MiR-20a ISH of male glioblastoma patient tissue sections and qPCR data of matched frozen tissue samples. A) Positive signal of miR-20a was observed for four of the six tissue sections, 
miR-20a signal was observed to be strongest in the nucleus of cells in three of the sections however cytoplasmic staining was also observed, BTNW 816 displayed cytoplasmic staining of miR-20a only. 
B) Comparison of ISH and qPCR miR-20a expression data showed no significant difference in expression of miR-20a for two of the three matched tissue lysate samples compared to matched serum 
samples. BTNW 816 showed a significantly higher expression of miR-20a in the tissue lysate compared to matched serum.  Data shown as mean of replicates (n = 3) plus SD, analysed by Mann-
Whitney U test. Significance between groups indicated by a solid black line, **p < 0.01. Scale bars – 10 µm, 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.31 MiR-34a ISH of female glioblastoma patient tissue sections and qPCR data from matched frozen tissue samples. A) Positive signals for miR-34a were obtained for three of the viable 
female tissue sections, BTNW 743, BTNW 871 and BTNW 1186. MiR-34a ISH signal showed strong nuclear staining and weak cytoplasmic staining. B) Comparison of ISH and qPCR data showed that 
BTNW 1186 tissue lysate miR-34a expression was significantly lower compared to matched serum expression, BTNW 1186 showed a weak miR-34a ISH signal. MiR-34a was not detected in the 
matched tissue lysate sample for BTNW 429 and ISH miR-34a signal for this patient was negative. Data shown as mean of replicates (n = 3) plus SD, analysed by Mann-Whitney U test. Significance 
between groups indicated by a solid black line, ***p < 0.001. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.32 MiR-34a ISH of male glioblastoma patient tissue sections and qPCR data for matched frozen tissue samples. A) Positive signals were obtained for five of the six male tissue sections. MiR-
34a was observed to be enriched in the nucleus of cells demonstrated by a strong signal and a weaker cytoplasmic signal. B) Comparison of miR-34a ISH and qPCR expression showed a down-
regulation of miR-34a expression in tissue lysate samples for all three patients compared to matched serum samples. Data shown as mean of replicates (n = 3) plus SD, analysed by Mann-Whitney U 
test. Significance indicated between groups by solid black line, *p < 0.05, **p < 0.01. Scale bars – 10 µm, inset 1 µm.  Blue signal – miRNA target, red signal – nuclear fast red counterstain. 
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Figure 5.33 MiR-92a ISH of female glioblastoma patient tissue sections and qPCR data from matched frozen tissue samples. A) A positive miR-92a signal was observed for two of the five viable 
female tissue sections, BTNW 1186 and BTNW 743 with the remaining four displaying negative signals. Positive staining for BTNW 1186 was enriched in the nucleus of cells within the section. B) 
Comparison of ISH and qPCR data for miR-92a expression showed a down-regulation of miR-92a in the tissue lysate sample compared to matched serum and signal for BTNW 429 ISH was negative. 
Tissue lysate miR-92a expression was down-regulated compared to the serum of BTNW 1186 which displayed a positive ISH signal. Data shown as mean of replicates (n = 3) plus SD, analysed by 
Mann-Whitney U test. Significance indicated between groups by a solid black line, ***p < 0.001. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear fast red counterstain.  
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Figure 5.34 MiR-92a ISH of male glioblastoma patient tissue sections and qPCR data from matched frozen tissue samples. A) Positive miR-92a ISH signals were observed for four of the six male 
tissue sections BTNW 448, BTNW 850, BTNW 758 and BTNW 1078, with nuclear enrichment in three of the four positive sections except BTNW 758. B) Comparison of ISH and qPCR miR-92a 
expression showed signficantly lower expression in tissue lysate miR-92a expression compared to matched serum samples in all three patients.  Data shown as mean of replicates (n = 3), plus SD, 
analysed by Mann-Whitney U test. Significance between groups indicated by a solid black line, *p < 0.05, ***p < 0.001. Scale bars – 10 µm, inset 1 µm. Blue signal – miRNA target, red signal – nuclear 
fast red counterstain. 
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5.2.6 Expression of Serum Biomarkers in Cerebrospinal Fluid 
 
The use of serum as a relatively non-invasive test for glioblastoma biomarkers is 
attractive however the proximity of cerebrospinal fluid to the location of glial tumours 
may provide a more accurate representation of glioblastoma miRNA expression. 
Expression of the serum miRNA biomarkers identified in Section 4.2.4, in cerebrospinal 
fluid (CSF), from four glioblastoma patients and six patients with other neurological 
disorders (Table 5.2), was measured to determine whether there were similarities with 
serum miRNA expression. If expression of the serum miRNAs was similar it may 
suggest that CSF could be a more useful and accurate means of diagnosing and 
predicting prognosis for glioblastoma patients. Although found to be not significantly 
altered in expression in the validation study, miR-150 was included in the CSF study to 
determine whether expression may be significantly altered in an alternative sample 
type.  
Table 5.2 Neurological disorders of patient CSF samples utilised as controls. 
Patient Number Neurological Disorder 
1208 Dermoid Cyst 
1289 Normal Pressure Hydrocephalus 
1293 Dermoid Cyst 
1210 Hydrocephalus 
1234 Normal Pressure Hydrocephalus 
1238 Normal Pressure Hydrocephalus 
 
MiR-20a and miR-92a were detected in the CSF of glioblastoma patients however, miR-
30c, miR-34a and miR-150 were undetected. MiR-20a showed higher expression in the 
CSF of glioblastoma patients aged between 40 and 39 years and reduced expression in 
glioblastoma patients aged over 60 years (Figure 5.32). CSF samples from glioblastoma 
patients aged between 20 and 39 years were not available for this study. MiR-92a 
expression was significantly higher (p < 0.001) in the CSF of male glioblastoma patients 
compared to sex matched controls (Figure 5.33).  
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Figure 5.35 Expression of miR-20a in the cerebrospinal fluid of glioblastoma patients grouped by age. CSF from 
glioblastoma patients aged between 40 and 59 years exhibited a higher expression of miR-20a compared to CSF 
obtained from glioblastoma patients over the age of 60 years and age matched controls. There was no significant 
difference in miR-20a expression between glioblastoma patients over the age of 60 years and age matched controls. 
Data shown as mean of replicates (n = 3 per group) plus SD, analysed by one way ANOVA with Tukey post-hoc test. 
Significance between groups indicated by a solid black line, ***p < 0.001. 
 
 
Figure 5.36 Expression of miR-92a in the cerebrospinal fluid of glioblastoma patients grouped by gender. MiR-92a 
expression was significantly higher in the CSF of male glioblastoma patients compared to gender matched controls. 
Data shown as mean of replicates (n = 3 per group) plus SD, analysed by unpaired student’s t-test, ***p < 0.001.  
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5.2.7 MicroRNA Expression of Lymphocytes  
 
To further determine whether the miRNA biomarkers detected within the serum of 
glioblastoma patients originated from a source other than the glioblastoma 
microenvironment, the expression of miR-20a, 30c, 34a and 92a was measured in 
lymphocytes obtained from glioblastoma patients. The buffy coat containing 
lymphocytes was collected from fresh blood samples from four glioblastoma patients 
from the Brain Tumour North West tissue bank upon diagnosis and analysed using 
qPCR. Due to the unavailability of non-cancerous control blood samples three control 
patients, two low-grade glioma and one gliosarcoma were used for this study. As a 
result of the small sample size, patients were not grouped by age or gender for 
analysis. Analysis of the four serum miRNA biomarkers in lymphocytes showed no 
significant difference (p > 0.05) in expression between glioblastoma patients and 
control patients (Figure 5.34).  
 
Figure 5.37 Expression of serum miRNA biomarkers in lymphocytes. Expression of the four serum miRNA 
biomarkers was not significantly different in lymphocytes obtained from glioblastoma patients compared to those 
obtained from control patients. Data shown as mean of replicates (n = 4 glioblastoma patients, n = 3 control 
patients) analysed by Mann-Whitney U test, p > 0.05.  
MiR-20a  MiR-30c  
MiR-34a  MiR-92a  
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5.3 Discussion  
 
Following the identification and validation of four miRNA biomarkers in the serum of 
glioblastoma patients, the human serum cell culture model developed in Chapter 3 
was used to investigate the origin of the serum miRNA biomarkers and investigate the 
effect of patient serum on the expression of miRNA biomarkers in U87MG and SVGp12 
cells.  Initial studies were performed to compare the expression of the miRNA 
biomarkers in pools of serum samples from glioblastoma and control patients to the 
expression of the miRNAs in cell lines cultured in 10 % FBS. Expression of the miRNA 
biomarkers in the glioblastoma and control serum pools were compared to ensure that 
the initial expression of the miRNAs in the serum reflected the expression determined 
in Section 4.2.4 and 4.2.5. Subsequent studies were performed to determine the effect 
of replacing FBS with patient serum on the biomarker expression in the cell lines.  
MiR-34a expression was not significantly different in the 60+ glioblastoma patient 
serum pool compared to the 60+ control patient serum pool. MiR-34a expression in 
60+ glioblastoma patient and 60+ control patient serum pools was significantly lower 
compared to miR-34a expression in both U87MG and SVGp12 cell lines cultured in 10 
% FBS. This could be as a result of the lower expression of miRNA observed in the 
serum of patients compared to tissue expression (Skog et al., 2008). Comparison of the 
60+ glioblastoma serum pool to U87MG cells cultured in FBS showed no significant 
difference between intracellular and extracellular expression. MiR-34a expression in 
the 60+ glioblastoma patient pool showed the greatest significant decrease compared 
to the spent media of U87MG cells. This significant decrease was also observed 
between the 60+ glioblastoma pool and intracellular U87MG expression but was not as 
large. This suggests that miR-34a expression in U87MG cells cultured in 10 % FBS is 
significantly higher in exosomes within the media compared to miR-34a expression 
within the cells. This is similar to the high expression of miR-34a observed in the serum 
in Section 4.2.4 and 4.2.5 in this thesis and the down-regulation of miR-34a in 
glioblastoma tissue reported by other studies (Gao et al., 2013, Genovese et al., 2012, 
Li et al., 2011a). MiR-34a expression in the 60+ glioblastoma patient serum pool was 
significantly lower than SVGp12 expression extracellularly. No significant difference 
was observed between intracellular and extracellular SVGp12 expression cultured in 10 
% FBS, suggesting that miR-34a expression is not significantly different between 
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exosomes in the media and expression within SVGp12 cells. MiR-34a expression in the 
60+ glioblastoma patient serum pool was significantly lower compared to intracellular 
SVGp12 expression than intracellular U87MG expression. This suggests that 
intracellular miR-34a expression in U87MG cells is lower than miR-34a expression in 
SVGp12 cells. This is again in accordance with previous reports of miR-34a down-
regulation in the tissue of glioblastoma patients (Li et al., 2011a, Li et al., 2009).  
When cultured in 60+ glioblastoma patient serum, intracellular miR-34a expression in 
U87MG cells was significantly higher compared to U87MG cells cultured in 10 % FBS. 
MiR-34a expression in U87MG cells intracellularly was significantly higher compared to 
extracellular U87MG expression and SVGp12 expression. Extracellular U87MG miR-34a 
expression and SVGp12 miR-34a expression, intracellular and extracellular was not 
significantly different when cultured in 10 % 60+ glioblastoma serum compared to 
culture in 10 % FBS. This trend was also observed in cells cultured in 10 % 60+ control 
patient serum and comparison of intracellular U87MG miR-34a expression showed no 
significant difference in expression between cells cultured in 60+ glioblastoma patient 
serum and 60+ control patient serum.  
U87MG expresses wild-type p53 and miR-34a is a transcriptional target of p53 and is 
part of a positive feedback loop which results in up-regulation of miR-34a (Okada et 
al., 2014). The increase in miR-34a expression in U87MG cells cultured in patient 
serum may be due to an increase in miR-34a taken up by U87MG cells from the patient 
serum resulting in a cumulative increase in expression of this miRNA compared to 
U87MG cells cultured in FBS (Okada et al., 2014). Expression of miR-34a in SVGp12 
cells however, was not significantly different between those cultured in the 60+ 
patient serum pools and those cultured in FBS. SVGp12 cells also express wild-type p53 
(Henriksen et al., 2014b), therefore if the up-regulation of miR-34a in U87MG cells was 
a result of the positive feedback loop between miR-34a and p53, a similar increase 
would be expected in SVGp12 cells. Furthermore the intracellular increase in miR-34a 
expression in U87MG cells was observed in cells cultured in both 60+ glioblastoma 
patient serum and 60+ control patient serum, and the increase was not significantly 
different between the serum pools. As miR-34a expression was determined to be 
higher in the 60+ glioblastoma patient serum pool than the 60+ control patient serum 
pool, a greater increase in U87MG cells culture in the glioblastoma pool would be 
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expected if the increase was related to the positive feedback loop, therefore 
alternative factors are likely to be the cause of the increase in expression that was 
observed.  
Comparison of miR-92a expression in pooled male glioblastoma serum and pooled 
male control serum showed that miR-92a expression was significantly higher in male 
glioblastoma serum compared to male control patient serum as observed in Sections 
4.2.4 and 4.2.5. MiR-92a expression in both male patient serum pools was significantly 
lower compared to miR-92a expression in U87MG and SVGp12 cells cultured in 10 % 
FBS. Again, this is likely to be due to the lower expression of miRNA in exosomes within 
the circulation compared to tissue (Skog et al., 2008). MiR-92a expression in the male 
control serum pool compared to intracellular SVGp12 expression showed the most 
significant difference in expression than extracellular SVGp12 expression and 
intracellular U87MG expression. This suggests that intracellular SVGp12 miR-92a 
expression is higher than that of exosomes in the media of SVGp12 cells as well as 
U87MG cells.  
MiR-92a expression of U87MG cells cultured in 10 % male glioblastoma serum and 10 
% male control serum showed no significant difference compared to those cultured in 
10 % FBS. Intracellular miR-92a expression of SVGp12 cells cultured in 10 % male 
glioblastoma serum was significantly higher compared to those cultured in 10 % FBS. 
Intracellular miR-92a expression of SVGp12 cells cultured in 10 % male control patient 
serum showed no significant difference in expression compared to FBS. This suggests 
that exosomes containing a higher expression of miR-92a in male glioblastoma patient 
serum could be taken up by non-cancerous cells causing an increase in intracellular 
miR-92a. MiR-92a has been shown to target CDH1, a transmembrane glycoprotein 
which promotes cell-cell adhesion of epithelial cells the loss of which is a key hallmark 
of the epithelial-mesenchymal transition (Ding, 2014). Increased miR-92a expression in 
recipient non-cancerous cells could down-regulate expression of CDH1 reducing cell-
cell adhesion and promoting cell motility and invasiveness (Ding, 2014), thereby 
promoting glioblastoma growth and invasion.   
MiR-20a and 30c were detected intracellularly alone in U87MG cells cultured in 10 % 
FBS only. The absence of expression of these two miRNAs in SVGp12 cells both 
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intracellularly and extracellularly may be due to these miRNAs not being expressed by 
this particular cell line or being expressed below the limit of detection by qPCR. The 
lack of U87MG extracellular expression of these two miRNAs may suggest that these 
particular miRNAs are not exported from U87MG cells cultured in standard FBS 
conditions which may be due to the selectivity of exosomal packaging (Chen et al., 
2012).   
Comparison of miR-20a expression in glioblastoma patient and control patient serum 
pools showed expression was significantly higher in the glioblastoma serum pool. No 
significant difference in expression between miR-20a expression in glioblastoma 
patient serum compared to U87MG cells cultured in 10 % FBS. MiR-20a expression in 
control patient serum was significantly lower compared to U87MG cells cultured in 10 
% FBS. As miR-20a was highly expressed in the serum of glioblastoma patients and is 
up-regulated in glioblastoma patient tissue (Srinivasan et al., 2011), this suggests miR-
20a expression in U87MG cells is similarly up-regulated to miR-20a expression in the 
serum of glioblastoma patients and therefore expresses miR-20a at a higher level than 
control patient serum.  
U87MG cells cultured in 10 % glioblastoma patient serum and 10 % control patient 
serum showed no significant difference in miR-20a expression compared to those 
cultured in 10 % FBS. This suggests that human serum does not affect miR-20a 
expression in U87MG cells.  
Comparison of miR-30c expression in 20-39 glioblastoma patients and 20-39 control 
patients showed miR-30c was significantly lower in the glioblastoma patient serum 
pool compared to the control patient serum pool as observed in Sections 4.2.4 and 
4.2.5. MiR-30c expression in the 20-39 glioblastoma patient serum pool was 
significantly lower compared to U87MG cells cultured in 10 % FBS. MiR-30c has been 
previously found to be up-regulated in TRAIL-resistant gliomas and down-regulated in 
TRAIL-sensitive gliomas (Quintavalle et al., 2012). The expression of miR-30c in the 
U87MG cell line has not previously been reported however a previous study 
investigating the effect of TRAIL on glioma cell lines demonstrated U87MG to be 
resistant to TRAIL treatment, suggesting that U87MG is a TRAIL-resistant cell line (Kim 
et al., 2004) which as a result, may express miR-30c at a higher level.  
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The culture of U87MG cells in 10 % 20-39 glioblastoma patient serum resulted in an 
up-regulation in expression of miR-30c compared to those cultured in 10 % FBS. No 
significant difference in miR-30c expression was observed between U87MG cells 
cultured in 10 % 20-39 control patient serum and 10 % FBS. As miR-30c was reduced in 
20-39 glioblastoma patient serum, a high level of expression in U87MG cells cultured in 
glioblastoma serum is unlikely to be due to a positive feedback mechanism and may be 
due to the presence of alternative factors within the serum which may promote the 
expression of miR-30c. 
Initial identification of miRNA expression in tissue samples obtained from glioblastoma 
patients over the age of 60 years showed that of the five serum biomarkers identified 
in Section 4.2.4, three were detected. In male 60+ glioblastoma tissue miR-92a and 
miR-30c showed relatively high expression whereas in female 60+ glioblastoma tissue 
miR-92a showed lower levels of expression. MiR-30c has previously been observed to 
be up-regulated in TRAIL-resistant glioblastomas (Quintavalle et al., 2012). The gender 
difference in male and female tissue miR-92a expression in Section 5.2.1 is similar to 
that observed in Section 4.2.4 in the serum data. MiR-150 was expressed in male 60+ 
glioblastoma tissue alone, exhibiting a higher level of expression compared to age and 
sex matched control tissue. MiR-150 was not detected in the serum of glioblastoma 
patients over the age of 60 years (Section 4.2.4), further investigation of tissue profiles 
in the additional age groups would allow a comparison of miR-150 expression by age in 
glioblastoma tissue, which could further permit elucidation of tissue expression of this 
miRNA compared to serum expression. The role of miR-150-5p in glioblastoma has not 
been investigated in previous studies, however miR-150* is reported to be down-
regulated in grade II-IV glioma serum samples (Yang et al., 2013a). MiR-20a was not 
detected in patient tissue, which may be due to the inverse correlation of miR-20a 
expression and age, identified in Section 4.2.4 and also observed in the TCGA dataset 
in Section 5.2.2. Mir-34a was not detected in the tissue of glioblastoma patients over 
the age of 60 years, and yet miR-34a was detected in the serum of glioblastoma 
patients in this age group in Section 4.2.4 however miR-34a has previously been shown 
to be down-regulated in glioblastoma tissue (Yin et al., 2013) which may attribute to 
the absence of miR-34a in the tissue samples. Further studies investigating the 
expression of the three biomarkers in glioblastoma tissue from patients aged between 
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20 and 39 years and 40-59 years would provide a more complete analysis of serum 
miRNA biomarker expression in glioblastoma tissue.   
Further analysis of tissue miRNA expression using microarray data from the TCGA 
identified all four validated serum miRNA biomarkers to be expressed in glioblastoma 
tissue. Contrary to published data, miR-34a was detected in the tissue of glioblastoma 
patients and the level of expression was correlated with age. The high expression of 
miR-34a in tissue analysed in the TCGA is in contrast to other studies which have 
identified miR-34a as being down-regulated in glioblastoma tissue thus hindering its 
tumour suppressive functions (Gao et al., 2013). The correlation of miR-34a expression 
and age in the tissue data is similar to the observed correlation of serum miR-34a 
expression and age in this study (Section 4.2.4) as well as in previous studies (Li et al., 
2011b, Sawada et al., 2014). Patients with a higher expression of miR-34a were found 
to have a worse prognosis than those with a low expression of miR-34a a previous 
study investigating miR-34a expression and prognosis in grade III and grade IV gliomas 
demonstrated that patients with a high expression had a better prognosis than those 
with a low expression (Gao et al., 2013), this is in contrast to the TCGA data analysed in 
this thesis. Differences in prognosis based on miR-34a between these two studies may 
be due to the size of the patient groups analysed, 558 from the TCGA dataset in 
contrast to 79 patients analysed by Gao et al. (2013) however the improved survival of 
patients observed in the TCGA dataset in Section 5.2.2 with a reduced expression of 
miR-34a does not correlate with the role of this miRNA as a tumour suppressor, as the 
up-regulation of a tumour suppressor would suggest an improved prognosis. A 
previous study of the role of miR-34a in a Kras-induced mouse lung cancer model 
demonstrated that miR-34a down-regulation alone was not sufficient to promote an 
oncogenic effect rather, the combination of miR-34a down-regulation and altered p53 
expression strongly promotes tumourigenesis, suggesting the p53-miR-34a positive 
feedback loop is an important feature in tumourigenesis (Okada et al., 2014). Patients 
with an up-regulation of miR-34a may therefore have wild-type p53 status which could 
contribute to a better prognosis. However another study utilising TCGA data to 
investigate the role of miR-34a expression in glioblastoma also identified patients with 
a low expression of miR-34a as having better prognosis than those with a high 
expression which was further confirmed with microarray analysis (Genovese et al., 
204 
 
2012). Furthermore, the study by Genovese et. al. demonstrated that miR-34a down-
regulation was most frequently associated with the proneural glioblastoma subtype, 
which displays a better prognosis than other glioblastoma subtypes. The glioblastoma 
subtypes of the patients whose samples were used in this thesis were unknown, 
therefore further investigation utilising samples whose subtype is known would 
identify whether the miRNA biomarkers in this thesis are subtype specific.  
MiR-92a was up-regulated in the tissue of glioblastoma patients in the TCGA dataset, 
but was not correlated with age. MiR-92a has previously been reported to be up-
regulated in glioblastoma tissue (Niu et al., 2012). However, no significant difference in 
miR-92a expression was observed between genders in glioblastoma tissue in contrast 
to the gender difference observed in the serum data in Chapter 4. MiR-92a was also 
up-regulated in the male frozen tissue sample in Section 5.2.1, but was down-
regulated in the female tissue sample. The differences in expression between the 
TCGA data and the data obtained in Section 5.2.1 as well as 4.2.2 may be due to 
differences in methods as microarray data and qRT-PCR expression data can often 
differ (Pritchard et al., 2012a). The small sample size of frozen tissue used in this study 
and the large sample size of the TCGA dataset, however, suggests that the TCGA data 
can be interpreted with more confidence. On the other hand, miRNA microarray data 
often requires validation by qRT-PCR (Morey et al., 2006). The high expression of miR-
92a in glioblastoma tissue of both male and female patients suggests that the 
differences in serum miR-92a expression observed in Section 4.2.4 may be due to 
gender differences in exosomal packaging and release. Patients with a higher 
expression of miR-92a had a better prognosis than those with a lower expression. 
Similar to miR-34a TCGA survival data, miR-92a, an oncomiR which supresses 
apoptosis, thereby exhibiting pro-tumourigenic effects (Niu et al., 2012), therefore the 
better prognosis observed with an up-regulation of miR-92a does not conform to its 
tumourigenic role. 
MiR-20a was also relatively high in the tissue of glioblastoma patients and, as observed 
in the serum data (Section 4.2.4), expression was inversely correlated with age. The 
inverse correlation with age for miR-20a has previously been reported in a number of 
replicative cell aging models (Hackl et al., 2010). Patients with a higher expression of 
miR-20a were found to have a better median survival than those with a down-
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regulation as seen in the serum. A previous study utilising TCGA data also identified 
miR-20a as being highly expressed in glioblastoma and also to be correlated with a 
better prognosis (Srinivasan et al., 2011). The TCGA data in Section 5.2.2 and the 
serum data in Section 4.2.4 showed a similar trend in miR-20a expression and 
prognosis, suggesting that the profile of this miRNA in the serum closely reflects that of 
glioblastoma tissue.   
Furthermore, analysis of correlation in the TCGA dataset in Section 5.2.2 between miR-
20a and miR-92a expression in the tissue of glioblastoma patients showed that 
expression of these two miRNAs was significantly correlated. The correlation of 
expression between these two miRNAs is likely due to their location in the same 
cluster, the 17~92 cluster of miRNAs located within the non-protein coding gene 
MIR17HG, which is transcribed together (Hackl et al., 2010).  
Analysis of miR-30c and miR-150 tissue expression in the TCGA dataset showed no 
significant change in expression for either miRNA in glioblastoma patients. 
Furthermore miR-30c and miR-150 displayed no gender or age related differences in 
expression and had no association with survival of glioblastoma patients.  As 
mentioned previously miR-150-5p dysregulation has not been associated with 
glioblastoma to date (Yang et al., 2013a).  
Analysis of tissue and serum miRNA biomarker expression of patients used in this 
current study was performed to determine whether tissue miRNA expression 
correlated with serum expression. Expression of miR-34a in the serum of 60+ 
glioblastoma patients was significantly higher compared to miR-34a expression in the 
tissue. As previous studies have identified miR-34a to be down-regulated in the tissue 
of glioblastoma patients (Gao et al., 2013) and serum data obtained in Section 4.2.4 
showed a high expression of miR-34a in the serum of glioblastoma patients, the trend 
of higher serum miR-34a expression in Section 5.2.3 confirms the serum data obtained 
in this study and the tissue data obtained in other studies. As miRNA expression in the 
circulation has been found to be lower than miRNA expression in donor cells (Skog et 
al., 2008), the observation that miR-34a is expressed at a higher level in serum 
compared to glioblastoma tissue suggests that either miR-34a is actively secreted at a 
high level from glioblastoma or is secreted from an alternative source.  
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Expression of miR-92a in the serum of male glioblastoma patients was reduced 
compared to tissue expression. MiR-92a is known to be up-regulated in the tissue of 
glioblastoma patients (Niu et al., 2012), which is reflected in its high expression in the 
serum of male glioblastoma patients in Section 4.2.4. The lower expression of miR-92a 
in the serum compared to tissue is again likely to be due to the general lower 
expression of miRNA in the circulation compared to tissue as mentioned previously 
(Skog et al., 2008). Expression of miR-20a in matched serum and tissue samples was 
not significantly different, suggesting that expression of miR-20a in serum is similar to 
that in the tissue of glioblastoma patients as observed previously in the serum data 
Section 4.2.4 and the TCGA data in Section 5.2.2.  
The localisation of the miRNA serum biomarkers in glioblastoma tissue was 
determined using ISH. Three of the five miRNA biomarkers were selected for 
investigation using ISH. ISH provides a visual representation of miRNA expression in 
tissue sections as qualitative data, qPCR analysis of tissue miRNA expression was also 
performed in parallel to the ISH study to provide quantitative data and validate the ISH 
data. As patient tissue samples were limited, only five matched patient tissue lysate 
and tissue sections were used in the ISH study meaning ISH data for a small sample of 
the patient cohort was compared to the qPCR data, however those analysed by both 
ISH and qPCR could provide some information on the correlation between the 
localisation of the miRNA biomarkers in the tissue sections and expression of the 
miRNAs in the tissue determined by qPCR. Optimisation of the probe hybridisation 
temperature exhibited positive signal for both miR-21 and U6 snRNA positive controls 
and negative staining for the scrambled probe at both temperatures. A final 
hybridisation temperature of 37 ° C was selected as a higher temperature reduces the 
extent of non-specific binding of the probes to similar sequences (Nielsen, 2012).  
In Situ analysis of miR-20a in female and male glioblastoma patient tissue sections 
displayed both positive and negative staining for the cohort. Differences in miR-20a 
expression between the glioblastoma patient tissue sections is similar to that observed 
for serum miR-20a expression in which up-regulation of miR-20a was observed for a 
sub-group of the patient cohort who were also observed to have a better prognosis 
than those without an up-regulation in miR-20a expression. This may be due to 
differences in miRNA expression between different molecular subtypes of glioblastoma 
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(Tang et al., 2013). Comparison of tissue lysate and tissue section miR-20a expression 
showed similar expression of miR-20a in the tissue lysate when compared to tissue 
section miR-20a expression. MiR-20a ISH signal was uniform across the majority of the 
patient sections, exhibiting both cytoplasmic and nuclear expression. Patients 
exhibiting cytoplasmic and nuclear staining of miR-20a expression in the sections 
exhibited similar ΔCt values of miR-20a in tissue lysate and serum miR-20a expression. 
BTNW 816 frozen tissue miR-20a expression was observed to be lower than serum 
miR-20a expression. Furthermore, ISH miR-20a expression for this patient was 
observed to be restricted to the nucleus of cells within the section. The localisation of 
miR-20a in the nucleus of BTNW 816 suggests miR-20a expression is enriched in the 
nucleus which has been observed for a number of miRNAs previously (Roberts, 2014). 
The combination of both nuclear and cytoplasmic expression of miR-20a in the 
remaining patient sections may attribute to the higher tissue expression determined 
by qPCR compared to the tissue expression of BTNW 816.  
In Situ analysis of miR-34a in male and female glioblastoma patient tissue sections 
showed a correlation between expression and age similar to that observed in the 
serum of glioblastoma patients in Section 4.2.8.  Comparison of frozen tissue and 
serum miR-34a expression exhibited a lower expression of miR-34a in the tissue of 
glioblastoma patients compared to matched serum. This confirms previous findings of 
a reduced expression of miR-34a in glioblastoma tissue in other studies as well as in 
this thesis in Section 5.2.3 (Gao et al., 2013, Li et al., 2009). Patients with a down-
regulation in frozen tissue miR-34a expression compared to serum also showed weak 
or negative miR-34a signal in the tissue sections, showing a correlation between ISH 
and qPCR miR-34a expression. BTNW 850 a glioblastoma patient aged between 20 and 
39 years exhibited a positive miR-34a signal in the tissue section, this patient 
glioblastoma may exhibit wild-type p53 status, which targets miR-34a and promotes its 
expression in the tissue of glioblastoma patients (Okada et al., 2014), which would 
therefore account for the positive signal observed.  
In Situ analysis of miR-92a in female glioblastoma patients exhibited no staining for all 
sections excluding BTNW 743 and BTNW 1186. ISH and qPCR data for BTNW 429 
showed contrasting results, ISH for this patient showed a negative signal for miR-92a in 
the tissue section however miR-92a tissue expression determined by qPCR exhibited 
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an up-regulation in miR-92a expression compared to the matched serum sample. This 
may be due to the section utilised for ISH being taken from around the glioblastoma, 
thereby containing non-cancerous cells with a different miR-92a expression. MiR-92a 
expression in tissue sections of male glioblastoma tissue sections showed positive 
staining for all but one of the patients, suggesting that miR-92a is up-regulated in the 
tissue of male glioblastoma patients. MiR-92a has previously been found to be up-
regulated in the tissue of glioblastoma patients (Niu et al., 2012) as well as in the 
serum of male glioblastoma patients shown in Section 4.2.4.  Both male and female 
patients with a positive miR-92a ISH signal displayed a down-regulation of tissue miR-
92a expression compared to matched serum by qPCR, this suggests patients with 
tissue miR-92a expression have a higher expression of miR-92a in the serum.  
ISH analysis of miR-92a and in particular miR-20a localisation displayed strong nuclear 
expression. All three miRNAs showed both nuclear and cytoplasmic signal in the tissue 
sections of patients, previous analysis of miRNA localisation intracellularly has found 
that the majority of mature miRNAs are distributed in both nuclear and cytoplasmic 
compartments (Roberts, 2014). A study of rat primary cortical neurons identified a 
significant enrichment of mature miR-92a in the nucleus (Khudayberdiev et al., 2013), 
as observed in Section 5.2.3.  
Recently, the presence of miRNAs in the cerebrospinal fluid of glioblastoma patients 
has been reported (Teplyuk et al., 2012, Baraniskin et al., 2012). The presence of the 
BBB, a highly selective barrier, leads to a restricted composition of cerebrospinal fluid, 
therefore the detection of miRNAs in this biofluid may be more specific to 
glioblastoma and provide a more accurate biomarker profile of the tumour due to a 
lower level of miRNA released from other non-cancerous cell types. The miRNA profile 
of cerebrospinal fluid was investigated as a comparison to serum as a source of 
biomarkers. Total RNA obtained from cerebrospinal fluid samples following extraction 
was markedly lower than that of serum (Appendix 5). Following identification and 
validation of miRNA biomarkers in the serum, these markers were measured in 
cerebrospinal fluid. MiR-30c, miR-34a and miR-150 were not detected in the 
cerebrospinal fluid of glioblastoma patients however miR-92a and 20a were found to 
be expressed. Due to the limited availability of cerebrospinal fluid samples, no samples 
from the 20-39 age group were analysed for this study, however expression of miR-20a 
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was up-regulated in the cerebrospinal fluid of glioblastoma patients aged between 40 
and 59 years compared to those aged over 60 years and patients without glioblastoma, 
this trend was also observed in the serum of glioblastoma patients. MiR-20a was found 
to be down-regulated in the cerebrospinal fluid of glioblastoma patients aged over 60 
years compared to those without glioblastoma. MiR-92a was up-regulated in the 
cerebrospinal fluid of male glioblastoma patients and down-regulated in the 
cerebrospinal fluid of female glioblastoma patients, this trend was also observed in the 
serum of glioblastoma patients.  
The detection of two of the three serum miRNA biomarkers in the cerebrospinal fluid 
of glioblastoma patients suggests that this biofluid could also be used as a source of 
biomarkers. MiR-34a however was not detected in the cerebrospinal fluid of 
glioblastoma patients, which could have been due to the low yield of RNA obtained 
from these samples or alternatively miR-34a may not originate from the glioblastoma 
which correlates with previous studies (Gao et al., 2013). The use of a larger biomarker 
panel for glioblastoma would provide a more accurate representation of disease state, 
therefore serum miRNA, in this instance, would provide the best source of biomarkers. 
To further investigate the origin of the four serum biomarkers in the serum of 
glioblastoma patients, lymphocytes isolated from the buffy coat of glioblastoma 
patient blood samples were analysed for expression of the miRNA biomarkers. 
Expression of all four miRNA biomarkers was not significantly different in glioblastoma 
patient lymphocytes compared to control patient serum. This suggests that the change 
in expression in the biomarkers detected in the serum is not related to an alteration in 
expression in lymphocytes. The small sample size however, did not permit analysis of 
miRNA biomarkers in patient lymphocytes grouped by age and gender, which could 
have provided a more in depth analysis of miRNA expression in lymphocytes. 
Furthermore, the use of control lymphocytes from patients with other neoplastic brain 
diseases could have also affected the data obtained. Detection of the miRNA 
biomarkers in the serum utilised serum from control patients with no diagnosed 
neoplasm and the expression of the miRNA biomarkers was not investigated for 
specificity for glioblastoma alone. The miRNAs identified in the serum therefore, may 
also display a similar dysregulation in other glioma types and grades as well as other 
brain neoplasms. Further work utilising a larger patient cohort and control samples 
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obtained from non-neoplastic patients grouped by age and gender could therefore 
provide a more accurate description of miRNA biomarker expression in lymphocytes in 
glioblastoma patients.  
Data from Chapter 5 have shown differences in correlation between serum and tissue 
miRNA biomarker expression. MiR-20a exhibited a similar expression between serum 
and tissue samples in the human serum cell culture model in Section 5.2.1, TCGA data 
in Section 5.2.2, qPCR serum and tissue expression comparison in Section 5.2.3 and 
from comparison of ISH data and qPCR tissue data in Section 5.2.4. Furthermore 
correlation between age and miR-20a expression and prognosis was observed in the 
TCGA dataset as previously seen in serum data in Section 4.2.4. TCGA data, qPCR and 
ISH analysis all identified miR-20a expression trends to be closely similar between 
serum and tissue samples. This suggests that the expression of miR-20a in the serum 
closely reflects the expression in glioblastoma tissue, therefore circulating miR-20a is 
likely to originate from the glioblastoma itself.  Expression of miR-34a was reduced in 
the tissue compared to serum in Section 5.2.3 and 5.2.4 as observed in Section 4.2.4 
however, TCGA expression data did not correlate with glioblastoma tissue miR-34a 
expression in the qPCR and ISH data. MiR-34a was not expressed in the cerebrospinal 
fluid of glioblastoma patients and results from lymphocyte expression were 
inconclusive. Taken together, the origin of miR-34a in the serum of glioblastoma 
patients is still unknown. MiR-92a expression was significantly higher in glioblastoma 
tissue in the TCGA dataset analysis, matched serum and tissue samples and ISH. The 
gender difference observed in Chapter 4 in the serum however, was not observed for 
glioblastoma tissue in this chapter. This suggests that although miR-92a may originate 
from the tumour, gender differences in exosomal packaging and release may have led 
to the higher detection observed in male glioblastoma serum samples.   
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6.1 Summary 
This thesis aimed to profile the serum miRNA expression of glioblastoma patients and 
identify a panel of dysregulated miRNAs which could be used for the diagnosis of 
glioblastoma.  A human serum cell culture model was developed to investigate the 
effects of glioblastoma and non-cancerous human serum on miRNA expression within 
the glioblastoma cell line U87MG and the non-cancerous astrocyte cell line SVGp12. 
Following investigation of human serum effects in cell culture, profiling of serum from 
glioblastoma patients identified a number of dysregulated miRNAs which, following 
validation, led to a panel of four miRNA biomarkers which could potentially be used for 
diagnosis of glioblastoma. It was further demonstrated that miR-20a may also have the 
potential to be a prognostic biomarker, likely to be associated with the oligoneural 
glioblastoma subtype (Kim et al., 2011). To further understand the miRNA biomarker 
panel identified, studies were performed in order to elucidate the origin of these 
miRNAs in relation to the presence of the glioblastoma and it was demonstrated that 
some of the miRNAs from this panel may originate from the glioblastoma itself and 
other miRNAs in the panel may originate from alternative sources such as cells of the 
immune system. Ultimately, these studies have identified a miRNA biomarker panel 
which could improve or enhance current diagnostic techniques for glioblastoma as well 
as further our understanding of how dysregulation of miRNAs may lead to 
glioblastoma progression, malignancy or prognosis.      
6.2 Development of a human serum cell culture model for investigation 
of miRNA expression  
 
Current research into the expression and targets of miRNAs for disease in vitro 
employs immortalised human cell lines cultured in medium containing a supplement of 
10 % FBS. Whilst this provides a good starting point for in vitro studies, the use of 
serum obtained from a separate species is likely to affect the data obtained from such 
studies. The foetal origin of FBS means it is rich in growth factors and hormones which 
promote the growth of cells. Although it is known that FBS contains growth promoting 
components, the exact composition is unknown and some components have not been 
identified or the effect on cell lines is unknown (Brunner et al., 2010). Batch to batch 
variability in FBS composition is also a limitation on studies utilising cultured cells 
(Witzeneder et al., 2013). The first aim of this thesis was to develop a cell culture 
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model using human serum from patients both with and without glioblastoma and to 
investigate the characteristics of U87MG and SVGp12 cells in this model.  
The culture of U87MG and SVGP12 cells in human serum in Chapter 3 resulted in 
changes in rate of proliferation, morphology and miRNA expression. This suggested 
that the serum type used does have an effect on the characteristics of a cell line and 
subsequently the data obtained. Whilst the use of a human serum cell culture model 
may be more closely representative of in vivo conditions, the use of immortalised cell 
lines themselves may also influence the data obtained from in vitro studies. Analysis of 
miRNA profiles of U87MG and SVGp12 cells cultured in standard 10 % FBS conditions 
identified a number of miRNAs whose expression did not match that of glioblastoma 
tissue in vivo. Prolonged culture of these cell lines and the process of immortalisation 
introduces mutations and chromosomal aberrations that are not representative of the 
tissue source (Li et al., 2008), therefore whilst the human serum model provides a 
closer representation of glioblastoma in vivo, data must still be interpreted with 
caution and further studies must be performed using primary cell lines and tissue to 
validate findings.  
The culture of U87MG and SVGp12 cells in the human serum model was found to alter 
the intrinsic cellular expression of miRNAs as well as the secreted extracellular miRNA 
when compared to cells cultured in FBS. The alteration of intrinsic miRNA expression 
was not always found to be correlated with extracellular expression and vice versa. 
This suggests that the process of miRNA packaging and release is a regulated process 
that is not solely dependent on the expression levels of a particular miRNA within cells. 
Whilst still not wholly understood, the packaging of miRNAs into exosomes and 
subsequent release into the extracellular environment is known to be a selective 
process (Hu et al., 2012). This suggests that miRNAs which are released into the 
circulation have a specific role extracellularly. The selective release of miRNAs from 
glioblastoma can alter the tumour microenvironment promoting growth, invasion and 
angiogenesis (Li et al., 2013). The measurement of such miRNAs, therefore, offers a 
good source of biomarkers which could provide information about an individual’s 
disease for personalised treatment. It has been previously shown that FBS itself 
contains miRNAs of a bovine origin packaged within exosomes (Shelke et al., 2014) 
which could potentially share sequence similarity with the human miRNAs analysed in 
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Chapter 3. The use of FBS as a control therefore, from which changes in miRNA 
expression were measured, prevented expression analysis of both bovine and human 
miRNAs. To further improve the reliability of the studies performed in Chapter 3 using 
the human serum cell culture model exosome depleted FBS could have been used for 
culture (Shelke et al., 2014), thereby eliminating the presence of any miRNAs other 
than those present in the human patient serum. The human serum cell culture model 
developed in Chapter 3 therefore provides a novel in vitro model which more closely 
represents in vivo.  
6.3 Identification and Validation of Serum MiRNA Biomarkers   
 
The primary aim of this thesis was to identify miRNAs in the serum of glioblastoma 
patients which could be used as biomarkers to improve diagnosis and treatment 
decisions. Data from Chapter 3 indicated differences in composition between serum 
from glioblastoma patients and non-cancerous control patient serum. From these 
data, Chapter 4 aimed to elucidate whether one component of serum, miRNA, differed 
between glioblastoma patient and control patient serum and whether this could be 
used to identify miRNA biomarkers for glioblastoma. Whilst many studies have 
investigated the identification of circulating miRNA biomarkers, few have considered 
the effects of gender and age on miRNA expression. One such previous study utilised 
the TCGA dataset to determine race and gender specific miRNAs which could be 
associated with the prognosis of glioblastoma patients (Delfino et al., 2011). Delfino et 
al. identified 19 miRNAs with gender, race and therapy associations with glioblastoma 
survival.  
This thesis, therefore, aimed to identify miRNA biomarkers within patients grouped by 
aged and gender, to provide biomarkers with a greater specificity initially for diagnosis 
but also for prognostic purposes. Selection of age groups was based on the study by 
Crocetti et al., (2012) who grouped epidemiological data by the age groups of 20-39, 
40-59 and over the age of 60 years. 
To further improve the validity of the miRNA biomarkers identified in this thesis, initial 
identification was performed using a small patient cohort, further confirmed using a 
larger patient sample set and subsequently validated using an independent patient 
cohort the size of which was determined using power analysis. Power analysis provides 
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a confidence level that statistically significant differences in expression of miRNA 
between groups will be detected by the study if one exists, and ensures the sample 
number is large enough to detect such a difference (Suresh and Chandrashekara, 
2012). In this study, the expected difference, also known as effect size (Suresh and 
Chandrashekara, 2012), was a fold change of one for each miRNA, therefore the power 
analysis determined the sample size required to detect a difference of one fold change 
between the glioblastoma and control patient cohorts. The minimum power required 
for a study is 80 % power (Suresh and Chandrashekara, 2012), therefore the 
appropriate sample size for each miRNA was selected to provide 80 % power. For 
miRNAs which required a small sample number for 80 % power, more samples were 
included to increase the power to 90 % and thereby increase confidence in statistical 
significance, therefore validation of miR-34a and miR-20a provided 90 % power.  
Initial miRNA identification was performed using the miScript brain cancer array panel 
containing 84 miRNAs with a known role in brain cancers, including glioma. Whilst this 
provided a large number of miRNAs as a starting pool for biomarker identification, the 
use of this array did not permit the identification of novel miRNAs with unknown roles 
in brain cancer. Further studies using alternative methods such as the employment of 
cDNA libraries from size fractionated small RNA (Berezikov et al., 2006) or microarrays 
(Liu et al., 2008) could be utilised to identify novel miRNAs in the serum of 
glioblastoma patients and expand the biomarker panel. Although the miScript brain 
cancer panel allowed profiling of a large set of miRNAs, only one sample could be 
analysed per 96 well plate hence due to the cost of the miScript panels, only a cohort 
of three glioblastoma patients per group with a limited number of control patients 
could be analysed using this method. Further analysis of dysregulated miRNAs in a 
larger patient cohort utilised the NCode first strand cDNA synthesis kit and goTaq SYBR 
green master mix which provided a lower cost method for miRNA expression analysis 
and therefore permitted analysis of larger patient cohorts. The miScript and NCode 
methods use the same principal for the reverse transcription and qRT-PCR of miRNAs. 
Prior to reverse transcription, poly(A) polymerase was used to add a poly(A) tail onto 
the miRNA (Benes and Castoldi, 2010). A universal reverse primer and a forward 
primer specific to the target miRNA was subsequently used for qPCR (Benes and 
Castoldi, 2010). Both miScript and NCode use the SYBR green detection method to 
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perform relative quantification and the cel-miR-39 spike in was used in both instances 
for normalisation (Kroh et al., 2010). Currently there is no universally agreed 
endogenous control for circulating miRNA qRT-PCR normalization. Analysis of tissue 
miRNA expression normally utilises the U6 snRNA endogenous control. A number of 
controls have been proposed and are utilised for circulating miRNA expression studies 
however, other studies investigating the nature of expression of some of these 
endogenous controls have found altered expression in diseased states. To effectively 
normalise qPCR data for miRNA expression in this thesis, the Cel-miR-39 spike in was 
utilised. With no mammalian homologue, the use of the cel-miR-39 spike in permitted 
confidence in no in vivo related variability and could be additionally used to determine 
efficiency of the RNA extraction process (Kroh et al., 2010). Maintaining the same 
methods for detection, relative quantification and normalisation of miRNA ensured 
minimal bias between data generated from the profiling and validation studies.  
The primary method of miRNA detection utilised in this thesis was qRT-PCR, 
quatification of miRNAs using this method presents some unique challenges compared 
to the quantification of mRNA. The small size of miRNAs and GC content provides 
challenges in primer design, requiring primers which include the whole mature miRNA 
sequence to obtain an appropriate Tm between 55 °C and 65 °C (Benes and Castoldi, 
2010).  
MiRNAs which are to be used as biomarkers must have little variation in expression 
between patients to ensure good sensitivity and specificity to prevent false-positive or 
false-negative results which could subsequently delay correct diagnosis or affect the 
choice of treatment strategies (Diamandis, 2010).   Following serum profiling using the 
initial miScript miRNA panel, changes in expression in glioblastoma patient serum were 
analysed for significance to identify potential biomarkers for validation studies. In the 
patient cohort used for identification of biomarkers a number of the non-significant 
miRNAs were observed to vary in fold change expression between individual 
glioblastoma patient samples. As certain miRNAs were not significantly different from 
the control patient serum as a result of high variation, they were therefore deemed 
unsuitable for use as biomarkers. From the initial panel, there were however three 
miRNAs found to be significantly different in glioblastoma patient serum compared to 
control patient serum. MiR-34a was found to be up-regulated in the serum of 
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glioblastoma patients over the age of 60 years. MiR-92a was found to be up-regulated 
in the serum of male glioblastoma patients and miR-20a was found to be up-regulated 
in a subset of glioblastoma patients however further studies would need to be 
performed to confirm this finding. The identification of age and gender specific miRNA 
dysregulation in this study further supports the use of matched samples and patient 
grouping by age to identify specific miRNAs for different patient cohorts, which 
without grouping could be identified as not significantly dysregulated.  
MiR-34a was found to be up-regulated in the serum of glioblastoma patients over the 
age of 60 years compared to age matched controls.  MiR-34a expression has previously 
been shown to be correlated with age (Li et al., 2011b, Sawada et al., 2014). As the fold 
change difference of this miRNA was determined using age matched control samples, 
this indicated that the increase of miR-34a expression was not solely due to the age of 
the patients but also due to the presence of the glioblastoma. MiRNA-34a is a 
transcriptional target of p53 which, upon expression, mediates a number of 
downstream effects including cell cycle arrest and apoptosis by post-transcriptional 
mRNA targeting in a context-dependent manner (Table 6.1) (Okada et al., 2014). 
Expression of miR-34a and p53 is part of a positive feedback loop in which miR-34a 
targets Mdm4, a negative regulator of p53, promoting p53 activity and thereby 
expression of miR-34a (Okada et al., 2014).  
Table 6.1 Targets of miR-34a and subsequent effects. 
Target  Effect    Reference  
CDK4/6 Cell cycle arrest  (He et al., 2007) 
Cyclin D1/E2 Cell cycle arrest  (He et al., 2007, Sun et al., 2008) 
c-Met Cell cycle arrest  (He et al., 2007) 
Myc Apoptosis  (Wei et al., 2008) 
Bcl-2 Apoptosis (Sun et al., 2008) 
YY1  Migration and proliferation. (Yin et al., 2013) 
Notch-1/Notch-2  Proliferation  (Li et al., 2009, Li et al., 2011a) 
PDGFRA Tumourigenesis  (Genovese et al., 2012) 
Smad4 Tumourigenesis (Genovese et al., 2012) 
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MiR-92a expression was higher in the serum of male glioblastoma patients compared 
to gender matched controls. MiR-92a is a protumourigenic miRNA, known to be up-
regulated in glioblastoma tissue and which targets the proapoptotic Bcl-2-like protein 
11 (BIM), thereby exhibiting anti-apoptotic effects (Niu et al., 2012). Furthermore, 
overexpression of miR-92a has been linked to angiogenesis. MiR-92a is part of the 
17~92 cluster of miRNAs which produces a single primary transcript containing all six 
miRNAs which make up the cluster (Olive et al., 2010). The 17~92 cluster is a direct 
transcriptional target of c-Myc, N-Myc, E2F1 and E2F3 (Olive et al., 2010). Also known 
as ‘oncomiR 1’, the 17~92 cluster is well studied and its role in a number of cancer 
types has been previously identified, however the roles and targets of the specific 
miRNAs which make up this cluster have yet to be elucidated fully (Olive et al., 2010). 
The over-expression of this cluster in gliomas is characterised by high expression levels 
of mature miR-17 and miR-20a, however the remaining miRNAs in this cluster are not 
found to be up-regulated, suggesting alternative post-transcriptional processing which 
have not yet been fully elucidated (Lages et al., 2011). The 17~92 cluster has a 
homologous cluster on the X chromosome, which contains miR-92a-2, which is 
identical in sequence to miR-92a-1, located in the 17~92 cluster and also targets BIM 
(Olive et al., 2010). As discussed in Section 4.3, X-chromosome inactivation (XCI) in 
females could potentially explain why the up-regulation of miR-92a was observed 
solely in the serum of male glioblastoma patients. Alternatively, the up-regulation of 
miR-92a in the serum of male glioblastoma patients could be a result of an immune 
response towards the presence of the glioblastoma (Ohyashiki et al., 2011), although 
why this immune response is gender specific is unknown. Up-regulation of the 17~92 
cluster in gliomas is usually characterised by higher expression of miR-17 and miR-20a, 
however miR-17 was not observed to be dysregulated in glioblastoma patient serum. 
The increase of miR-92a expression in male glioblastoma patients observed in this 
study may be a result of over-expression of miR-92a-2, located in the homologous 
cluster on the X chromosome (Olive et al., 2010). 
In this thesis, miR-20a was increased in a subset of glioblastoma patients compared to 
non-cancerous controls in the identification cohort but not the validation cohort. MiR-
20a is another miRNA which makes up the 17~92 cluster and plays a role in cell cycle 
regulation and apoptosis by targeting E2F1. Although miR-20a is located in the same 
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cluster as miR-92a, the cluster can be grouped into four different families based on the 
homology of the seed sequence. MiR-92a and miR-20a do not share seed sequence 
homology and therefore are not grouped into the same family (Mogilyansky and 
Rigoutsos, 2013), which may account for differences in expression profiles, with miR-
20a being up-regulated in a subset of glioblastoma patients and miR-92a observed to 
be up-regulated in male glioblastoma patients only.  
The difference in miR-20a expression between glioblastoma patients could be a result 
of glioblastoma subtypes which differ in gene, protein and miRNA expression (Mischel 
et al., 2003, Tang et al., 2013). MiR-20a over-expression has been identified previously 
in the pro-neural glioblastoma subtype. Further work investigating miR-20a expression 
in the serum and tissue grouped by glioblastoma subtypes could elucidate differences 
in expression which may explain the difference in expression observed in this thesis.  
Higher expression of miR-20a in the serum of glioblastoma patients was found to be 
correlated with better prognosis compared to those who showed no change in 
expression compared to matched controls. Previous studies of miR-20a in glioblastoma 
tissue have found that an up-regulation of miR-20a is linked to improved prognosis 
most likely to be related to the targets of this miRNA, E2F1 and cyclin D1 (Srinivasan et 
al., 2011) which have both previously been linked to improved prognosis (Liu et al., 
2011, Sallinen et al., 1999). The miR-20a target E2F1, is a cell cycle regulator which 
controls the G1/S checkpoint of the cell cycle and targets cell cycle, DNA replication 
and apoptotic genes (Esquela-Kerscher and Slack, 2006). E2F1 is also part of a positive-
feedback loop with MYC, which transcriptionally targets both the 17~92 cluster and 
E2F1 itself. Up-regulation of MYC, therefore, promotes over-expression of E2F1 which 
subsequently promotes further MYC expression leading to hyperproliferation. MYC is 
an oncogenic protein, frequently mutated or amplified in cancer and can promote both 
cell proliferation and apoptosis. MYC has been observed to be over-expressed in the 
majority of glioblastomas (Annibali et al., 2014). The up-regulation of miR-20a and 
miR-17, which is also encoded by the 17~92 cluster, inhibits the translation of E2F1 
mRNA thereby interrupting the positive-feedback loop between E2F1 and MYC and 
subsequently reducing the cell-proliferative effects of MYC (Esquela-Kerscher and 
Slack, 2006). A previous study by Alonso et al. (2005) identified E2F1 as a prognostic 
factor for glioblastoma patients. Analysis of 61 glioma tissue samples found those with 
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a lower expression of E2F1 exhibited a better survival than those with an over-
expression (Alonso et al., 2005). Glioblastoma tissue samples obtained from long-term 
survivors, defined as surviving 2 or more years after diagnosis, also displayed a lower 
expression of E2F1. The combination of miR-20a up-regulation and subsequent down-
regulation of E2F1 may therefore contribute to a better prognostic outlook compared 
to patients with no change in miR-20a expression (Alonso et al., 2005). Research has 
found that E2F1 has contradicting effects in different cancer types, with the ability to 
act as both a tumour suppressor and an oncogenic factor however, in regards to 
gliomas E2F1 is considered to be oncogenic (Alonso et al., 2008) and therefore the up-
regulation of miR-20a and inhibition of E2F1 translation is likely to be tumour 
suppressive in this context.   
The difference in miR-20a expression between glioblastoma patients observed in this 
study could be likely due to difference in patient glioblastoma subtype. Whilst this 
difference was detected for miR-20a, no similar trends were observed for the 
remaining biomarkers. Current diagnostic techniques identify certain genetic markers, 
EGFRvIII, IDH1 and NF1, which have been associated with particular subtypes (Verhaak 
et al., 2010), however identification of an individual’s glioblastoma subtype is not 
currently standard protocol during diagnosis. The cohort utilised in this study 
therefore, may not include the full range of glioblastoma subtypes which could have 
led to subtype specific expression patterns of the remaining biomarkers not being 
detected in this thesis. Further work establishing a panel of glioblastoma serum 
samples from all glioblastoma subtypes and analysis of differences in miRNA biomarker 
expression between these subtypes could further improve the sensitivity of the 
biomarker panel. This could subsequently provide information on a patient’s subtype 
at diagnosis therefore improving treatment strategies.    
6.4 Determination of circulating miRNA biomarker origin  
 
Whilst the four serum miRNA biomarkers validated in Section 4.2.5 provided a panel 
which could be utilised in the diagnosis and prediction of prognosis for glioblastoma 
patients, further investigation to elucidate the pathophysiological origin of secreted 
biomarkers provided a further understanding of the cause and effect of glioblastoma 
on circulating miRNA expression.   
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The methods utilised for determining biomarker origin included qRT-PCR, TCGA 
dataset analysis and in situ hybridisation. All three methods were used to determine 
miRNA expression however each method provided an independent aspect on 
biomarker origin. Analysis of miRNA expression in glioblastoma tissue using qRT-PCR 
provided matched data for the patients whose serum was utilised for biomarker 
identification in this thesis. The use of matched samples provided an accurate, patient 
specific illustration of miRNA expression both in the circulation of the patients and 
within the glioblastoma itself.  Analysis of glioblastoma tissue miRNA expression using 
the TCGA dataset provided a much larger patient cohort than could have been 
realistically analysed in this thesis and the large sample number added statistical 
robustness to the findings. In situ analysis of matched tissue sections to patient tissue 
lysate permitted determination of the localisation of the individual markers within the 
glioblastoma which, combined with qRT-PCR data of patient tissue, provided a more in 
depth analysis of miRNA expression in subsets of cells found within the heterogenous 
glioblastoma tissue.  
In situ analysis of miRNA expression in glioblastoma tissue sections permits 
observation of specific cell types or locations of miRNA expression within the 
glioblastoma which would not be so readily performed using qRT-PCR or microarray 
analysis due to the diffuse nature of glioblastoma. Successful in situ hybridisation is 
reliant on a number of variables which can affect signal strength, including extent of 
fixation of the sections and the age of the sections. It has been previously found that 
the length of fixation of a section can reduce signal strength and require a longer 
protease digestion step to provide an adequate probe signal (Thompson et al., 2007). 
On the other hand, prolonged protease digestion can lead to poor tissue morphology 
and equally reduced signal (Thompson et al., 2007). Differences in the extent of 
fixation may explain why signal strength for certain sections utilised in Chapter 5 
varied for example for the U6 positive control, however the in situ data obtained may 
still be used to determine the localisation of the miRNAs within the tumour and the 
additional analysis of miRNA tissue expression using qRT-PCR provided quantitative 
data on miRNA expression.         
Following validation of the four serum biomarkers, analysis of expression was 
performed in cerebrospinal fluid (CSF). Due to the close proximity of CSF to the brain 
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and the spinal cord, the presence of a glioma within the CNS results in the alteration of 
CSF composition.  The abundance of certain substances alters as a result of: humoral 
responses (Tainsky, 2009); breakdown of structures within the CSF, such as the blood-
brain barrier (BBB) (de Bont et al., 2006); or as a result of up-regulated production and 
secretion by the glioma cells themselves (Niclou et al., 2010). The presence of miRNAs 
in the cerebrospinal fluid of glioma patients has initiated studies into the potential of 
CSF as a source of biomarkers. Although cerebrospinal fluid is not routinely obtained 
from patients with glioma (Baraniskin et al., 2011), the proximity of cerebrospinal fluid 
to gliomas and its isolation from general circulation means it could potentially provide 
a more specific and accurate miRNA profile in comparison to serum (Teplyuk et al., 
2012).  
A number of previous studies have been performed investigating the use CSF as a 
miRNA biomarker source for glioblastoma (Baraniskin et al., 2012, Teplyuk et al., 
2012). Four biomarkers were identified in this thesis in the serum of glioblastoma 
patients however only two were detected in the CSF, which suggested that for this 
particular panel of miRNAs, serum was the more useful biofluid for detection. Previous 
studies investigating miRNAs as biomarkers in CSF for glioma have also identified a 
limited number of miRNAs which are significantly dysregulated in the CSF of glioma 
patients. Baraniskin et al., (2011) identified two miRNAs, miR-15b and miR-21, with 
altered expression in CSF and Teplyuk et al., (2012) also identified two miRNAs, miR-
10b and miR-21, with significant altered expression in glioma CSF. Serum as a biofluid 
for miRNA expression therefore, can provide a larger panel of miRNAs for a more 
accurate diagnosis of glioblastoma.   
As CSF is part of a closed system in the CNS, with a highly selective barrier, alternative 
sources of miRNAs are less frequent and would provide a more specific miRNA panel 
which would be likely to originate from the glioblastoma itself. Alternative miRNA 
sources present within the serum which may be affected by the presence of the 
neoplasm, such as immune cells, could convey a picture of the glioblastoma, and 
additionally responses of other systems in the body could provide information on an 
individual’s disease, prognosis and their response to treatment. The less invasive 
nature of serum collection compared to CSF collection also provides a clinical 
advantage for serum biomarkers over CSF. Lumbar punctures are not routine for 
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glioblastoma diagnosis and would therefore be an additional diagnostic test and the 
collection of CSF during surgery would negate the use of the biomarker panel for 
earlier and improved diagnosis.  
One of the major limitations of determining the origin of the miRNA biomarkers in this 
thesis was the lack of available matched samples for analysis which therefore resulted 
in a limited number of samples. Whilst the data in Chapter 5 can be used to elucidate 
the origin of miRNA expression differences between serum and tissue, further work 
using a greater number of matched sample sets would provide a more robust dataset.   
6.5 Theoretical Application of MiRNA Biomarkers  
 
The identification of four serum miRNAs with altered expression in glioblastoma 
patients could provide a panel which for both diagnosis and prognosis of glioblastoma. 
Extensive further studies however would be required to validate these miRNAs as 
biomarkers. Theoretically, female patients over the age of 60 years would be tested for 
miR-34a and miR-20a up-regulation, those with an up-regulation in both of these 
miRNAs would be diagnosed with glioblastoma. Further analysis of miR-20a expression 
would determine whether these patients were predicted to have a good prognosis 
thereby assisting in treatment decisions. Female patients aged between 20 and 59 
years would be tested for up-regulation of miR-20a, those with an up-regulation would 
be suspected of having glioblastoma. Those with a down-regulation or no change in 
miR-20a expression would require further tests to confirm a diagnosis of glioblastoma. 
Female patients aged between 20 and 39 years would also be tested for a down-
regulation in miR-30c, which in combination with an up-regulation of miR-20a, would 
suggest a diagnosis of glioblastoma. The diagnosis of glioblastoma from one miRNA 
however may result in an incorrect diagnosis and therefore miRNA expression would 
need to be used in conjunction with standard diagnostic techniques.  
Male patients over the age of 60 years would be tested for miR-34a and miR-92a up-
regulation which would result in a diagnosis of glioblastoma. Further determination of 
miR-20a expression would predict the prognosis of these patients. Male patients aged 
between 20 and 59 years would be diagnosed based on miR-92a expression and 
prognosis predicted by miR-20a. Male patients aged between 20 and 39 years would 
also be tested for a down-regulation in miR-30c, a down-regulation of this miRNA with 
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an up-regulation of both miR-20a and miR-92a would suggest a diagnosis of 
glioblastoma.  
The use of miR-20a as a prognostic indicator would improve treatment decisions for 
individual glioblastoma patients. Patients predicted to have a poor prognosis would 
require aggressive therapy such as a higher and more frequent dosage of 
chemotherapy and radiotherapy from the beginning of their treatment. Those with a 
better prognosis could be treated with therapies at a lower, less frequent dosage  with 
less side effects initially and more aggressive treatment following progression, 
improving the quality of life for these patients during treatment. A recent study 
highlighted a link between miR-20a expression and temozolomide resistance of 
glioblastoma (Wei et al., 2015). Treatment of the U251 glioblastoma cell lines and 
xenografts with a miR-20a mimic led to temozolomide resistance (Wei et al., 2015). If a 
similar mechanism is present in vivo in glioblastoma, patients with an up-regulation of 
miR-20a could be treated with alternative chemotherapeutic agents such as the 
alkylating agent cisplatin or the VEGF monoclonal antibody, bevacizumab (Neagu et al., 
2015).  
Whilst these diagnostic pathways using the miRNA biomarker panel would be useful 
for glioblastoma patients, additional studies are still required to further validate the 
use of this panel as biomarkers before they could be applied in a clinical setting. It has 
been previously found that a number of variables can affect the expression of miRNAs 
in the circulation including, diet, drug treatments and the presence of other diseases 
(Mathers et al., 2010). Patients with glioblastoma are often prescribed steroids such as 
dexamethasone to treat cerebral oedema (Sur et al., 2005), and anti-epileptic drugs 
(van Breemen et al., 2009) in addition to chemotherapeutics. Other treatments may 
also affect the expression of the miRNA biomarkers in the serum of patients, therefore 
further studies investigating the effect of steroids and anti-epileptic drugs on miRNA 
expression could be performed.  
For this panel to be effective as a diagnostic panel for glioblastoma, the effect of 
variables such as those mentioned should be investigated to ensure that expression is 
not significantly altered which could lead to incorrect diagnosis. Furthermore, 
alterations of the miRNA biomarker panel expression during the course of treatment 
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could also be investigated to determine whether the expression of these miRNAs alters 
during progression of the glioblastoma and could potentially be used to predict 
recurrence.    
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Figure 6.1 Theoretical application of the female miRNA biomarker diagnostic and prognostic pathway. Female patients between the age of 20 and 39 years suspected of having glioblastoma would 
be tested for miR-30c decreased expression and miR-20a increased expression. Female patients aged between 40 and 59 years would be tested for miR-20a increased expression. Female patients 
over the age of 60 years would be tested for miR-34a increased expression. All patients following a diagnosis of glioblastoma would be tested for miR-20a increased expression to determine 
prognosis.  
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Figure 6.2 Theoretical application of the male miRNA biomarker diagnostic and prognostic pathway. All male patients suspected of having glioblastoma would be tested for miR-92a increased 
expression. Male patients between the age of 20 and 39 years would also be tested for decreased miR-30c expression and increased miR-20a expression. Male patients over the age of 60 years would 
also be tested for miR-34a increased expression. Following diagnosis all patients would be tested for miR-20a expression to determine prognosis.  
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Following the identification of the role of miRNAs in aberrant signalling within cancer, 
including glioblastoma, an area of miRNA research has begun to investigate the 
targeting of particular miRNAs as a novel method of treatment. The use of miRNA 
mimics, to restore expression of a tumour suppressor miRNAs, and miRNA inhibitors or 
sponges, to down-regulate an ‘oncomiR’ has been researched in order to develop new 
treatments for cancer. A miR-34a mimic has recently been advanced to Phase I clinical 
trials for the treatment of liver cancer in which miR-34a is down-regulated (Bouchie, 
2013). The delivery of MRX34, the miR-34a mimic, restores endogenous expression 
levels of miR-34a, reinstating the tumour suppressor effect of this miRNA in the p53 
pathway (Bouchie, 2013). The miRNA biomarkers identified in this thesis could be 
further studied as targets for the treatment of glioblastoma, miR-30c, up-regulated in 
TRAIL-resistant glioblastomas, could be targeted using a miRNA inhibitor to down-
regulate expression and in conjunction with TRAIL therapy could reduce resistance of 
the tumour to this treatment method.  
6.6 Limitations and Future Work  
 
The primary aim of this thesis was to identify miRNA biomarkers for glioblastoma. To 
further improve the specificity of any miRNA biomarkers discovered in this study, 
patients were grouped by both age and gender. Although this improved the specificity 
of miRNA biomarkers, the number of variables accounted for, both genders and three 
age groups, restricted the number of samples studied for each group. Limiting sample 
number in each group therefore could have resulted in false positives or false 
negatives, and a smaller number of significant miRNAs which could have been 
identified. Further work investigating either age or gender separately would increase 
the sample size in each group and therefore the potential for the identification of a 
larger number of biomarkers.  
Utilising patient samples also provided a limitation for this work in respect to sample 
availability. Due to the incidence of GBM being highest in patients over the age of 60 
years; the number of samples from patients aged between 20 and 39 years was 
limited. This meant that analysis of miRNA expression in this age group was limited. In 
addition to this, the availability of matched tissue and serum samples also restricted 
the comparison of circulating and tissue miRNA expression resulting in data which 
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should be interpreted with caution. Future work utilising larger patient cohorts could 
provide more robust data on the miRNA biomarkers identified in this thesis.  
Section 5.2.1 aimed to identify the effect of human serum on cell line miRNA 
biomarker expression. Although this provided insight into the effect of serum 
components on miRNA expression, it could not definitively be concluded that the 
miRNAs within the serum itself had cause this effect. Future work transfecting miRNA 
sponges and mimics could identify whether the miRNA biomarkers within human 
serum could affect their own expression intracellularly.  
In Section 5.2.6, the expression of serum miRNA biomarkers was measured in CSF 
samples from glioblastoma patients. This provided insight into the differences in 
expression of these particular miRNA in different sample types. To determine whether 
CSF could be utilised as a source of biomarkers for diagnosis and prognosis however, 
further work could be carried utilising the 84 miRNA panel to identify CSF miRNA 
biomarkers that may be different to those in the serum.   
Differences in miRNA expression between GBM patients such as miR-20a expression 
was theorised to be as a result of GBM subtypes. To further validate this hypothesis 
future work utilising GBM samples grouped by subtypes could be performed to 
identify sub-type specific miRNA biomarkers.  
6.7 Conclusions  
 
Since the discovery of tumour derived exosomes containing miRNA in the circulation of 
patients, the identification of miRNA biomarkers for the diagnosis and prognosis of a 
range of cancer types has been of great interest for the improvement of current 
diagnostic techniques and subsequently overall treatment of the disease. The primary 
aim of this thesis was to identify a panel of gender and age specific circulatory miRNAs 
within the serum for the diagnosis of glioblastoma and to predict prognosis.  Four 
miRNA biomarkers were identified and validated for the diagnosis of glioblastoma, 
with one miRNA, miR-20a, showing significant prognostic potential.  
Additional to the primary aim, a human serum cell line model was developed to 
provide an improved in vitro method for investigation of miRNA expression. This model 
was utilised in further studies to determine the origin of the serum miRNA biomarkers 
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in addition to analysis of TCGA data and in situ hybridisation. Future studies utilising 
short-term primary glioblastoma cell lines could further improve the human serum cell 
culture model and the representation of an in vivo system.  
Further to the identification of four serum miRNA biomarkers, investigation into the 
source of the biomarkers suggested that not all the miRNAs in the panel originate from 
the glioblastoma itself. As well as glioblastoma tissue as a source of serum miRNAs, 
lymphocytes were also investigated as a source. Although an initial study was 
performed, the small sample size did not permit robust data to conclude whether cells 
of the immune system secrete the miRNA biomarkers. Further work utilising a larger 
sample set would provide more information on miRNA expression in lymphocytes. The 
investigation of alternative sources of miRNA biomarkers provides a greater 
understanding of the underlying pathophysiology of glioblastoma and could highlight 
novel treatment targets.  
The serum miRNA biomarker panel identified in this thesis has the potential to provide 
a relatively non-invasive diagnostic test for glioblastoma. Further to the diagnostic 
ability of this panel, miR-20a provides a prognostic indicator. Future work elucidating 
difference in miRNA biomarker expression in glioblastoma subtypes could also provide 
a more detailed picture of an individual’s glioblastoma, including likely mutations and 
likelihood of recurrence. This would further improve treatment strategies and the 
management of a patient’s neoplasm which could potentially improve median survival 
times and patient outcome.   
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Appendix 1: BTNW Tissue Bank and University Ethical Approval 
Documents  
 
8 January 2013 
 
Lisa Shaw / Charlotte Bellamy 
School of Pharmacy & Biomedical Sciences 
University of Central Lancashire 
 
Dear Lisa / Charlotte 
 
Re: STEM Ethics Committee Application 
Unique reference Number: STEM 041 
The STEM ethics committee has granted approval of your proposal application 
‘Identification of Biomarkers for Glioma Progression’. 
 
Please note that approval is granted up to the end of project date or for 5 years, 
whichever is the longer.  This is on the assumption that the project does not 
significantly change in which case, you should check whether further ethical clearance 
is required. 
 
We shall e-mail you a copy of the end-of-project report form to complete within a 
month of the anticipated date of project completion you specified on your application 
form.   This should be completed, within 3 months, to complete the ethics governance 
procedures or, alternatively, an amended end-of-project date forwarded to 
roffice@uclan.ac.uk together with reason for the extension. 
 
Please also note that it is the responsibility of the applicant to ensure that the ethics 
committee that has already approved this application is either run under the auspices 
of the National Research Ethics Service or is a fully constituted ethics committee, 
including at least one member independent of the organisation or professional group.  
 
Yours sincerely  
Tal Simmons 
Chair 
STEM Ethics Committee 
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Application for clinical samples/data from the 
Brain Tumour North West and  
the Walton Research Tissue Banks 
 
Applicant:     Duration of Project: 
Name  …Charlotte Bellamy………… 
Address …MB30 Maudland Building………… 
  …School of Pharmacy and Biomedical Science 
      University of Central Lancashire 
      PR1 2HE 
Tel:  ………………………………………… 
Email:  …cbellamy@uclan.ac.uk…………… 
Student (delete as appropriate) 
Project Title:  ……Identification of Biomarkers for Glioma Progression…………… 
Is the application for samples to support the project being made to: 
Joint application to both banks      (delete as required) 
Funding: 
Is the funding for the project    
b) internal (eg funded from a researchers laboratory or institutional budget) 
               
 
If the project has been submitted as a grant application for external funding?     
Was the application successful?      yes / no  
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Was the project externally peer-reviewed?     yes / no 
 
External Funding body:   ……………………………………… 
Details of Funding:  Total £ …3000…… (staff …………………and consumables £3000……) 
 
Approvals:  
Ethics Approval 
Does the project have ethics approval? Internal applicant applying for generic ethical approval    
by proxy       
If yes, please supply reference number ………….and date of approval ………….. 
Both Tissue Banks have generic ethical approval to supply tissue/data for projects conducted by internal applicants, 
without the need for further ethics approval. External researchers wishing to use tissue or data supplied by the bank 
need to apply to REC for individual ethical approval. 
Research Governance 
a) Are the applicants employed by NHS establishment(s)?    no 
b) Does the project involve research activity using the anonymised samples/data in an NHS 
establishment?         no 
If yes to a or b, the project may require research governance approval and applicants should consult the Research 
Governanc Manager at their hospital 
Co-applicants:  Name      Affiliation 
Outline of Project   
Please give a brief outline of the project under the headings below (not more than 1-3 A4 pages) or attach 
the external funding application 
 
 
 
 
BTNW & WRTB project application form: version 2   19/05/11 
Page 250 
Hypothesis and Study Aim  
Working Hypothesis: Can changes in the composition of cerebrospinal fluid, blood or serum be 
used to form a panel of biomarkers for the prediction of glioma progression. 
(i). Main aim:  The main aim of this study is to identify and isolate components of cerebrospinal 
fluid, blood and serum, from adult and paediatric glioma patients which are related to aspects of 
tumour progression, prognosis, diagnosis, likelihood of recurrence, and response to therapy. In 
addition, tissue samples will be utilised to compare the differences in components between the 
sample types.  
(ii). Specific aims:  
1. To identify potential components of each fluid type that could be used as biomarkers through a 
literature search. 
2. To optimise the growth of glioma cell lines in serum by identifying the optimum concentration 
of serum to be used and comparing the growth affects of human serum and bovine serum by using 
cell culture methods. 
3.  To compare differences in phenotype between glioma cell lines grown in human serum and 
bovine serum using immunocytochemistry. 
4. To isolate and quantify the abundance of specific microRNA/proteins, from glioma 
cerebrospinal fluid, blood, serum and tissue samples, identified from the literature search to form 
a biomarker panel.   
5. To perform intervention studies altering the abundance of the identified biomarkers to confirm 
an effect on cell phenotype and behaviour.  
6. To analyse the data statistically and present them as a PhD thesis.  
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Plan of Project  
(number of cases  including samples from other banks) 
Proposed programme of work 
(a) In vitro cell culture  
 
1. Basic Cell Culture  
One glioma cell line will be used for this work, U87MG grade IV glioblastoma cell line. 
One non-cancerous SVGP12 astrocyte cell line will also be used. Growth curves will be 
made for each cell line and characterisation of the cells will be performed to confirm they 
are the appropriate cells.   
 
2. Weaning of cells off bovine serum:  
Human obtained from adult glioma patients and patients without glioma will be used for 
optimisation. Glioma cell lines grown in medium supplemented with bovine serum will be 
weaned off the serum by decreasing the concentration of bovine serum and replacing it with 
equal amounts of human serum, gradually increasing the concentration of human serum to 
replace the full concentration of bovine serum.  
 
3. Culture of cells in human serum:  
Glioma and non-cancerous cell lines will be cultured in human serum, growth curves will be 
performed to compare the rate of growth to cell lines cultured in normal cell culture 
conditions (10% foetal bovine serum (FBS)).  
 
4. Comparison of cell culture in different serum conditions:  
Glioma and non-cancerous cell lines will be weaned off FBS and onto human serum.  
The cells will be incubated with the different serum and then characterised using 
immunocytochemistry. Changes in cell expression and phenotype will be investigated using 
fluorescent markers and confocal microscopy.   
 
5. Comparison of cell culture with different human serum samples:  
Cells will be cultured with different human serum samples from patients with varying age 
and gender and immunocytochemistry will be used to determine whether the characteristics 
of the sample affect the phenotype of the cell. 
 
(b) MicroRNA and Protein Isolation and Quantification  
 
1. Pilot studies of microRNA/protein extraction and quantification: 
Pilot studies for method development will be performed to determine the optimum technique 
for the isolation, extraction and quantification of microRNAs and proteins. Method 
development will make use of methods used in related literature and practical development 
using PCR and western blotting. A single microRNA/protein will be chosen to focus on 
method development.  
 
2. MicroRNA/Protein Isolation and quantification of abundance: 
Using the method developed, specific microRNAs and proteins will be isolated and 
quantified from a range of serum/whole blood/tissue/cerebrospinal fluid samples to 
determine differences between age, gender, cancerous and non-cancerous states. The results 
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will be analysed and used to form a panel of biomarkers that could potentially be used to 
gain information about glioma diagnosis and prognosis.  
 
(c) Intervention Studies  
 
1. Alteration in the abundance of biomarker panel:  
Cell lines will be incubated with patient samples and subsequently each potential biomarker 
will be isolated and removed from the sample to determine any changes in phenotype and 
cell characteristics using immunocytochemistry and confocal microscopy.  
 
Experimental Methodology for A1 and A2 only (see proposed programme of study above) 
Serum Replacement Study  
This study will investigate the effect of different serum conditions on the microRNA expression of 
SVGP12 and U87MG cell lines. Studies have shown that cells in culture secrete lipoprotein 
microvesicles containing microRNAs which can be isolated from the medium and measured using 
qRT-PCR. U87MG and SVGP12 cell lines will be cultured in T25 flasks and weaned off the standard 
cell culture serum (10% foetal bovine serum) and onto either, non-cancerous human serum 
(sigma), human serum from glioma patients or serum free medium. The glioma serum will be 
obtained from three glioma patients and pooled for use.  
Protocol  
Medium was aspirated from the T25 flask and washed with PBS.  
1ml of trypsin was added and incubated for five minutes.  
1ml of medium containing new serum concentration was added and 1ml of cell suspension was 
removed.  
The cell suspension was added to fresh T25 flask and 4ml of medium containing new serum 
concentration was also added.  
The cells were incubated for 48 hours and then passaged, increasing concentration each time. The 
concentration of serum was increased in intervals which were: 0%, 3%, 5%, 7%, 10%, of total 
medium volume for the human serum and glioma serum and 25%, 50%, 75% and 100% serum free 
medium, as shown in Table 1.  
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After 72 hour incubation with the final concentration, 1ml of spent medium was collected and 
centrifuged to remove cells.  
Total RNA including microRNAs were isolated from the media, reverse transcribed and abundance 
measured using qRT-PCR, with each serum condition being run in duplicate.  
Table 1. Human Non-Cancerous Serum and Human Glioma Serum 
Replacement Serum Concentration Composition  
0%  600 µl FBS, 5400 µl medium 
3% 180µl human serum, 420µl FBS, 5400µl 
medium 
5% 300 µl human serum, 300 µl FBS, 5400 µl 
medium 
7% 420 µl human serum, 180 µl FBS, 5400 µl 
medium 
10% 600 µl human serum, 5400 µl medium 
 
Serum Free Medium 
Serum Free Medium Concentration Composition 
0% 6000µl medium supplemented with 10% FBS 
25% 1500µl serum free medium, 4500µl medium with 
10% FBS 
50% 3000µl serum free medium, 3000µl medium 
supplemented with 10% FBS 
75% 4500µl serum free medium, 1500µl medium 
supplemented with 10% FBS  
100% 6000µl serum free medium 
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Tissue Required – Please indicate whether you require paraffin embedded tissue, fresh frozen 
tissue, cellular component of blood, plasma or serum and how many samples you require.   
Please indicate if all samples are required at the start of the project or if further applications for 
samples will be made in the light of initial findings. 
Tissue, serum, cerebrospinal fluid and whole blood needed throughout the project.  
For further information please contact: 
BTNW Tissue Bank:  Prof T Dawson email: Timothy.Dawson@lthtr.nhs.uk 
Walton Research Tissue Bank: Dr C Walker email: carol.walker@thewaltoncentre.nhs.uk 
Please email completed applications to: 
BTNW Tissue Bank:  Prof T Dawson  email: Timothy.Dawson@lthtr.nhs.uk  
Walton Research Tissue Bank: Dr C Walker email: carol.walker@thewaltoncentre.nhs.uk 
Or to both for joint applications to both banks 
For BTNW or WRTB use only: 
Date Application Received 08/06/2012 
Application Number 1206 
Project Title Identification of Biomarkers for Glioma 
Progression 
Date sent to BTNW/WRTB Review Panel 18/06/12 
Names of Reviewers 
 
Prof C H G Davis, Dr Tracy Warr, Prof R W Lee 
 
 
 
 
Decision of BTNW/WRTB Committees Approve 
Date: 19/06/2012 
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Appendix 2: Determination of nanodrop accuracy in measuring Total 
RNA samples.  
 
RNA Standard 
Concentration 
(ng/µl) 
Nanodrop Concentration (ng/µl) 
1 2 3 
1000 1008.3 1004.3 1009.7 
100 102.7 103.5 102.9 
10 9.7 10.0 10.0 
5 4.8 4.9 4.9 
1 -0.2 0.1 -0.3 
0.1 -0.5 -0.9 -1.0 
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Appendix 3: Non-significant biomarkers from identification panel 
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Appendix 4:Reanalysis of non-significant miRNAs 
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Appendix 5: Comparison of CSF and Serum Total RNA Concentration 
 
CSF Sample Disease  Concentration (ng/µl) 
1223 GBM 13.9 
1195 GBM 18.4 
1301 GBM 16.0 
1300 GBM 58.8 
1208 Dermoid Cyst  17.0 
1289 NPH 24.3 
1293 Dermoid Cyst 68.6 
1210 Hydrocephalus 19.7 
1234 NPH 44.9 
1238 NPH 29.5 
 
Serum Sample Disease  Concentration (ng/µl) 
413 GBM 197.2 
927 GBM 1548.1 
907 GBM 1034.8 
611 GBM 254.9 
373 GBM  667.8 
1395 Control 1031.8 
575 Control  1109.7 
594 Control  303.9 
591 Control  342.0 
1527 Control  865.6 
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Appendix 6: Example QPCR Data 
 
  
    AVG Delta(Ct)  Standard Deviation 
  
Control 
Group Group 1 
Control 
Group Group 1 
A01 hsa-let-7b-5p -1.480625 -2.088233 0.590399 1.617479 
A02 hsa-miR-101-3p 2.905075 1.6818 1.644836 0.63808 
A03 hsa-miR-106b-5p 1.550925 1.471767 0.362923 0.741415 
A04 hsa-miR-107 4.668825 3.3974 1.267312 1.34556 
A05 hsa-miR-10b-5p 4.120325 2.897633 0.715486 1.66676 
A06 hsa-miR-124-3p 2.984525 2.1625 1.612239 1.523499 
A07 hsa-miR-125a-5p 0.291125 -0.3831 0.394247 0.538157 
A08 hsa-miR-125b-5p -1.901625 -2.219967 0.802248 0.406676 
A09 hsa-miR-127-5p 4.668825 3.3974 1.267312 1.34556 
A10 hsa-miR-128-3p 2.564625 1.649867 1.222482 1.275635 
A11 hsa-miR-129-5p 4.668825 3.3974 1.267312 1.34556 
A12 hsa-miR-130a-3p 2.114975 2.737067 0.299071 0.743141 
B01 hsa-miR-130b-3p 3.695825 2.905733 0.547195 2.102322 
B02 hsa-miR-132-3p 4.346725 3.077233 1.72283 0.876806 
B03 hsa-miR-133a-3p 4.668825 3.3974 1.267312 1.34556 
B04 hsa-miR-133b 4.668825 3.3974 1.267312 1.34556 
B05 hsa-miR-137 4.668825 3.3974 1.267312 1.34556 
B06 hsa-miR-138-5p 4.668825 2.759333 1.267312 0.948673 
B07 hsa-miR-141-3p 4.314625 3.3974 1.768227 1.34556 
B08 hsa-miR-144-3p 1.849125 2.183267 0.247098 0.510937 
B09 hsa-miR-146a-5p 4.110575 2.726767 0.477827 0.547367 
B10 hsa-miR-146b-5p 3.270975 2.7242 2.140943 0.741592 
B11 hsa-miR-148a-3p 3.045075 2.047667 1.029017 1.573276 
B12 hsa-miR-149-5p 4.397825 3.3974 1.650564 1.34556 
C01 hsa-miR-150-5p 3.491775 3.3974 0.805076 1.34556 
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C02 hsa-miR-153-3p 4.668825 3.3974 1.267312 1.34556 
C03 hsa-miR-15a-5p 4.668825 2.2387 1.267312 0.203821 
C04 hsa-miR-15b-5p 4.206375 1.9101 1.433129 0.829889 
C05 hsa-miR-16-5p -0.146875 -0.8589 0.320284 0.346535 
C06 hsa-miR-17-5p 2.380775 2.101833 0.675747 0.019412 
C07 hsa-miR-17-3p 4.668825 3.3974 1.267312 1.34556 
C08 hsa-miR-181a-5p 3.841725 1.279333 0.097616 2.053895 
C09 hsa-miR-181b-5p 2.256025 0.359 0.844887 1.05938 
C10 hsa-miR-182-5p 4.668825 3.3974 1.267312 1.34556 
C11 hsa-miR-183-5p 4.668825 3.3974 1.267312 1.34556 
C12 hsa-miR-184 4.668825 3.3974 1.267312 1.34556 
D01 hsa-miR-185-5p 4.668825 3.3153 1.267312 1.218508 
D02 hsa-miR-187-3p 4.668825 3.3974 1.267312 1.34556 
D03 hsa-miR-18a-5p 4.668825 3.284033 1.267312 1.171039 
D04 hsa-miR-190a-5p 4.668825 3.300033 1.267312 1.195259 
D05 hsa-miR-191-5p 3.451725 1.734733 1.415239 1.201328 
D06 hsa-miR-19a-3p 3.210775 2.417433 3.329306 2.209216 
D07 hsa-miR-19b-3p 3.435525 2.5718 3.011462 1.429178 
D08 hsa-miR-200a-3p 4.668825 3.3974 1.267312 1.34556 
D09 hsa-miR-203a-3p 4.668825 3.3974 1.267312 1.34556 
D10 hsa-miR-20a-5p 1.056925 0.738933 0.384843 0.70272 
D11 hsa-miR-21-5p -4.043175 -4.647733 0.073362 0.41495 
D12 hsa-miR-210-3p 4.668825 3.116033 1.267312 1.088886 
E01 hsa-miR-216a-5p 4.668825 3.3974 1.267312 1.34556 
E02 hsa-miR-217 4.668825 3.3974 1.267312 1.34556 
E03 hsa-miR-218-5p 4.668825 3.3974 1.267312 1.34556 
E04 hsa-miR-221-3p 0.363775 -0.834467 0.622219 0.735687 
E05 hsa-miR-222-3p 4.426125 2.5094 1.610542 2.125015 
E06 hsa-miR-222-5p 4.668825 3.3974 1.267312 1.34556 
E07 hsa-miR-23a-3p 0.066775 -1.370467 0.9308 0.689693 
E08 hsa-miR-23b-3p 1.695125 0.4042 1.203248 0.934103 
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E09 hsa-miR-24-3p -1.931725 -0.702233 1.343043 0.856061 
E10 hsa-miR-25-3p 2.189375 0.9708 1.525053 1.488279 
E11 hsa-miR-26a-5p -2.527275 -4.055067 1.259675 1.472554 
E12 hsa-miR-27a-3p 0.404025 -0.87 0.5298 0.899326 
F01 hsa-miR-296-5p 4.668825 3.301467 1.267312 1.369241 
F02 hsa-miR-29a-3p 0.336375 -0.657867 0.207854 0.78976 
F03 hsa-miR-29b-3p 3.177925 0.857533 0.986732 1.746567 
F04 hsa-miR-29c-3p 0.083475 -1.229533 0.511769 0.812761 
F05 hsa-miR-30b-5p 2.338725 0.958 0.658776 1.168934 
F06 hsa-miR-30c-5p 1.653375 0.1685 1.312921 1.141486 
F07 hsa-miR-31-5p 4.272925 2.557567 0.707425 1.34549 
F08 hsa-miR-320a 1.691325 0.1932 1.083323 1.11365 
F09 hsa-miR-323a-5p 4.631125 3.172367 1.213996 1.007027 
F10 hsa-miR-324-5p 4.401375 2.9899 0.889081 1.346387 
F11 hsa-miR-326 4.668825 3.3974 1.267312 1.34556 
F12 hsa-miR-328-3p 0.525925 -2.1129 2.135922 2.011041 
G01 hsa-miR-331-5p 4.668825 3.3974 1.267312 1.34556 
G02 hsa-miR-335-5p 4.668825 3.171833 1.267312 1.006269 
G03 hsa-miR-34a-5p 4.650075 2.415867 1.293829 1.312732 
G04 hsa-miR-425-5p 4.293275 2.688 0.736204 1.895129 
G05 hsa-miR-451a -1.348675 -1.716733 0.480019 1.65848 
G06 hsa-miR-486-5p 2.868275 1.164033 0.997834 1.434588 
G07 hsa-miR-7-5p 4.516975 2.764467 1.052564 0.587371 
G08 hsa-miR-9-5p -1.104375 -3.2088 1.255857 1.81362 
G09 hsa-miR-9-3p 1.304375 -0.432267 0.608784 1.489972 
G10 hsa-miR-92a-3p 0.492525 -1.591867 0.246533 0.912989 
G11 hsa-miR-93-5p 3.606575 2.3882 0.234936 1.104773 
G12 hsa-miR-96-5p 4.668825 3.100533 1.267312 1.479333 
 
 
